(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2014 (25.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/146246 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *C07D 471/04* (2006.01)
A61K 31/495 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:
PCT/CN2013/072867

(22) International Filing Date:
19 March 2013 (19.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant *(for all designated States except US)*: **MERCK SHARP & DOHME CORP.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).

(72) Inventors; and
(71) Applicants *(for US only)*: **CHILDERS, Matthew L.** [US/US]; Merck Sharp & Dohme Corp., 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **DINSMORE, Christopher** [US/US]; Merck Sharp & Dohme Corp., 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **FULLER, Peter H.** [US/US]; Merck Sharp & Dohme Corp., 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **GUERIN, David J.** [US/US]; Merck Sharp & Dohme Corp., 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **KATZ, Jason David** [US/US]; Merck Sharp & Dohme Corp., 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **PU, Qinglin** [CN/US]; Merck Sharp & Dohme Corp., 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **SCOTT, Mark E.** [CA/US]; Merck Sharp & Dohme Corp., 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **THOMPSON, Christopher F.** [US/US]; Merck Sharp & Dohme Corp., 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **ZHANG, Hongjun** [CN/US]; Merck Sharp & Dohme Corp., 33 Avenue Louis Pasteur, Boston, MA 02115-5727 (US). **CAI, Jiaqiang** [GB/CN]; WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). **DU, Xiaoxing** [CN/CN]; WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). **WANG, Chonggang** [CN/CN]; WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). **KONG, Norman** [US/CN]; Pharmaron Beijing, Co. Ltd., 6 Taihe Road, BDA, Beijing 100176 (CN). **LIU, Yumei** [CN/CN]; Pharmaron Beijing, Co. Ltd., 6 Taihe Road, BDA, Beijing 100176 (CN).

(74) Agent: **LIU, SHEN & ASSOCIATES**; A0601, Huibin Building, No.8 Beichen Dong Street, Chaoyang District, Beijing 100101 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2014/146246 A1

(54) Title: CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

(57) Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

BACKGROUND OF THE INVENTION

Protein kinases are a group of enzymes that regulate the activity of their target proteins by the addition of phosphate groups to the protein substrate. Kinases play an essential role in many physiological processes including cell division, differentiation, cellular homeostasis and signal transduction. Kinases can be subdivided by their target into Serine/Threonine kinases and Tyrosine kinases. Tyrosine kinases are further subdivided into receptor tyrosine kinases and non-receptor tyrosine kinases. The mammalian Janus kinase (JAK) family members are non-receptor tyrosine kinases.

The JAK family has four members; JAK1, JAK2, JAK3 and TYK2. JAK1, JAK2 and TYK2 are universally expressed, whereas JAK3 expression is limited to hematopoetic cells. The JAK family is involved in intracellular signal transduction from >70 different cytokines. Cytokines bind to their cell surface receptors resulting in receptor dimerization and subsequent activation/phosphorylation of JAK tyrosine kinases. The JAKs are either constitutively associated with the receptor or are recruited upon cytokine binding. Specific tyrosine residues on the receptor are then phosphorylated by activated JAKs and serve as docking sites for STAT proteins. STATs are phosphorylated by JAKs, dimerize, then translocate to the nucleus where they bind specific DNA elements and activate gene transcription. JAK1 signals in conjunction with all JAK isoforms in a cytokine dependent manner.

JAKs are essential for multiple physiological functions. This has been demonstrated using genetically engineered mouse models that are deficient in specific JAKs. $Jak1^{-/-}$ mice die perinatally, while $Jak2^{-/-}$ mice have deficiencies in erythropoesis and die around day E12. $Jak3^{-/-}$ mice are viable, but have a SCID phenotype with deficiencies in T cells, B cells and NK cells. $TYK2^{-/-}$ mice exhibit features of hyper IgE syndrome. These phenotypes demonstrate the essential and non-redundant roles of JAK activity in vivo (K. Ghoreschi, A. Laurence, J. J. O'Shea, *Immunol. Rev.* 228, 273 (2009)).

Furthermore, mutations in the JAK enzymes have been associated with diseases in humans. Inactivating mutations in JAK3 (or the cognate common gamma chain cytokine receptor) cause a severe SCID phenotype (J. J. O'Shea, M. Pesu, D. C. Borie, P. S. Changelian, *Nat. Rev. Drug Discov.* 3, 555 (2004)). Deletions of TYK2 result in hyper IgG syndrome and increased infection risk (Y. Minegishi *et al.*, *Immunity.* 25, 745 (2006)). No inactivating mutations have been reported for JAK1 or JAK2, consistent with the data from mice that demonstrates that JAK1 and JAK2 deficient mice are not viable. However, several mutations that result in constitutively active JAK2 have been identified, resulting in myeloproliferative diseases and confirming the central role of JAK2 in hematopoesis (O. bdel-Wahab, *Curr. Opin. Hematol.* 18, 117 (2011)). JAK2 is the sole JAK family member involved in signal transduction of the critical hematopoetic cytokines IL-3, GMCSF, EPO and TPO.

The wealth of mouse and human genetic data demonstrating a central role for JAK kinase activity in autoimmune disease, hematopoesis and oncology has been supported by

the use of pan-JAK inhibitors in clinical trials for autoimmune diseases and neoplasms (See K. Ghoreschi, et al, *Immunol. Rev.* 228, 273 (2009), *and* A. Quintas-Cardama, H. Kantarjian, J. Cortes, S. Verstovsek, *Nat. Rev. Drug Discov.* 10, 127 (2011)).

A considerable body of literature has accumulated that link the Jak/STAT pathway to various diseases and disorders including hyperproliferative disorders and cancer such as leukemia and lymphomas, immunological and inflammatory disorders such as transplant rejection, asthma, chronic obstructive pulmonary disease, allergies, rheumatoid arthritis, type I diabetes, amyotropic lateral sclerosis and multiple sclerosis.

SUMMARY OF THE INVENTION

The present invention provides novel compounds which are inhibitors of JAKs. The invention also provides a method for the treatment and prevention of JAK-mediated diseases and disorders using the novel compounds, as well as pharmaceutical compositions containing the compounds.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides compounds of formula I or pharmaceutically acceptable salts, or stereoisomers thereof:



I

A is selected from aryl and heteroaryl;
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, or 4;
p is 0, 1, 2, 3, or 4;
R^1 is selected from:

halogen,

Oxo (=O),

C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{1-10} heteroalkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{2-10} alkenyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

aryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{3-8} cycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

heteroaryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
(C_{1-10})heteroalkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
C_{3-8} cycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
aryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
heteroaryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
C_{0-10} alkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
(C_{1-10})heteroalkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{3-8} cycloalkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
aryl C_{0-10} alkylaminoamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
heteroaryl C_{0-10} alkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
(C_{3-8})heterocycloalkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{0-10} alkylsulfonylC_{0-10} alkyl,
C_{1-10} heteroalkylsulfonylC_{0-10} alkyl,
(C_{3-8})cycloalkylC_{0-10}alkylsulfonylC_{0-10} alkyl,
(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfonylC_{0-10} alkyl,
heteroarylC_{0-10} alkylsulfonylC_{0-10} alkyl,
arylC_{0-10} alkylsulfonylC_{0-10} alkyl,
C_{1-10} alkylsulfamoylC_{0-10} alkyl,
C_{1-10} heteroalkylsulfamoylC_{0-10} alkyl,
(C_{3-8})cycloalkylC_{0-10} alkylsulfamoylC_{0-10} alkyl,
(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfamoylC_{0-10} alkyl,
heteroarylC_{0-10} alkylsulfamoylC_{0-10} alkyl,
arylC_{0-10} alkylsulfamoylC_{0-10} alkyl,
(C_{0-10} alkyl)$_{1-2}$ amino,
-CO_2(C_{0-10} alkyl),
-(C_{0-10} alkyl)CO_2H,
-SO_2NH_2,
-SO_2NH(C_{1-10} alkyl),
-SO_2N(C_{0-10} alkyl)$_2$,
-SO_2CF_3,
-SO_2CF_2H,
C_{1-10} alkylsulfinylC_{0-10} alkyl,
C_{1-10} heteroalkylsulfinylC_{0-10}alkyl,
(C_{3-8})cycloalkylC_{0-10}alkylsulfinylC_{0-10}alkyl,

(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfinylC_{0-10}alkyl,
heteroarylC_{0-10} alkylsulfinylC_{0-10}alkyl,
arylC_{0-10}alkylsulfinylC_{0-10}alkyl,
C_{0-10} alkylsulfinylaminoC_{0-10} alkyl,
C_{1-4}acylamino C_{0-10} alkyl,
hydroxy,
-$(C_{1-10}$ alkyl)OH,
-C_{0-10} alkylalkoxy,
cyano,
$(C_{1-6}$alkyl)cyano, and
C_{1-6}haloalkyl;

R^2 is selected from:
halogen,
Oxo (=O),
C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{3-8} cycloalkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{0-10} alkylaminoC_{0-10} alkyl,
(C_{1-10})heteroalkylaminoC_{0-10}alkyl,
C_{3-8} cycloalkyl C_{0-10} alkylaminoC_{0-10} alkyl,
aryl C_{0-10} alkylaminoC_{0-10} alkyl,
heteroaryl C_{0-10} alkylaminoC_{0-10} alkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkylaminoC_{0-10} alkyl,
C_{1-10} alkylsulfonyl,
(C_{3-8})cycloalkylC_{0-10}alkylsulfonyl,
(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfonyl,
$(C_{0-10}$ alkyl$)_{1-2}$ amino,
-$CO_2(C_{0-10}$ alkyl),
-$(C_{0-10}$ alkyl)CO_2H,
-SO_2CF_3,
-SO_2CF_2H,
C_{1-10} alkylsulfinyl,
hydroxy,
-$(C_{1-10}$ alkyl)OH,
-C_{0-10} alkylalkoxy,
cyano,
$(C_{1-6}$alkyl)cyano, and
C_{1-6}haloalkyl, and

wherein two R^2 may optionally join together with the ring atoms to which they are attached and form a 3 to 6 membered ring; and

wherein R^1 and R^2 are each optionally substituted with 1, 2, 3, or 4 R^3 substituents;

R^3 is independently selected from:

halogen,
C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, and
C_{1-10} heteroalkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{2-10} alkenyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
aryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{3-8} cycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
heteroaryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
$((C_{0-10})alkyl)_{1-2}$aminocarbonyloxy,
aryl (C_{0-10})alkylaminocarbonyloxy,
$-CO_2(C_{0-10}$ alkyl),
$-(C_{0-10}$ alkyl)CO_2H,
Oxo (=O),
$-SO_2NH_2$,
$-SO_2NH(C_{1-10}$ alkyl),
$-SO_2N(C_{0-10}$ alkyl$)_2$,
$-SO_2CF_3$,
$-SO_2CF_2H$,
C_{1-10} alkylsulfinyl,
amino,
$(C_{0-10}$ alkyl$)_{1-2}$ amino,
$-(oxy)_{0-1}$(carbonyl)$_{0-1}N(C_{0-10}$ alkyl$)_{1-2}$
hydroxy,
$(C_{1-10}$ alkyl)OH,
C_{1-10} alkoxy,
$(C_{1-10}$ alkyl)cyano,
cyano, and
C_{1-6}haloalkyl; and

R^3 is optionally substituted with 1, 2, or 3 R^4 substituents selected from hydrogen, hydroxy, (C_{1-6})alkyl, (C_{1-6})alkoxy, $(C_{1-10}$ alkyl)OH, halogen, CO_2H, $-(C_{0-6})$alkylCN, $-O(C=O)C_1$-C_6 alkyl, NO_2, trifluoromethoxy, trifluoroethoxy, trifluoromethyl, trifluoroethyl, $-N$-$C(O)O(C_{0-6})$alkyl, C_{1-10} alkylsulfonyl, oxo (O=), aminosulfonyl, $-SO_2NH_2$,

-$SO_2NH(C_{1-10}$ alkyl), -$SO_2N(C_{0-10}$ alkyl)$_2$, -SO_2C_{1-6}alkyl, -SO_2CF_3, -SO_2CF_2H, -C_{1-10} alkylsulfinyl, -$O_{(0-1)}(C_{1-10})$haloalkyl, amino(C_{1-6}alkyl)$_{0-2}$ and NH_2.

Representative compounds of the instant invention include, but are not limited to the following compounds and their pharmaceutically acceptable salts and stereoisomers thereof:

2-{3-[(4-fluorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{3-[(2-fluoropyridin-4-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}-5-{[1-cyclopropylethyl]amino}cyclohexanecarbonitrile;

5-hydroxy-2-(4-oxo-3-{[4-(trifluoromethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-azetidin-1-yl-2-(4-oxo-3-{[4-(trifluoromethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-{[1-cyclopropylethyl]amino}-2-(4-oxo-3-{[4-(trifluoromethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-{[1-cyclopropylethyl]amino}-2-(4-oxo-3-{[4-(trifluoromethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-azetidin-1-yl-2-{3-[(4-chloro-3-fluorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(4-chloro-3-fluorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}-5-(dimethylamino)cyclohexanecarbonitrile;

2-{3-[(4-chloro-3-fluorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}-5-{[1-cyclopropylethyl]amino}cyclohexanecarbonitrile;

5-azetidin-1-yl-2-{3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}-5-(dimethylamino)cyclohexanecarbonitrile;

5-azetidin-1-yl-2-(4-oxo-3-{[4-(trifluoromethoxy)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-{[1-cyclopropylethyl]amino}-2-(4-oxo-3-{[4-(trifluoromethoxy)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-(dimethylamino)-2-(4-oxo-3-{[4-(trifluoromethoxy)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{4-oxo-3-[(2,2,2-trifluoroethyl)amino]-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}-5-(3-hydroxy-3-methylazetidin-1-yl)cyclohexanecarbonitrile;

2-{3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}-5-(3-hydroxyazetidin-1-yl)cyclohexanecarbonitrile;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-*N*,*N*-dimethylbenzenesulfonamide;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzenesulfonamide;

(2-{3-[(2-fluoropyridin-4-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclopentanecarbonitrile;

(2-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile;

2-[4-oxo-3-({4-[2,2,2-trifluoro-1-hydroxyethyl]phenyl}amino)-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(4-oxo-3-{[1-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1*H*-isoindol-5-yl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

4-({1-[2-cyanocyclopentyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-*N,N*-dimethylbenzenesulfonamide;

2-(4-oxo-3-{[1-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1*H*-isoindol-5-yl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile;

2-(4-oxo-3-{[4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile;

4-({1-[2-cyanocyclopentyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzenesulfonamide;

2-[3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-N-(1-methyl-1H-pyrazol-3-yl)acetamide;

N-[3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]-1,3-oxazole-5-carboxamide;

N-[3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]pyrimidine-2-carboxamide;

2-[3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-N-(1-methyl-1H-pyrazol-3-yl)acetamide;

tert-butyl [3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]carbamate;

2-(3-{[3-(aminomethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-N-(1-methylethyl)benzenesulfonamide;

N-benzyl-4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzenesulfonamide;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-N-(cyclopropylmethyl)benzenesulfonamide;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-N-(2-methoxyethyl)benzenesulfonamide;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-N-cyclohexylbenzenesulfonamide;

2-(3-{[4-(morpholin-4-ylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-[4-oxo-3-(phenylamino)-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[3-methyl-4-(pyrrolidin-1-ylcarbonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(4-oxo-3-{[3-(2H-1,2,3-triazol-2-ylmethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

N-[4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]-1,3-oxazole-5-carboxamide;

N-[4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]pyrimidine-2-carboxamide;

2-(3-{[3-(1-hydroxyethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

tert-butyl [4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]carbamate;

2-(3-{[4-(aminomethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[3-(aminomethyl)-4-fluorophenyl]amino}-4-oxo-4,5-dihydro-*1H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[3-(morpholin-4-ylmethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

tert-butyl [5-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-2-fluorobenzyl]carbamate;

tert-butyl [3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-5-fluorobenzyl]carbamate;

2-{3-[(3-{[4-(1-hydroxy-1-methylethyl)-1*H*-1,2,3-triazol-1-yl]methyl}phenyl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-(3-{[3-(1-hydroxy-2-methoxy-1-methylethyl)-4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[3-(1,3-dihydroxy-1-methylpropyl)-4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[3-(1,2-dihydroxy-1-methylethyl)-4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-[3-(2,3-dihydro-1*H*-isoindol-5-ylamino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-[3-({3-[(4-methyl-1*H*-1,2,3-triazol-1-yl)methyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-[3-({3-[1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

N-{1-[3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-2,2,2-trifluoroethyl}-2-methylpropane-2-sulfinamide;

2-(4-oxo-3-{[3-(2,2,4-trimethyl-1,3-dioxolan-4-yl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{4-oxo-3-[(3-{[(2,2,2-trifluoroethyl)amino]methyl}phenyl)amino]-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-(3-{[3-(aminomethyl)-4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

6-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile;

N-[5-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-2-(dimethylsulfamoyl)benzyl]acetamide;

2-[3-({3-[(dimethylamino)methyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[3-(1,2-dihydroxy-1-methylethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

4-{[1-(5-cyanospiro[2.5]oct-6-yl)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl]amino}-*N,N*-dimethylbenzenesulfonamide;

2-(aminomethyl)-4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-*N,N*-dimethylbenzenesulfonamide;

2-(4-oxo-3-{[3-(1*H*-pyrazol-1-ylmethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(4-oxo-3-{[4-(pyrrolidin-1-ylcarbonyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(4-oxo-3-{[4-(1*H*-1,2,3-triazol-1-ylmethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[3-(1*H*-imidazol-1-ylmethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

6-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile;

2-(3-{[4-hydroxy-4-(hydroxymethyl)-1,1-dioxido-3,4-dihydro-2*H*-thiochromen-6-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{3-[(2-methyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-(4-oxo-3-{[3-(1*H*-1,2,4-triazol-1-ylmethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(4-oxo-3-{[3-(1*H*-1,2,4-triazol-4-ylmethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{3-[(4-{[4-(1-hydroxy-1-methylethyl)-1*H*-1,2,3-triazol-1-yl]methyl}phenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(2-tert-butyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1*H* -pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

N-{1-[4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-2,2,2-trifluoroethyl}-2-methylpropane-2-sulfinamide;

2-[3-({4-[1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-{4-oxo-3-[(4-{[(2,2,2-trifluoroethyl)amino]methyl}phenyl)amino]-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-[4-oxo-3-({4-[(pyrrolidin-1-ylsulfonyl)methyl]phenyl}amino)-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[1,1-dioxido-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{3-[(1,1-dioxido-2,3-dihydro-1-benzothiophen-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(2-ethyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(2-tert-butyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclopentanecarbonitrile;

2-(3-{[1,1-dioxido-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile;

2-(4-oxo-3-{[2-(2,2,2-trifluoroethyl)-2,3-dihydro-1*H*-isoindol-5-yl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-2,3-dihydro-1*H*-indene-2-carboxylic acid;

2-{3-[(2-methyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclopentanecarbonitrile;

2-(3-{[2-(cyclopropylmethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{3-[(2-methyl-2,3-dihydro-1*H*-isoindol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-[3-({4-[1-(dimethylamino)-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[2-(cyclopentylmethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{4-oxo-3-[(4-{1-[(2,2,2-trifluoroethyl)amino]ethyl}phenyl)amino]-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-*N*,*N*,2-trimethylbenzamide;

2-(3-{[3-methyl-4-(morpholin-4-ylcarbonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-2-cyclopropyl-*N*,*N*-dimethylbenzamide;

2-[3-({4-[1-amino-2,2-difluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[4-(2,2-difluoro-1-hydroxyethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-[4-oxo-3-({4-[pyrrolidin-2-yl]phenyl}amino)-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-{4-oxo-3-[(4-{1-[(2,2,2-trifluoroethyl)amino]ethyl}phenyl)amino]-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-(3-{[2-(1-methylethyl)-2,3-dihydro-1*H*-isoindol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[2-(2-methylpropyl)-2,3-dihydro-1*H*-isoindol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{3-[(2-ethyl-2,3-dihydro-1*H*-isoindol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-(3-{[2-(cyclopropylmethyl)-2,3-dihydro-1*H*-isoindol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-[3-({3-[(methylsulfanyl)methyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[2-(1-methylethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[2-(2-hydroxyethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[2-(3-hydroxy-1,1-dimethylpropyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-[4-oxo-3-({4-[1-(1*H*-1,2,3-triazol-1-yl)ethyl]phenyl}amino)-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-[3-({4-[1-methyl-1-(1*H*-1,2,3-triazol-1-yl)ethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[2-(3-hydroxy-2,2-dimethylpropyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-[3-({4-[1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclopentanecarbonitrile;

2-[3-({4-[1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclopentanecarbonitrile;

2-(3-{[2-(2-methoxyethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile; and

2-(3-{[3-(aminomethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile.

The invention also encompasses pharmaceutical compositions containing a compound of formula I or II, and methods for treatment or prevention of JAK mediated diseases using compounds of formula I or II.

The invention is described using the following definitions unless otherwise indicated.

As used herein except where noted, "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups, including all isomers, having the specified number of carbon atoms. Commonly used abbreviations for alkyl groups are used throughout the specification, e.g. methyl may be represented by "Me" or CH_3, ethyl may be represented by "Et" or CH_2CH_3, propyl may be represented by "Pr" or $CH_2CH_2CH_3$, butyl may be represented by "Bu" or $CH_2CH_2CH_2CH_3$, etc. "C_{1-6} alkyl" (or "C_1-C_6 alkyl") for example, means linear or branched chain alkyl groups, including all isomers, having the specified number of carbon atoms. C_{1-6} alkyl includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. "C_{1-4} alkyl" means n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.

The term "alkylene" refers to both branched- and straight-chain saturated aliphatic hydrocarbon groups, including all isomers, having the specified number of carbons, and having two terminal end chain attachments. For illustration, the term "unsubstituted A-C4alkylene-B" represents A-CH_2-CH_2-CH_2-CH_2-B.

The term "alkoxy" represents a linear or branched alkyl group of indicated number of carbon atoms attached through an oxygen bridge.

"Acyl" means a –C(O)R radical Where R is optionally substituted alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl heteroaryl, etc.

"Acylamino" means a –NRR' radical where R is H, OH, or alkoxy and R' is acyl, as defined herein.

The term "alkyl" refers to an aliphatic hydrocarbon group which may be straight or branched and having the indicated number of carbon atoms. Non-limiting examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl, pentyl, hexyl, and the like.

The term "heteroalkyl" refers to an alkyl group where 1, 2, or 3 of the carbon atoms is substituted by a heteroatom independently chosen from N, O, or S.

"Alkenyl" refers to an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and having the indicated number of carbon atoms. Preferably alkenyl contains one carbon to carbon double bond, and up to four nonaromatic carbon-carbon double bonds may be present. Examples of alkenyl groups include ethenyl, propenyl, *n*-butenyl, 2-methyl-1-butenyl, 3-methylbut-2-enyl, *n*-pentenyl, octenyl and decenyl.

"Alkynyl" refers to an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and having the indicated number of carbon atoms. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl.

"Alkoxy" refers to an alkyl-O- group in which the alkyl group is as described above. C_{1-6}alkoxy, for example, includes methoxy, ethoxy, propoxy, isopropoxy, and the like.

"Alkoxyalkyl" refers to an alkyl group as described above in which one or more (in particular 1 to 3) hydrogen atoms have been replaced by alkoxy groups. Examples include CH_2OCH_3, $CH_2CH_2OCH_3$ and $CH(OCH_3)CH_3$.

"Aminoalkyl" refers to an alkyl group as described above in which one hydrogen atom has been replaced by an amino, monoalkylamino or dialkylamino group. Examples include CH_2NH_2, $CH_2CH_2NHCH_3$ and $CH(N(CH_3)_2)CH_3$.

The term "C_0" as employed in expressions such as "C_{0-6} alkyl" means a direct covalent bond; or when the term appears at the terminus of a substituent, C_{0-6} alkyl means hydrogen or C1-6alkyl. Similarly, when an integer defining the presence of a certain number of atoms in a group is equal to zero, it means that the atoms adjacent thereto are connected directly by a bond. For example, in the structure 

, wherein s is an integer equal to zero, 1 or 2, the structure is 

when s is zero.

The term "C_{3-8} cycloalkyl" (or "C_3-C_8 cycloalkyl") means a cyclic ring of an alkane having three to eight total carbon atoms (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl). The terms "C_{3-7} cycloalkyl", "C_{3-6} cycloalkyl", "C_{5-7} cycloalkyl" and the like have analogous meanings.

The term "halogen" (or "halo") refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro (F), chloro (Cl), bromo (Br), and iodo (I)).

The term "aryl" refers to aromatic mono- and poly-carbocyclic ring systems, wherein the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond. Suitable aryl groups include phenyl, naphthyl, 2,3-dihydro-1*H*-indenyl, and biphenyl.

The term "carbocycle" (and variations thereof such as "carbocyclic" or "carbocyclyl") as used herein, unless otherwise indicated, refers to (i) a C_3 to C_8 monocyclic, saturated or unsaturated ring or (ii) a C_7 to C_{12} bicyclic saturated or unsaturated ring system. Each ring in (ii) is either independent of, or fused to, the other ring, and each ring is saturated or unsaturated. The carbocycle may be attached to the rest of the molecule at any carbon atom which results in a stable compound. The fused bicyclic carbocycles are a subset of the carbocycles; i.e., the term "fused bicyclic carbocycle" generally refers to a C_7 to C_{10} bicyclic ring system in which each ring is saturated or unsaturated and two adjacent carbon atoms are shared by each of the rings in the ring system. A fused bicyclic carbocycle in which one ring is saturated and the other is saturated is a saturated bicyclic ring system. A fused bicyclic carbocycle in which one ring is benzene and the other is saturated is an unsaturated bicyclic ring system. A fused bicyclic carbocycle in which one ring is benzene and the other is unsaturated is an unsaturated ring system. Saturated carbocyclic rings are also referred to as cycloalkyl rings, e.g., cyclopropyl, cyclobutyl, etc. Unless otherwise noted, carbocycle is unsubstituted or substituted with C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkynyl, aryl, halogen, NH_2 or OH. A subset of the fused bicyclic unsaturated carbocycles are those bicyclic carbocycles in which one ring is a benzene ring and the other ring is saturated or unsaturated, with attachment via any carbon atom that results in a stable compound. Representative examples of this subset include the following:



"Cyanoalkyl" refers to an alkyl group as described above in which one hydrogen atom has been replaced by a cyano group. Examples include CH_2CN, CH_2CH_2CN and $CH(CN)CH_3$.

"Cycloalkyl" means a carbocyclic ring system having 3 to 12 ring carbon atoms; said ring system may be (a) a monocyclic saturated carbocycle optionally fused to a benzene or a partially unsaturated carbocycle, or (b) a bicyclic saturated carbocycle. For a bicyclic system,

within either (a) or (b), the rings are fused across two adjacent ring carbon atoms (e.g., decalin), at one ring carbon atom (e.g., spiro[2.2]pentane), or are bridged groups (e.g., norbornane). Additional examples within the above meaning include, but are not limited to, cyclopropane, cyclobutane, cyclopentane, cyclohexane, perhydroindan, decalin, spiro[4.5]decane, bicyclo[2.2.2]octane, and the like.

"Haloalkyl" refers to an alkyl group as described above wherein one or more (in particular 1 to 5) hydrogen atoms have been replaced by halogen atoms, with up to complete substitution of all hydrogen atoms with halo groups. C_{1-6}haloalkyl, for example, includes $-CF_3$, $-CF_2CF_3$, $CHFCH_3$, and the like.

"Heterocycle", "heterocyclic" or "heterocyclyl" represents a monocyclic or bicyclic 3-12 membered ring system in which at least one ring is non-aromatic (saturated or partially unsaturated) and containing at least one heteroatom selected from O, S and N. In a bicyclic ring system, the second ring may be a heteroaryl, heterocycle or a saturated, partially unsaturated or aromatic carbocycle, and the point(s) of attachment to the rest of the molecule may be on either ring. "Heterocyclyl" therefore includes heteroaryls, as well as dihydro and tetrathydro analogs thereof. Attachment of a heterocyclyl substituent can occur via a carbon atom or via a heteroatom.

Examples of heterocycles (heterocyclyl) include, but are not limited to, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, dihydroimidazolyl, dihydroindolyl, 1,2,3,4-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine, 2,3-dihydrobenzofuranyl, benzo-1,4-dioxanyl, benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridinyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, aziridinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof.

Saturated heterocyclics form a subset of the heterocycles; i.e., the terms "saturated heterocyclic and (C_{3-12})heterocycloalkyl" generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is saturated. The term "saturated heterocyclic ring" refers to a 4- to 8-membered saturated monocyclic ring or a stable 7- to 12-membered bicyclic ring system which consists of carbon atoms and one or more heteroatoms selected from N, O and S. Representative examples include piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl (or tetrahydrofuranyl)

Heteroaromatics form another subset of the heterocycles; i.e., the term "heteroaromatic" (alternatively “heteroaryl”) generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is an aromatic ring system. The term "heteroaromatic ring" refers a 5- or 6-membered monocyclic aromatic ring or a 7- to 12-membered bicyclic which consists of carbon atoms and one or more heteroatoms selected from N, O and S. For a bicyclic heteroaryl only one of the rings need to be heteroaromatic, the second ring may be a heteroaromatic or an aromatic, saturated, or partially unsatuated carbocycle, and the point(s) of attachment to the rest of the molecule may be on either ring. In the case of substituted heteroaryl rings containing at least one nitrogen atom (e.g., pyridine), such substitutions can be those resulting in N-oxide formation. Examples of heteroaryl include, but are not limited to, furanyl, thienyl (or thiophenyl), pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, isoquinolinyl, naphthyridinyl, benzothienyl, benzofuranyl, benzimidazole, benzpyrazolyl, indolyl, isoindolyl, indolizinyl, indazolyl, purinyl, quinolizinyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzoxazolyl, benzisoxazolyl, 5,6,7,8-tetrahydroquinolinyl, imidazo[1,2-*a*]pyridinyl, imidazo[1,2-*a*]-pyrimidinyl, 5,6-dihydropyrrolo[1,2-*b*]pyrazolyl, pyrrolo[3,2-*c*]pyridinyl, pyrrolo[2,3-*b*]pyridinyl, thieno[2,3-*b*]pyrrolyl, furopyridine and thienopyridine.

Representative examples of bicyclic heterocycles include benzotriazolyl, indolyl, isoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzo-1,4-dioxinyl (i.e., ), imidazo(2,1-b)(1,3)thiazole, (i.e., ), and benzo-1,3-dioxolyl (i.e., ). In certain contexts herein,  is alternatively referred to as phenyl having as a substituent methylenedioxy attached to two adjacent carbon atoms.

Non-limiting examples of substituted heteroaryls include: isoindolinone, isoindolin-1-one, 2,3-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-4(5*H*)-one, 2,3,4,5-tetrahydrobenzo[*d*]isothiazole 1,1-dioxide, and 2,3,4,5-tetrahydrobenzo[*b*]thiophene 1,1-dioxide.

"Hydroxyalkyl" refers to an alkyl group as described above in which one or more (in particular 1 to 3) hydrogen atoms have been replaced by hydroxy groups. Examples include CH_2OH, CH_2CHOH and $CHOHCH_3$.

"Alkylene," "alkenylene," "alkynylene," "cycloalkylene," "arylene," "heteroarylene," and "heterocyclylene" refer to a divalent radical obtained by the removal of one hydrogen atom from an alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl group, respectively, each of which is as defined above.

Unless expressly stated to the contrary, an "unsaturated" ring is a partially or fully unsaturated ring. For example, an "unsaturated monocyclic C_6 carbocycle" refers to cyclohexene, cyclohexadiene, and benzene.

Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heterocycle described as containing from "1 to 4 heteroatoms" means the heterocycle can contain 1, 2, 3 or 4 heteroatoms.

When any variable occurs more than one time in any constituent or in any formula depicting and describing compounds of the invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

The term "sulfamoyl" is a suffix to denote radicals derived from sulfamide such as $-SO_2NH_2$, and $-SO_2N(RR^1)$.

The term "substituted" (e.g., as in "aryl which is optionally substituted with one or more substituents ...") includes mono- and poly-substitution by a named substituent to the extent such single and multiple substitution (including multiple substitution at the same site) is chemically allowed.

The term "oxy" means an oxygen (O) atom. The term "thio" means a sulfur (S) atom. The term "oxo" means "=O". The term "carbonyl" means "C=O."

When any variable (e.g., R^2, R^3, etc.) occurs more than one time in any substituent or in formula I or formula II its definition in each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

Under standard nomenclature used throughout this disclosure, the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment. For example, a C_{1-5} alkylcarbonylamino C_{1-6} alkyl substituent is equivalent to 

.

In choosing compounds of the present invention, one of ordinary skill in the art will recognize that the various substituents, i.e. R^1, R^2, R^3, etc., are to be chosen in conformity with well-known principles of chemical structure connectivity.

Lines drawn into the ring systems from substituents indicate that the indicated bond can be attached to any of the substitutable ring atoms. If the ring system is polycyclic, it is intended that the bond be attached to any of the suitable carbon atoms on the proximal ring only.

It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups can be on the same carbon or on different carbons, so long as a stable structure results. The phrase "optionally substituted with one or more substituents" should be taken to be equivalent to the phrase "optionally substituted with at least one substituent" and in such cases one embodiment will have from zero to three substituents.

Structural representations of compounds having substituents terminating with a methyl group may display the terminal methyl group either using the characters "CH_3", e.g. "-CH_3" or using a straight line representing the presence of the methyl group, e.g. "——", i.e., "§——CH_3" and "§——" have equivalent meanings.

For variable definitions containing terms having repeated terms, e.g., $(CR^iR^j)_r$, where r is the integer 2, R^i is a defined variable, and R^j is a defined variable, the value of R^i may differ in each instance in which it occurs, and the value of R^j may differ in each instance in which it occurs. For example, if R^i and R^j are independently selected from the group consisting of methyl, ethyl, propyl and butyl, then $(CR^iR^j)_2$ can be



.

"Patient" includes both human and animals.

"Mammal" means humans and other mammalian animals.

"Therapeutically effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.

The term "treatment" or "treating" includes alleviating, ameliorating, relieving or otherwise reducing the signs and symptoms associated with a disease or disorder.

The term "composition", as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of formula I or II, and pharmaceutically acceptable excipients.

The term "optionally substituted" means "unsubstituted or substituted," and therefore, the generic structural formulas described herein encompasses compounds containing the specified optional substituent as well as compounds that do not contain the optional substituent.

Each variable is independently defined each time it occurs within the generic structural formula definitions. For example, when there is more than one substituent for aryl/heteroaryl, each substituent is independently selected at each occurrence, and each substituent can be the same or different from the other(s). As another example, for the group $-(CR^3R^3)_2-$, each occurrence of the two R^3 groups may be the same or different. As used herein, unless explicitly stated to the contrary, each reference to a specific compound of the present invention or a generic formula of compounds of the present invention is intended to include the compound(s) as well as pharmaceutically acceptable salts thereof.

In one embodiment of the invention, A is selected from phenyl, pyridinyl, 2,3-dihydro-1*H*-isoindolyl, thiochromanenyl, 2,3-dihydro-1,2-benzisothiazolyl, 2,3 dihydro-1-benzothiophenyl, and 2,3-dihydro-1*H*-indenyl.

In an embodiment of the invention, R^1 is selected from: halogen, Oxo (=O), C_{1-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{1-10} heteroalkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, aryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{3-8} cycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, heteroaryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, (C_{3-8})heterocycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl, heteroaryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl, C_{0-10} alkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, heteroaryl C_{0-10} alkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{0-10} alkylsulfonylC_{0-10} alkyl, (C_{3-8})cycloheteroalkylC_{0-10}alkylsulfonylC_{0-10} alkyl, C_{1-10} alkylsulfamoylC_{0-10} alkyl, (C_{3-8})cycloalkylC_{0-10} alkylsulfamoylC_{0-10} alkyl, (C_{3-8})cycloheteroalkylC_{0-10}alkylsulfamoylC_{0-10}alkyl, arylC_{0-10} alkylsulfamoylC_{0-10} alkyl, -(C_{0-10} alkyl)CO_2H, $-SO_2NH_2$, $-SO_2NH(C_{1-10}$ alkyl) $-SO_2N(C_{0-10}$ alkyl)$_2$, C_{0-10} alkylsulfinylaminoC_{0-10} alkyl, -(C_{1-10} alkyl)OH, $-C_{0-10}$ alkylalkoxy, and C_{1-6}haloalkyl; wherein R^1 is optionally substituted with 1, 2, 3, or 4 R^3 substituents.

In an embodiment of the invention, R^1 is selected from: fluoro, methylsulfonyl, chloro, trifluoromethyl, trifluoromethoxy, dimethylsulfamoyl, sulfamoyl, hydroxyethyl, trifluoroethyl, pyrazolylcarbamoylmethyl, pyrazolylcarbonylaminomethyl, *tert*-butyloxycarbonylaminomethyl, aminomethyl, isopropylsulfamoyl, benzylsulfamoyl, (cyclopropylmethyl)sulfamoyl, ethylsulfomoyl, cyclohexylsulfamoyl, piperidinylsulfonyl, morpholinylsulfonyl, triazolylmethyl, pyrrolidinylcarbonyl, oxazolylcarbonylaminomethyl, pyrimidinylcarbonylaminomethyl, hydroxyethyl, 1-hydroxyethyl, morpholinylmethyl, 1-hydroxymethylethyl , hydroxy(methylpropyl), 1-hydroxy(methylpropyl), hydroxypropyl, ethylhydroxy, (*tert*-butyl)sulfinylaminomethyl, dioxolanyl, methylaminomethyl, methylcarbonylaminomethyl, (dimethylamino)methyl, pyrazolylmethyl, imidazolylmethyl, oxo, hydroxy, hydroxymethyl, methyl, *tert*-butyl, (tert-butyl)sulfinylaminomethyl, (ethyl)aminomethyl, pyrrolidinylsulfonylmethyl, trifluoroethyl, (2,2,2,-trifluoroethyl), carboxy, cyclopropylmethyl, dimethylaminomethyl, cyclopentylmethyl, methylaminoethyl, 1-(methylamino)ethyl, ethylaminomethyl, dimethylaminocarbonyl, dimethylcarbamoyl, morpholinylcarbonyl, cyclopropyl, aminoethyl, 1-aminoethyl, pyrrolidinyl, methylethyl, isobutyl, cyclopropylmethyl, methylsulfanylmethyl, 3-hydroxy(dimethylpropyl), triazolylmethyl, 3-hydroxy-2,2,-dimethylpropyl, and methoxyethyl; wherein R^1 is optionally substituted with 1, 2, 3, or 4 R^3 substituents.

In an embodiment of the invention, R^2 selected from: halogen, C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, hydroxy, (C_{3-8})heterocycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{3-8} cycloalkyl C_{0-10} alkylaminoC_{0-10} alkyl, and $(C_{0-10}$ alkyl$)_{1-2}$ amino; and wherein two R^2 may optionally join together with the ring atoms to which they are attached and form a 3 to 6 membered ring; and wherein R^2 is optionally substituted with 1, 2, 3, or 4 R^3 substituents.

In one embodiment of the invention, R^2 selected from: cyclopropylethylamino, 1-cylopropylethylamino, hydroxy, azetidinyl, dimethylamino, trifluoroethyl, methyl, ethyl; wherein two R^2 may optionally join together with the ring atoms to which they are attached and form a 3 to 6 membered ring; and wherein R^2 is optionally substituted with 1, 2, 3, or 4 R^3 substituents.

In one embodiment of the invention R^3 is independently selected from: halogen, C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, Oxo (=O), amino, hydroxy, $(C_{1-10}$ alkyl)OH,

C_{1-10}alkoxy, and C_{1-6}haloalkyl; wherein R^3 is optionally substituted with 1, 2, or 3 R^4 substituents.

In another embodiment of the invention R^3 is independently selected from: chloro, fluoro, methoxy, methyl, trifluoroethyl, hydroxymethylethyl, hydroxy, isopropyl, ethyl; wherein R^3 is optionally substituted with 1, 2, or 3 R^4 substituents.

In one embodiment of the invention, R^4 is independently selected from hydrogen, hydroxy, (C_{1-6})alkyl, (C_{1-6})alkoxy, $(C_{1-10}$ alkyl)OH, halogen, $-O(C=O)C_1-C_6$ alkyl, trifluoromethoxy, trifluoroethoxy, trifluoromethyl, trifluoroethyl, oxo (O=), $-O_{(0-1)}(C_{1-10})$haloalkyl, amino$(C_{1-6}$alkyl$)_{0-2}$ and NH_2.

In another embodiment of the invention, R^4 is independently selected from hydrogen, hydroxy, methyl, oxo, trifluoromethyl, methoxy,1-hydroxy-1-methylethyl, amino, methoxyethyl, difluoromethyl, dimethylamino, ethyl, and NH_2.

In one embodiment of the invention, n is 0, 1, 2, 3 or 4. In one embodiment of the invention, n is 0, 1, 2, or 3. In a variant of this embodiment, n is 0, 1, or 2.

In one embodiment of the invention, m is 0, 1, 2, 3 or 4. In one embodiment of the invention, m is 0, 1, 2, or 3. In a variant of this embodiment, m is 0, 1, or 2.

In one embodiment of the invention, p is 0, 1, 2, or 3. In a variant of this embodiment, p is 1, 2, or 3.

In one embodiment, the present invention is selected from compounds of formula II or pharmaceutically acceptable salts, or stereoisomers thereof:



II

A is selected from aryl and heteroaryl;
n is 0 or 1;
m is 0, 1, 2, or 3;
p is 0, 1, 2, 3, or 4;

R^{1a} is selected from:
halogen,
Oxo (=O),
C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
(C_{1-10})heteroalkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10}alkyl,
C_{0-10} alkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
$(C_{0-10}$ alkyl$)_{1-2}$ amino,
hydroxy,
-$(C_{1-10}$ alkyl)OH,
-C_{0-10} alkylalkoxy, and
C_{1-6}haloalkyl;

R^{2a} is selected from:
halogen,
Oxo (=O),
C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{0-10} alkylaminoC_{0-10} alkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkylaminoC_{0-10} alkyl,
$(C_{0-10}$ alkyl$)_{1-2}$ amino,
-$CO_2(C_{0-10}$ alkyl),
-$(C_{0-10}$ alkyl)CO_2H,
hydroxy,
-$(C_{1-10}$ alkyl)OH,
-C_{0-10} alkylalkoxy, and
C_{1-6}haloalkyl, wherein two R^{2a} may optionally join together with the ring atoms to which they are attached and form a 3 to 6 membered ring;

wherein R^{1a} and R^{2a} are independently optionally substituted with 1, 2, 3, or 4 R^{3a} substituents;

R^{3a} is independently selected from:
halogen,
C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, and
C_{1-10} heteroalkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
Oxo (=O),
hydroxy,
$(C_{1-10}$ alkyl)OH,
C_{1-10} alkoxy, and
C_{1-6}haloalkyl;

R^{3a} is optionally substituted with 1, 2, or 3 R^{4a} substituents selected from hydrogen, hydroxy, (C_{1-6})alkyl, (C_{1-6})alkoxy, $(C_{1-10}$ alkyl)OH, halogen, CO_2H, -(C_{0-6})alkylCN,

-O(C=O)C_1-C_6 alkyl, NO_2, trifluoromethoxy, trifluoroethoxy, trifluoromethyl, trifluoroethyl, -N-C(O)O(C_{0-6})alkyl, C_{1-10} alkylsulfonyl, oxo (O=), aminosulfonyl, -SO_2NH_2, -$SO_2NH(C_{1-10}$ alkyl), -$SO_2N(C_{0-10}$ alkyl)$_2$,-SO_2C_{1-6}alkyl, -SO_2CF_3, -SO_2CF_2H, -C_{1-10} alkylsulfinyl, -$O_{(0-1)}(C_{1-10})$haloalkyl, amino(C_{1-6}alkyl)$_{0-2}$ and NH_2;

R^{1b} is selected from:

hydrogen,

halogen,

Oxo (=O),

C_{1-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{1-10} heteroalkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{2-10} alkenyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

aryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{3-8} cycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

heteroaryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

(C_{3-8})heterocycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,

(C_{1-10})heteroalkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,

C_{3-8} cycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,

aryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,

heteroaryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,

(C_{3-8})heterocycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,

C_{0-10} alkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

(C_{1-10})heteroalkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{3-8} cycloalkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

aryl C_{0-10} alkylaminoamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

heteroaryl C_{0-10} alkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

(C_{3-8})heterocycloalkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{0-10} alkylsulfonylC_{0-10} alkyl,

C_{1-10} heteroalkylsulfonylC_{0-10} alkyl,

(C_{3-8})cycloalkylC_{0-10}alkylsulfonylC_{0-10} alkyl,

(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfonylC_{0-10} alkyl,

heteroarylC_{0-10} alkylsulfonylC_{0-10} alkyl,

arylC_{0-10} alkylsulfonylC_{0-10} alkyl,

C_{1-10} alkylsulfamoylC_{0-10} alkyl,

C_{1-10} heteroalkylsulfamoylC_{0-10} alkyl,

(C_{3-8})cycloalkylC_{0-10} alkylsulfamoylC_{0-10} alkyl,

(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfamoylC_{0-10} alkyl,

heteroarylC_{0-10} alkylsulfamoylC_{0-10} alkyl,

arylC_{0-10} alkylsulfamoylC_{0-10} alkyl,

$(C_{0-10}$ alkyl$)_{1-2}$ amino,

$-CO_2(C_{0-10}$ alkyl),

$-(C_{0-10}$ alkyl)CO_2H,

$-SO_2NH_2$,

$-SO_2NH(C_{1-10}$ alkyl),

$-SO_2N(C_{0-10}$ alkyl$)_2$,

$-SO_2CF_3$,

$-SO_2CF_2H$,

C_{1-10} alkylsulfinylC_{0-10} alkyl,

C_{1-10} heteroalkylsulfinylC_{0-10}alkyl,

(C_{3-8})cycloalkylC_{0-10}alkylsulfinylC_{0-10}alkyl,

(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfinylC_{0-10}alkyl,

heteroarylC_{0-10} alkylsulfinylC_{0-10}alkyl,

arylC_{0-10}alkylsulfinylC_{0-10}alkyl,

C_{0-10} alkylsulfinylaminoC_{0-10} alkyl,

C_{1-4}acylamino C_{0-10} alkyl,

hydroxy,

$-(C_{1-10}$ alkyl)OH,

$-C_{0-10}$ alkylalkoxy,

cyano,

$(C_{1-6}$alkyl)cyano, and

C_{1-6}haloalkyl;

R^{2b} is selected from:

hydrogen,

halogen,

Oxo (=O),

C_{1-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{3-8} cycloalkyl,

(C_{3-8})heterocycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{0-10} alkylaminoC_{0-10} alkyl,

(C_{1-10})heteroalkylaminoC_{0-10}alkyl,

C_{3-8} cycloalkyl C_{0-10} alkylaminoC_{0-10} alkyl,

aryl C_{0-10} alkylaminoC_{0-10} alkyl,

heteroaryl C_{0-10} alkylaminoC_{0-10} alkyl,

(C_{3-8})heterocycloalkyl C_{0-10} alkylaminoC_{0-10} alkyl,

C_{1-10} alkylsulfonyl,

(C_{3-8})cycloalkylC_{0-10}alkylsulfonyl,

(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfonyl,

(C_{0-10} alkyl)$_{1-2}$ amino,

-CO_2(C_{0-10} alkyl),

-(C_{0-10} alkyl)CO_2H,

-SO_2CF_3,

-SO_2CF_2H,

C_{1-10} alkylsulfinyl,

hydroxy,

-(C_{1-10} alkyl)OH,

-C_{0-10} alkylalkoxy,

cyano,

(C_{1-6}alkyl)cyano, and

C_{1-6}haloalkyl; wherein R^{1b} and R^{2b} are each optionally substituted with 1, 2, or 3 R^3 substituents;

R^3 is independently selected from: halogen, C_{1-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, Oxo (=O), amino, hydroxy, (C_{1-10} alkyl)OH, C_{1-10}alkoxy, and C_{1-6}haloalkyl; wherein R^3 is optionally substituted with 1, 2, or 3 R^4 substituents; and

R^4 is independently selected from hydrogen, hydroxy, (C_{1-6})alkyl, (C_{1-6})alkoxy, (C_{1-10} alkyl)OH, halogen, -O(C=O)C_1-C_6 alkyl, trifluoromethoxy, trifluoroethoxy, trifluoromethyl, trifluoroethyl, oxo (O=), -O$_{(0-1)}$(C_{1-10})haloalkyl, amino(C_{1-6}alkyl)$_{0-2}$ and NH_2.

In an embodiment of this invention of formula II, R^{1b} is selected from: hydrogen, halogen, Oxo (=O), C_{1-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{1-10} heteroalkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, aryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{3-8} cycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, heteroaryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, (C_{3-8})heterocycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC$_{0-10}$ alkyl, heteroaryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC$_{0-10}$ alkyl, C_{0-10} alkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, heteroaryl C_{0-10} alkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{0-10} alkylsulfonylC$_{0-10}$ alkyl, (C_{3-8})cycloheteroalkylC$_{0-10}$alkylsulfonylC$_{0-10}$ alkyl, C_{1-10} alkylsulfamoylC$_{0-10}$ alkyl, (C_{3-8})cycloalkylC$_{0-10}$ alkylsulfamoylC$_{0-10}$ alkyl, (C_{3-8})cycloheteroalkylC$_{0-10}$alkylsulfamoylC$_{0-10}$alkyl, arylC$_{0-10}$ alkylsulfamoylC$_{0-10}$ alkyl, -(C_{0-10} alkyl)CO_2H, -SO_2NH_2, -SO_2NH(C_{1-10} alkyl), -SO_2N(C_{0-10} alkyl)$_2$, C_{0-10} alkylsulfinylaminoC$_{0-10}$ alkyl, -(C_{1-10} alkyl)OH, -C_{0-10} alkylalkoxy, and C_{1-6}haloalkyl; wherein R^{1b} is optionally substituted with 1, 2, or 3 R^3 substituents.

In one embodiment, R^{1b} is selected from: fluoro, methylsulfonyl, chloro, trifluoromethyl, trifluoromethoxy, dimethylsulfamoyl, sulfamoyl, hydroxyethyl, trifluoroethyl, pyrazolylcarbamoylmethyl, pyrazolylcarbonylaminomethyl, *tert*-butyloxycarbonylaminomethyl, aminomethyl, isopropylsulfamoyl, benzylsulfamoyl, (cyclopropylmethyl)sulfamoyl, ethylsulfomoyl, cyclohexylsulfamoyl, piperidinylsulfonyl, morpholinylsulfonyl, triazolylmethyl, pyrrolidinylcarbonyl, oxazolylcarbonylaminomethyl, pyrimidinylcarbonylaminomethyl, hydroxyethyl, 1-hydroxyethyl, morpholinylmethyl, 1-hydroxymethylethyl , hydroxy(methylpropyl), 1-hydroxy(methylpropyl), hydroxypropyl, ethylhydroxy, (*tert*-butyl)sulfinylaminomethyl, dioxolanyl, methylaminomethyl, methylcarbonylaminomethyl, (dimethylamino)methyl, pyrazolylmethyl, imidazolylmethyl, oxo, hydroxy, hydroxymethyl, methyl, *tert*-butyl, (tert-butyl)sulfinylaminomethyl,

(ethyl)aminomethyl, pyrrolidinylsulfonylmethyl, trifluoroethyl, (2,2,2,-trifluoroethyl), carboxy, cyclopropylmethyl, dimethylaminomethyl, cyclopentylmethyl, methylaminoethyl, 1-(methylamino)ethyl, ethylaminomethyl, dimethylaminocarbonyl, dimethylcarbamoyl, morpholinylcarbonyl, cyclopropyl, aminoethyl, 1-aminoethyl, pyrrolidinyl, methylethyl, isobutyl, cyclopropylmethyl, methylsulfanylmethyl, 3-hydroxy(dimethylpropyl), triazolylmethyl, 3-hydroxy-2,2,-dimethylpropyl, and methoxyethyl; wherein R^{1b} is optionally substituted with 1, 2, 3, or 4 R^3 substituents.

In another embodiment of the invention, R^{2b} is selected from: hydrogen, halogen, C_{1-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, (C_{3-8})heterocycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{3-8} cycloalkyl C_{0-10} alkylaminoC_{0-10} alkyl, and (C_{0-10} alkyl)$_{1-2}$ amino; wherein R^{2b} is optionally substituted with 1, 2, or 3 R^3 substituents.

In one embodiment of the invention, R^{2b} selected from: cyclopropylethylamino, 1-cylopropylethylamino, hydroxy, azetidinyl, dimethylamino, trifluoroethyl, methyl, ethyl; and wherein R^{2b} is optionally substituted with 1, 2, 3, or 4 R^3 substituents.

In one embodiment of the invention R^{3a} is chosen from oxo, methyl, fluoro, trifluoromethyl, hydroxymethyl, hydroxy, ethyl, cyclopropyl, (methylsulfanyl)methyl, hydroxypropyl, hydroxyethyl, methoxyethyl, Cl, aminomethyl, difluoromethyl, and (methylcarbonyl)aminomethyl.

In one embodiment of the invention, R^{4a} is selected from hydrogen, hydroxy, methyl, oxo, trifluoromethyl, methoxy,1-hydroxy-1-methylethyl, amino, methoxyethyl, difluoromethyl, dimethylamino, and ethyl.

Optical Isomers - Diastereomers - Geometric Isomers – Tautomers

Compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of the present invention, either as single species or mixtures thereof.

Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixture thereof are encompassed with compounds of formula I or formula II.

Specific embodiments of the present invention include a compound which is selected from the group consisting of the subject compounds of the Examples herein or a pharmaceutically acceptable salt thereof.

The compounds of the present invention may contain one or more asymmetric centers and can thus occur as "stereoisomers" including racemates and racemic mixtures, enantiomeric mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the scope of this invention. The present invention is meant to comprehend all such isomeric forms of these compounds. When bonds to the chiral carbon are depicted as straight lines in the Formulas of the invention, it is understood that both the (R) and (S) configurations of the chiral carbon, and hence both enantiomers and mixtures thereof, are embraced within the Formula. For example, Formula I shows the structure of the class of compounds without specific stereochemistry. When the compounds of the present invention contain one chiral center, the term "stereoisomer" includes both enantiomers and mixtures of enantiomers, such as the specific 50:50 mixture referred to as racemic mixtures.

The compounds of the present invention may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.

Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual

diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC column.

It is also possible that the compounds of Formula (I) may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.

All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). (For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.) Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the *IUPAC* 1974 Recommendations. The use of the terms "salt", "solvate", “ester”, "prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.

In the present application when a particular stereomeric compound is named using an "and" in the stereomeric designation, for example, *tert*-butyl (3R,4S and 3S,4R)-4-(cyanomethyl)-3-methyl-4-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl)piperidine-1-carboxylate, the "and" indicates a racemic mixture of the enantiomers. That is, the individual enantiomers were not individually isolated.

When the stereomeric nomenclature includes "or", for example, *tert*-butyl 4-(cyanomethyl)-4-[4-oxo-3-({4-[(1*R* or 1*S*)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}amino)-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl]piperidine-1-carboxylate, the "or" indicates that chiral resolution of racemate into individual enantiomers was accomplished but the actual optical activity of the specific enantiomer was not nessissarily determined.

The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration. If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography. The coupling reaction is often the formation of salts using an enantiomerically pure acid or base. The diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue. The racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art. Alternatively, any enantiomer of a compound can be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.

Salts

The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, *N,N'*-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, *N*-ethyl-morpholine, *N*-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-

toluenesulfonic acid, 1-hydroxy-2-naphthoic acid (xinafoate) and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

It will be understood that, unless otherwise specified, references to the compound of formula I subsets thereof, embodiments thereof, as well as specific compounds are meant to also include the pharmaceutically acceptable salts and stereoisomers thereof.

Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such all forms are intended to be included in the present invention. In addition, some of the compounds of the instant invention may form solvates with water (hydrates) or common organic solvents. Such solvates are encompassed within the scope of this invention.

Labelled Compounds

In the compounds of generic Formula I, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I. For example, different isotopic forms of hydrogen (H) include protium (^{1}H) and deuterium (^{2}H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing *in vivo* half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within generic Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.

Utilities

Compound of formula I or its pharmaceutically acceptable salts and pharmaceutical compositions can be used to treat or prevent a variety of conditions or diseases mediated by Janus kinases, in particular diseases or conditions that can be ameliorated by the inhibition of a Janus kinase such as JAK1, JAK2, JAK3 or TYK2. Such conditions and diseases include, but are not limited to:

(1) arthritis, including rheumatoid arthritis, juvenile arthritis, and psoriatic arthritis; (2) asthma and other obstructive airways diseases, including chronic asthma, late asthma, airway hyper-responsiveness, bronchitis, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, recurrent airway obstruction, and chronic obstruction pulmonary disease including emphysema; (3) autoimmune diseases or disorders, including those designated as single organ or

single cell-type autoimmune disorders, for example Hashimoto's thyroiditis, autoimmune hemolytic anemia, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, autoimmune thrombocytopenia, sympathetic ophthalmia, myasthenia gravis, Graves' disease, primary biliary cirrhosis, chronic aggressive hepatitis, ulcerative colitis and membranous glomerulopathy, those designated as involving systemic autoimmune disorder, for example systemic lupus erythematosis, rheumatoid arthritis, Sjogren's syndrome, Reiter's syndrome, polymyositis-dermatomyositis, systemic sclerosis, polyarteritis nodosa, multiple sclerosis and bullous pemphigoid, and additional autoimmune diseases, which can be B-cell (humoral) based or T-cell based, including Cogan's syndrome, ankylosing spondylitis, Wegener's granulomatosis, autoimmune alopecia, Type I or juvenile onset diabetes, and thyroiditis; (4) cancers or tumors, including alimentary/gastro-intestinal tract cancer, colon cancer, liver cancer, skin cancer including mast cell tumor and squamous cell carcinoma, breast and mammary cancer, ovarian cancer, prostate cancer, lymphoma, leukemia, including acute myelogenous leukemia and chronic myelogenous leukemia, kidney cancer, lung cancer, muscle cancer, bone cancer, bladder cancer, brain cancer, melanoma including oral and metastatic melanoma, Kaposi's sarcoma, myelomas including multiple myeloma, myeloproliferative disorders, proliferative diabetic retinopathy, and angiogenic-associated disorders including solid tumors; (5) diabetes, including Type I diabetes and complications from diabetes; (6) eye diseases, disorders or conditions including autoimmune diseases of the eye, keratoconjunctivitis, vernal conjunctivitis, uveitis including uveitis associated with Behcet's disease and lens-induced uveitis, keratitis, herpetic keratitis, conical keratitis, corneal epithelial dystrophy, keratoleukoma, ocular premphigus, Mooren's ulcer, scleritis, Grave's ophthalmopathy, Vogt-Koyanagi-Harada syndrome, keratoconjunctivitis sicca (dry eye), phlyctenule, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, sympathetic ophthalmitis, allergic conjunctivitis, and ocular neovascularization; (7) intestinal inflammations, allergies or conditions including Crohn's disease and/or ulcerative colitis, inflammatory bowel disease, coeliac diseases, proctitis, eosinophilic gastroenteritis, and mastocytosis; (8) neurodegenerative diseases including motor neuron disease, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia, or neurodegenerative disease caused by traumatic injury, strike, glutamate neurotoxicity or hypoxia; ischemic/reperfusion injury in stroke, myocardial ischemica, renal ischemia, heart attacks, cardiac hypertrophy, atherosclerosis and arteriosclerosis, organ hypoxia, and platelet aggregation; (9) skin diseases, conditions or disorders including atopic dermatitis, eczema, psoriasis, scleroderma, pruritus and other pruritic conditions; (10) allergic reactions including anaphylaxis, allergic rhinitis, allergic dermatitis, allergic urticaria, angioedema, allergic asthma, or allergic reaction to insect bites, food, drugs, or pollen; (11) transplant rejection, including pancreas islet transplant rejection, bone marrow transplant rejection, graft- versus-host disease, organ and cell

transplant rejection such as bone marrow, cartilage, cornea, heart, intervertebral disc, islet, kidney, limb, liver, lung, muscle, myoblast, nerve, pancreas, skin, small intestine, or trachea, and xeno transplantation.

Accordingly, another aspect of the present invention provides a method for the treatment or prevention of a JAK-mediated disease or disorder comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of formula I. In one embodiment such diseases include asthma and rheumatoid arthritis.

Another aspect of the present invention provides for the use of a compound of formula I in the manufacture of a medicament for the treatment or prevention of a JAK-mediated diseases or disorder.

One aspect of the invention is the use of a compound of Formula I or a pharmaceutically acceptable salt or a stereoisomer thereof in the manufacture of a medicament for the treatment of a disease or a disorder ameliorated by selective inhibition of Janus kinases JAK1 and JAK2.

Another aspect of the invention is the use of a compound of Formula I or a pharmaceutically acceptable salt or a stereoisomer thereof and a second active agent in the manufacture of a medicament for the treatment of a disease or a disorder ameliorated by selective inhibition of Janus kinases JAK1 and JAK2.

Dose Ranges

The magnitude of prophylactic or therapeutic dose of a compound of formula I will, of course, vary with the nature and the severity of the condition to be treated and with the particular compound of formula I and its route of administration. It will also vary according to a variety of factors including the age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination and response of the individual patient. In general, the daily dose from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to about 10 mg per kg. On the other hand, it may be necessary to use dosages outside these limits in some cases.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.05 mg to 5 g, of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 99.95 percent of the total composition. In some cases, the dosage unit forms may contain from about 0.05 to about 3g of active ingredient. Dosage unit forms will generally contain between from about 0.1 mg to about 0.4 g of an active ingredient, typically 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, or 400 mg.

Pharmaceutical Compositions

Another aspect of the present invention provides pharmaceutical compositions comprising a compound of formula I with a pharmaceutically acceptable carrier. For the treatment of any of the prostanoid mediated diseases compounds of formula I may be administered orally, by inhalation spray, topically, parenterally or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose,

sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsion. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may

also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Dosage forms for inhaled administration may conveniently be formulated as aerosols or dry powders. For compositions suitable and/or adapted for inhaled administration, it is preferred that the active substance is in a particle-size-reduced form, and more preferably the size-reduced form is obtained or obtainable by micronization.

In one embodiment the medicinal preparation is adapted for use with a pressurized metered dose inhaler (pMDI) which releases a metered dose of medicine upon each actuation. The formulation for pMDIs can be in the form of solutions or suspensions in halogenated hydrocarbon propellants. The type of propellant being used in pMDIs is being shifted to hydrofluoroalkanes (HFAs), also known as hydrofluorocarbons (HFCs). In particular, 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) are used in several currently marketed pharmaceutical inhalation products. The composition may include other pharmaceutically acceptable excipients for inhalation use such as ethanol, oleic acid, polyvinylpyrrolidone and the like.

Pressurized MDIs typically have two components. Firstly, there is a canister component in which the drug particles are stored under pressure in a suspension or solution form. Secondly, there is a receptacle component used to hold and actuate the canister. Typically, a canister will contain multiple doses of the formulation, although it is possible to have single dose canisters as well. The canister component typically includes a valve outlet from which the contents of the canister can be discharged. Aerosol medication is dispensed from the pMDI by applying a force on the canister component to push it into the receptacle component thereby opening the valve outlet and causing the medication particles to be conveyed from the valve outlet through the receptacle component and discharged from an outlet of the receptacle. Upon discharge from the canister, the medication particles are "atomized", forming an aerosol. It is intended that the patient coordinate the discharge of aerosolized medication with his or her inhalation, so that the medication particles are entrained in the patient's aspiratory flow and conveyed to the lungs. Typically, pMDIs use propellants to pressurize the contents of the canister and to propel the medication particles out of the outlet of the receptacle component. In pMDIs, the formulation is provided in a liquid or suspension form, and resides within the container along with the propellant. The propellant can take a variety of forms. For example, the propellant can comprise a compressed gas or liquefied gas.

In another embodiment the medicinal preparation is adapted for use with a dry powder inhaler (DPI). The inhalation composition suitable for use in DPIs typically comprises particles of the active ingredient and particles of a pharmaceutically acceptable carrier. The particle size of the active material may vary from about 0.1 μm to about 10 μm; however, for effective delivery to the distal lung, at least 95 percent of the active agent particles are 5 μm or smaller. Each of the active agent can be present in a concentration of 0.01 - 99%. Typically however, each of the active agents is present in a concentration of about 0.05 to 50%, more typically about 0.2 - 20% of the total weight of the composition.

As noted above, in addition to the active ingredients, the inhalable powder preferably includes pharmaceutically acceptable carrier, which may be composed of any pharmacologically inert material or combination of materials which is acceptable for inhalation. Advantageously, the carrier particles are composed of one or more crystalline sugars; the carrier particles may be composed of one or more sugar alcohols or polyols. Preferably, the carrier particles are particles of dextrose or lactose, especially lactose. In embodiments of the present invention which utilize conventional dry powder inhalers, such as the Handihaler, Rotohaler, Diskhaler, Twisthaler and Turbohaler, the particle size of the carrier particles may range from about 10 microns to about 1000 microns. In certain of these embodiments, the particle size of the carrier particles may range from about 20 microns to about 120 microns. In certain other embodiments, the size of at least 90% by weight of the carrier particles is less than 1000 microns and preferably lies between 60 microns and 1000 microns. The relatively large size of these carrier particles gives good flow and entrainment characteristics. Where present, the amount of carrier particles will generally be up to 95%, for example, up to 90%, advantageously up to 80% and preferably up to 50% by weight based on the total weight of the powder. The amount of any fine excipient material, if present, may be up to 50% and advantageously up to 30%, especially up to 20%, by weight, based on the total weight of the powder. The powder may optionally contain a performance modifier such as L-leucine or another amino acid, and/or metals salts of stearic acid such as magnesium or calcium stearate.

Compounds of formula I may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ambient temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the compound of formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.) Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.

Combinations with Other Drugs

For the treatment and prevention of JAK mediated diseases, compound of formula I may be co-administered with other therapeutic agents. Thus in another aspect the present invention provides pharmaceutical compositions for treating JAK mediated diseases comprising a therapeutically effective amount of a compound of formula I and one or more other therapeutic agents. In particular, for the treatment of the inflammatory diseases rheumatoid arthritis, psoriasis, inflammatory bowel disease, COPD, asthma and allergic rhinitis a compound of formula I may be combined with agents such as: (1) TNF-α inhibitors such as Remicade® and Enbrel®); (2) non-selective COX-I/COX-2 inhibitors (such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin); (3) COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib and etoricoxib); (4) other agents for treatment of rheumatoid arthritis including low dose methotrexate, lefunomide, ciclesonide, hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold; (5) leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as zileuton; (6) LTD4 receptor antagonist such as zafirlukast, montelukast and pranlukast; (7) PDE4 inhibitor such as roflumilast; (8) antihistaminic H1 receptor antagonists such as cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine, and chlorpheniramine; (9) α1- and α2-adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, and ethylnorepinephrine hydrochloride; (10) anticholinergic agents such as ipratropium bromide, tiotropium bromide, oxitropium bromide, aclindinium bromide, glycopyrrolate, pirenzepine, and telenzepine; (11) β-adrenoceptor agonists such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol, or methylxanthanines including theophylline and aminophylline, sodium cromoglycate; (12) insulin-like growth factor type I (IGF-l) mimetic; (13) inhaled glucocorticoid with reduced systemic side effects, such as prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide and mometasone furoate.

METHODS OF SYNTHESIS

SCHEMES AND EXAMPLES

The abbreviations used herein have the following tabulated meanings. Abbreviations not tabulated below have their meanings as commonly used unless specifically stated otherwise.

ACN	acetonitrile
MeCN	acetonitrile
BAST	bis(2-methoxyethyl)aminosulfur trifluoride
Chiral SFC	chiral super critical fluid chromatography
CO_2	carbon dioxide
Cs_2CO_3	cesium carbonate
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene
DCE	1,2-dichloroethane
DCM	dichloromethane
DIPEA	N,N-diisopropylethylamine
DMF	N,N-dimethylformamide
DMSO	dimethyl sulfoxide
DSC	N,N-disuccinimidyl carbonate
EDC	3-(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine
EtOAc	ethyl acetate
HATU	O-(7-aza-1*H*-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
hr or h	hour
HCl	hydrogen chloride
HOBt	1-hydroxybenzotriazole
HPLC	high pressure liquid chromatography
IPA	2-propanol
LDA	lithium diisopropylamide
m-CPBA	meta-chloroperoxybenzoic acid
LRMS	low resolution mass spectrometry
MeI	iodomethane
Me-THF	2-methyltetrahydrofuran
MgSO4	magnesium sulfate
MP-$(OAc)_3BH$	solid supported (macro porous) triacetoxyborohydride
MPLC	medium pressure liquid chromatography
NaH	sodium hydride

Na_2SO_4	sodium sulfate
NaBH4	sodium borohydride
$NaHCO_3$	sodium bicarbonate
NaOMe	sodium methoxide
$Pd_2(dba)_3$	tris(dibenzylideneacetone)dipalladium(0)
$POCl_3$	phosphorus (V) oxychloride
Prep	preparative
PyBOP	(7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
Sat.	saturated
SEM-Cl	2-(trimethylsilyl)ethoxymethyl chloride
SiliaCat® DPP-Pd	silica bound diphenylphosphine palladium (II)
TBAF	tetra-n-butylammonium fluoride
TBS-Cl	*tert*-butyldimethylsilyl chloride
t-BuOH (*tert*-BuOH)	*tert*-butanol
TEA	triethylamine
TFA	trifluoroacetic acid
THF	tetrahydrofuran
X-Phos	2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl
Me_4-^{t}Bu-X-Phos	di-*tert*-butyl[3,4,5,6-tetramethyl-2',4',6'-tri(propan-2-yl)biphenyl-2-yl]phosphane
NMO	4-methylmorpholine N-oxide
rt or RT	Room temperature
Sat. aq.	Saturated, aqueous
TPAP	tetra-n-propylammonium perruthenate (VII)
HCOOH	formic acid
K^{t}OBu	potassium *tert*-butoxide
$Na_2S_2O_5$	sodium metabisulfite
NMR	nuclear magnetic resonance
TLC	thin layer chromatography
$(EtO)_2P(O)CH_2CN$	diethyl (cyanomethyl)phosphonate
MsCl	methanesulfonyl chloride

TsOH	p-toluenesulfonic acid
KCN	potassium cyanide
Si-DMT	silica supported Dimercaptotriazine
TMS	trimethylsilane
CF_3TMS	(trifluoromethyl)trimethylsilane
$PhI(OAc)_2$	Iodosobenzene diacetate
$Ti(OEt)_4$	Titanium (IV) ethoxide
$Ti(O\textit{i}\text{-}Pr)_4$	Titanium (IV) isopropoxide
$TMSCF_3$	trimethyl(trifluoromethyl)silane
BH_3	borane
$SOCl_2$	Thionyl chloride
LiHMDS	Lithium bis(trimethylsilyl)amide
BOC_2O	Boc-anhydride, or di-*tert*-butyl dicarbonate
$NaBH_4$	Sodium borohydride
i-PrMgCl	Isopropylmagnesium chloride
KOAc	Potassium acetate
K_3PO_4	Potassium phosphate tribasic
PG	Protecting group
IBX	2-Iodoxybenzoic acid
HNRR	A disubstituted amine
Ph_3PMeBr	Methyltriphenylphosphonium bromide
$AlCl_3$	Aluminum trichloride

Alkyl Group Abbreviations

Me	methyl
Et	ethyl
n-Pr	normal propyl
i-Pr	isopropyl
n-Bu	normal butyl
i-Bu	isobutyl
s-Bu	secondary butyl
t-Bu	tertiary butyl
c-Pr	cyclopropyl
c-Bu	cyclobutyl

c-Pen	cyclopentyl
c-Hex	cyclohexyl

METHODS OF SYNTHESIS

The compounds of the present invention can be prepared according to the following general schemes using appropriate materials, and are further exemplified by the subsequent specific examples. The compounds illustrated in the examples are not to be construed as forming the only genus that is considered as the invention. The illustrative Examples below, therefore, are not limited by the compounds listed or by any particular substituents employed for illustrative purposes. Substituent numbering as shown in the schemes does not necessarily correlate to that used in the claims and often, for clarity, a single substituent is shown attached to the compound where multiple substituents are allowed under the definitions of the instant invention herein above.

Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated:

All reactions were stirred (mechanically, stir bar/stir plate, or shaken) and conducted under an inert atmosphere of nitrogen or argon unless specifically stated otherwise.

All starting materials used to prepare the intermediates and final compounds described herein were obtained from commercial vendors, and were used as is upon receipt.

All temperatures are degrees Celsius (^{o}C) unless otherwise noted.

Ambient temperature is 15-25 ^{o}C.

Most compounds were purified by reverse-phase preparative HPLC, MPLC on silica gel, recrystallization and/or swish (suspension in a solvent followed by filtration of the solid).

The course of the reactions was followed by thin layer chromatography (TLC) and/or LCMS and/or NMR and reaction times are given for illustration only.

All end products were analyzed by NMR and LCMS. Intermediates were analyzed by NMR and/or TLC and/or LCMS.

Method 1

General procedures to prepare intermediates of the instant invention are described in Scheme 1. Using an appropriate base, such as DBU, in a suitable solvent, such as MeCN, EtOH, *n*-BuOH or *tert*-BuOH, at a temperature between 25–110 °C either protected pyrazolopyridone 1A (PG = a suitable protecting group) can undergo conjugate addition to optionally substituted nitriles 1B to yield adduct 1C, typically as a mixture of optical isomers, intermediates in the synthesis of examples of the instant invention. The isomers of intermediate 1C can be separated into its respective individual optical isomers using the appropriate chromatographic method (achiral and/or chiral). Intermediate 1C is cross coupled to substituted aryl and heteroaryl halides 1D using an appropriate catalytic palladium/ligand system, such as $Pd_2(dba)_3$ or $Pd_2(dba)_3 \cdot CHCl_3$, and 2-di-*tert*-butylphosphino-2′,4′,6′-triisopropylbiphenyl (t-Bu XPhos) or di-*tert*-butyl[3,4,5,6-tetramethyl-2',4',6'-tri(propan-2-yl)biphenyl-2-yl]phosphane (Me_4 ^{t}Bu-XPhos), or 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (XPhos). Typical conditions employ 1–2 equivalents of the aryl/heteroaryl halide relative to the pyrazolopyrimidine with 10-25% Pd precatalyst loading, using an approximate Pd:ligand ratio of 1:2 to 1:2.5. Typically, the cross coupling is carried out using either 2-propanol or *t*-amyl alcohol solvents, and between 1–3.1 equivalents of KOAc or K_3PO_4 base. Reactions were typically carried out between 65–80°C, to yield intermediates 1E of the instant invention. Intermediates 1E can be deprotected using either hydrogenolysis conditions (H_2 gas, Pd/C, in a suitable solvent such as EtOAc, EtOH, MeOH, or using combinations of solvents thereof), or promoted by a suitable acid to afford Examples 1F of the instant invention.

SCHEME 1



Method 2

General procedures to prepare intermediates of the instant invention are described in Scheme 2. Pyrazolo-pyridone 2A is oxidized using an appropriate oxidant such as IBX in a suitable solvent such as DMSO at a temperature of approximately 50 ^{0}C to afford ketone 2B. Ketone 2B can further be reacted with an substituted amine under reductive amination conditions using a borohydride such as $NaBH_3CN$ in a suitable solvent system such as MeOH/THF/AcOH to afford Examples 2C of the instant invention.

SCHEME 2



Method 3

General procedures to prepare intermediates of the instant invention are described in Scheme 3. Pyrazolo-pyridone 3A can be treated with a suitable acid such as TFA or HCl in an appropriate solvent such as DCM, EtOAc, or MeOH at approximately ambient temperature to afford the corresponding amine-containing Examples 3B of the instant invention. Alternatively, protected intermediates 3C may be reacted in a similar manner to afford Examples 3B.

SCHEME 3



Method 4

General procedures to prepare intermediates of the instant invention are described in Scheme 4. Intermediates 4B can be treated with 2-methylpropane-2-sulfinamide (or another suitable ammonia surrogate) in the presence of a lewis acid such as titanium isopropoxide followed by a reductant such as sodium borohydride to afford Examples 4A after hydrogenolysis

in the presence of an acid source (such as HCl) in a solvent such as EtOAc. Alternatively, Intermediates 4B can be treated with appropriately substituted amines using analogous conditions to afford Examples 4C of the instant invention. Intermediates 4B can also be treated with sodium borohydride in an appropriate solvent such as MeOH, followed by standard hydrogenolysis to afford alcohol-containing Examples 4D of the instant invention.

SCHEME 4



Method 5

General procedures to prepare intermediates of the instant invention are described in Scheme 5. Dioxolane containing Intermediates 5A can be treated with a suitable acid such as HCl in a solvent (THF) to afford diol-containing Examples 5B of the instant invention.

SCHEME 5



Method 6

General procedures to prepare intermediates of the instant invention are described in Scheme 6. Ester-containing Intermediates 6A can be treated with an appropriate base such as sodium hydroxide in a solvent system such as MeOH/water at ambient temperature to afford Examples 6B of the instant invention following hydrogenolysis.

SCHEME 6



Method 7

General procedures to prepare intermediates of the instant invention are described in Scheme 7. Lactone Intermediates 7A are reacted with amines in the presence of a lewis acid such as aluminum trichloride at or around 80 °C to afford the corresponding amide Intermediates 7B, which can then be further treated with *i*MgCl in a suitable solvent system such as THF/NMP followed by bis(dimethylamino)phosphoryl chloride at reflux temperature to afford intermediates 7C of the instant invention.

SCHEME 7



Method 8

General procedures to prepare intermediates of the instant invention are described in Scheme 8. Intermediates 8A can be reacted with an appropriately substituted heterocycle in the presence of a base such as potassium carbonate with an additive such as potassium iodide in a suitable solvent (such as acetone) at refluxing temperature to afford examples 8E of the instant invention. Alternatively, intermediates 8A can be reacted first with sodium azide in a solvent such as DMSO to afford an intermediate azide that can be further reacted with an appropriately substituted alkyne 8B in the presence of a copper salt (such as copper sulfate pentahydrate) and sodium ascorbate to afford the corresponding triazole intermediates 8C to be used in the synthesis of examples of the instant invention. Alternatively, intermediates 8A can be reacted with an appropriately substituted amine 8F in the presence of a base such as TEA in an appropriate solvent such as THF to afford intermediates 8G which can be used in the synthesis of examples of the instant invention.

SCHEME 8



Method 9

General procedures to prepare intermediates of the instant invention are described in Scheme 9. Trifluoromethyl ketone containing intermediates 9A can be reduced with a suitable reducing agent such as sodium borohydride in a solvent such as MeOH to afford the

corresponding alcohol intermediates 9B to be used in the synthesis of examples of the instant invention. Optical isomers may further be separated using appropriate chiral chromatographic methods to afford the corresponding diastereomers/enantiomers. Alternatively, intermediates 9A can be reacted with LiHMDS followed by a reducing agent such as borane-THF complex to afford the corresponding amine intermediates 9C. Optical isomers may further be separated using appropriate chiral chromatographic methods to afford the corresponding diastereomers/enantiomers to be used as intermediates in the syntheses of examples of the instant invention.

SCHEME 9



Method 10

General procedures to prepare intermediates of the instant invention are described in Scheme 10. Amine-containing intermediates 10A can be reacted with an appropriately substituted carboxylic acid 10B in the presence of amide coupling reagents (such as EDC and HOBt) in a solvent such as DCM to afford the corresponding amide intermediates 10C to be used in the synthesis of examples of the instant invention. Alternatively, intermediates 10A can be reacted with BOC_2O in a solvent such as EtOH or DCM to provide carbamate intermediates 10D to be used in the synthesis of examples of the instant invention.

SCHEME 10



Method 11

General procedures to prepare intermediates of the instant invention are described in Scheme 11. Sulfonyl chloride intermediates 11A can be reacted with an appropriately

substituted amine in the presence of a suitable base (such as DIPEA) in a solvent such as DCM to afford intermediates 11B that can be used in the synthesis of examples of the instant invention.

SCHEME 11



Method 12

General procedures to prepare intermediates of the instant invention are described in Scheme 12. Carboxylic acid intermediates 12A can be reacted under amide coupling conditions using reagents such as EDC or HOBt, or alternatively can be converted to the corresponding acid chloride using a reagent such as thionyl chloride to afford amide intermediates 12C that can be used in the synthesis of examples of the instant invention.

SCHEME 12



Method 13

General procedures to prepare intermediates of the instant invention are described in Scheme 13. Amine intermediates 13A or 13B can be reacted with an appropriate anhydride (or under suitable amide coupling conditions) to afford an intermediate amide that can further be reduced using a reductant such as borane-dimethylsulfide complex at approximately 75 °C to afford intermediates 13C or 13D which can be used in the synthesis of examples of the instant invention.

SCHEME 13



Method 14

General procedures to prepare intermediates of the instant invention are described in Scheme 14. Amine intermediates 14A can be reacted with an appropriately substituted aldehyde in the presence of a reductant such as sodium borohydride in a suitable solvent (such as MeOH) to afford intermediates 14B that can be used in the synthesis of examples of the instant invention. Alternatively, intermediates 14A can be reacted with an appropriately substituted alkyl halide in the presence of a base such as sodium hydride in DMF solvent to afford intermediates 14C that can be used in the synthesis of examples of the instant invention.

SCHEME 14



General procedures to prepare intermediates of the instant invention are described in Scheme 15. Appropriately substituted aldehydes 15A can be reacted with 2-methylpropane-2-sulfinamide (racemate or optically pure enantiomers may be used) in the presence of a lewis acid such as titanium ethoxide in a solvent such as THF at reflux temperature to afford the corresponding intermediates 15B that can further be treated with trimethyl(trifluoromethyl)silane and a fluoride source such as TBAF to afford intermediates 15C that can be used in the synthesese of examples of the instant invention. Optical isomers may further be separated using appropriate chiral chromatographic methods to afford the corresponding individual diastereomers/enantiomers.

SCHEME 15



Method 16

General procedures to prepare intermediates of the instant invention are described in Scheme 16. Sulfonyl chloride 16A can be reacted with an appropriately substituted amine in the presence of a suitable base such as triethylamine in a solvent such as dichloromethane to afford sulfonamide intermediates 16B. Intermediates 16B can be treated with oxidative conditions to effect intramolecular cyclization to afford intermediates 16C or 16E (protocols such as periodic acid with chromium trioxide and acetic acid; *or* iodobenzene diacetate and iodine can be used). Intermediates 16C can be reduced using a suitable reducing agent such as borane-tetrahydrofuran or borane-dimethylsulfide complex to afford intermediates 16D which can be used in the synthesis of examples of the instant invention. Alternatively, intermediates 16E can be reacted with an appropriately substituted alkyl halide in the presence of a base such as cesium carbonate to afford intermediates 16D following reduction with either borane-tetrahydrofuran or borane-dimethylsulfide complex.

SCHEME 16



INTERMEDIATES

The following experimental procedures detail the preparation of chemical materials used in the synthesis of Examples of the instant invention. The exemplified procedures are for illustrative purposes only, and are not intended to limit the scope of the instant invention in any way.

Intermediate 1

4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-3-amine



I-1

Step 1: 2-(benzyloxy)-4-methoxynicotinonitrile



I-1a

To a stirred suspension of 3-cyano-2-hydroxy-4-methoxypyridine (40.0 g, 266 mmol) in toluene (800 mL) was added silver carbonate (92.0 g, 333 mmol) followed by benzyl bromide (57.0 g, 333 mmol). The resulting mixture was heated to 50 °C and stirred overnight. The reaction mixture was filtered to remove the inorganic solids, rinsing the filter cake with DCM. The filtrate was concentrated *in vacuo*. Petroleum ether (100 mL) was added to the crude residue, and the triturated solids were collected by filtration to afford 2 -(benzyloxy)-4-methoxynicotinonitrile. LRMS (ESI) calc'd for $C_{14}H_{13}N_2O_2$: 241, found: 241. ^{1}H NMR (600 MHz $CDCl_3$) δ 8.21 (d, J = 6.6 Hz, 1H), 7.48 (d, J = 7.8 Hz, 2H), 7.38 (m, 2H), 7.32 (m, 1H), 6.58 (d, J = 6.0 Hz, 1H), 5.51 (s, 2H), 3.99 (s, 3H).

Step 2: 4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-3-amine

A stirred suspension of 2-(benzyloxy)-4-methoxynicotinonitrile (63 g, 0.26 mol) in a solvent mixture of hydrazine hydrate (210 mL) and anhydrous ethanol (420 mL) was heated to reflux at approximately 110 °C. The reaction was refluxed for 3 days, at which point LCMS indicated that the reaction was nearly complete. The mixture was concentrated *in vacuo* and diluted with EtOAc (200 mL), and washed with water and brine (20 mL each). The organic layer was dried over Na_2SO_4, filtered and concentrated *in vacuo* to afford a residue that was purified by silica gel column chromatography (PE/EA = 10:1-1:1) to afford 4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-3-amine, intermediate I-1. LRMS (ESI) calc'd for $C_{13}H_{13}N_4O$ $[M+H]^+$: 241, found 241. ^{1}H NMR (DMSO-d6, 400MHz): δ 11.87 (br s, 1H), δ 7.67 (d, 1H, J = 6.0 Hz), 7.38-7.49 (m, 2H), 7.34–7.38 (m, 2H), 7.28-7.31 (m, 1H), 6.80 (d, 1H, J = 4.0 Hz), 5.49 (s, 2H), 5.15 (s, 2 H).

Intermediate 2

(*cis*)-2-[3-amino-4-(benzyloxy)-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl]cyclohexanecarbonitrile (racemate)



I-2

To a solution of 4-(benzyloxy)-1*H*-pyrazolo[4,3-*c*]pyridin-3-amine, I-1, (15 mg, 0.062 mmol) in ethanol (0.2 mL) in a sealable tube was added 1-cyanocyclohexene (0.070 mL, 0.624 mmol) and DBU (0.019 mL, 0.125 mmol). The tube was sealed and heated at 90 °C for 24 hours. The reaction was then cooled to room temperature, concentrated *in vacuo*, and purified by silica gel chromatography (0 to 100% EtOAc/hexanes). The first eluting product is the minor (*trans*)-2-[3-amino-4-(benzyloxy)-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl]cyclohexanecarbonitrile and the second eluting product is the major (*cis*)-2-[3-amino-4-(benzyloxy)-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl]cyclohexanecarbonitrile. LRMS (ESI) calc'd for $C_{20}H_{22}N_5O$ $[M+H]^+$: 348, found 348. ^1H NMR (600 MHz, $CDCl_3$): δ 7.80 (d, *J* = 6.6 Hz, 1H), 7.45 (d, *J* = 7.2 Hz, 2H), 7.37 (t, *J* = 7.2 Hz, 2H), 7.32 (t, *J* = 7.2 Hz, 1H), 6.79 (d, *J* = 6.6 Hz, 1H), 5.51 (s, 2H), 4.45 (br s, 2H), 4.24 (m, 1H), 3.32 (s, 1H), 2.52 (qd, *J* = 12.6, 3.6 Hz, 1H), 2.12-2.18 (m, 2H), 2.07 (m, 1H), 1.71-1.78 (m, 3H), 1.46 (m, 1H).

Intermediate 3

(*trans*)-2-[3-amino-4-(benzyloxy)-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl]cyclohexanecarbonitrile (racemate)



I-3

4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-3-amine, I-1, (20.0 g, 83.0 mmol) was placed in a thick-wall reaction flask (500 mL) followed by the addition of acetontrile (167 ml), cyclohex-1-enecarbonitrile (71.0 g, 0.670 mol), and DBU (25.0 g, 0.170 mol). The flask was sealed and heated at 120 °C for 4 days. After 4 days, nearly ~80% conversion to the major trans-isomer took place with a minor amount of the cis-product detected. The mixture was cooled down, concentrated *in vacuo* and the residue was purified by gel silica chromatography

(petroleum ether / EtOAc loaded with 1% DCM) to afford the product (*trans*)-2-[3-amino-4-(benzyloxy)-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl]cyclohexanecarbonitrile (racemate). LRMS (ESI) calc'd for $C_{20}H_{22}N_5O$ $[M+H]^+$: 348, found 348; ^1H NMR (600 MHz, $CDCl_3$): δ 7.83 (d, J = 6.0 Hz, 1H), 7.46 (d, J = 7.8 Hz, 2H), 7.38 (t, J = 7.8 Hz, 2H), 7.32 (t, J = 7.2 Hz, 1H), 6.77 (d, J = 6.6 Hz, 1H), 5.50 (s, 2H), 4.44 (s, 2H), 4.18 (m, 1H), 3.19 (m, 1H), 2.30 (m, 1H), 1.90-1.98 (m, 3H), 1.84 (m, 1H), 1.74 (m, 1H), 1.44 (m, 1H), 1.32 (m, 1H).

Intermediates 4 and 5

(1R,2R)-2-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile

and

(1S,2S)-2-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile



I-4



I-5

The title compounds, I-4 and I-5, were separated from the racemic mixture following the procedure below:

Column Used: Chiral Technology IC 2.1 X 25cm, 5uM.

Mobile phase: 28% / 72% 2-Propanol/CO_2 (no other modifiers).

Flow rate: 65 mL/Min, 8 min run time, 10 minutes with impurity.

Wavelength: 220 nm.

Injection preparation: 7 grams of racemate was dissolved into methanol/DMF, 3:1 (80 ml), and filtered to remove any particulates. Injections of 0.30 ml were performed and elution of the individual enantiomers was observed at 4.97 minutes (1R,2R) and 6.02 minutes (1S,2S).

Intermediates 6 and 7

(1R,2R)-2-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile

and

(1S,2S)-2-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile



I-6



I-7

Into a 5000-mL 4-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed 4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-3-amine, I-1, (250 g, 1.04 mol), ethanol (3000 mL), cyclopent-1-ene-1-carbonitrile (300 g, 3.22 mol), and DBU (317 g, 2.08 mol). The resulting solution was heated to reflux and stirred overnight. The reaction mixture was cooled and concentrated *in vacuo*, and the resulting residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:10-1:2) to afford racemic-2-[3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclopentane-1-carbonitrile.

The racemic 2-[3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclopentane-1-carbonitrile (100 g mixture, 300 mmol, 1.00 equiv) was purified using Prep-SFC with the following conditions:

Column Used: Phenomenex Lux Cellulose-4, 2x25cm, 5um

Mobile phase: CO_2 (80%), methanol with 0.1% DEA (20%)

Wavelength: UV 254 nm.

This affords (Peak 1; 1R,2R)-2-[3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclopentane-1-carbonitrile and (Peak 2; 1S,2S)-2-[3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclopentane-1-carbonitrile.

Peak 1: LRMS (ESI) calc'd for $C_{19}H_{20}N_5O$ $[M+H]^+$: 334, found 334. ^{1}H-NMR (300MHz, $CDCl_3$): δ 7.86-6.84 (m, 7H), 5.55 (s, 2H), 4.94-4.86 (s, 2H), 4.49 (s, 1H), 3.34-3.26 (m, 1H), 2.39-2.01 (m, 6H).

Peak 2: LRMS (ESI) calc'd for $C_{19}H_{20}N_5O$ $[M+H]^+$: 334, found 334. ^{1}H-NMR (300MHz, $CDCl_3$): δ 7.86-6.84 (m, 7H), 5.55 (s, 2H), 4.94-4.86 (s, 2H), 4.49 (s, 1H), 3.34-3.26 (m, 1H), 2.39-2.01 (m, 6H).

Intermediates 8 and 9

(1R,2R,5S) and (1S,2S,5R)-2-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-hydroxycyclohexanecarbonitrile



I-8

enantiomer-peak1



I-9

enantiomer-peak2

To a flask was added 4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-3-amine, I-1, (6.00 g, 25.0 mmol), 5-hydroxycyclohex-1-enecarbonitrile (Intermediate 1; racemic, 9.23 g, 74.9 mmol), DBU (7.53 ml, 49.9 mmol), and EtOH (50 ml). The resulting mixture was heated at 85 °C for 50 h, then was cooled, concentrated *in vacuo*, and diluted with EtOAc/H_2O. The layers were separated and the organic layer was washed with H_2O and brine. The organic layer was dried over Na_2SO_4, filtered and concentrated *in vacuo* to afford a residue that was subjected to silica gel chromatography (0-50% acetone/DCM) to afford the major diastereomer as a racemic mixture of (1R,2R,5S) and (1S,2S,5R)-2-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-hydroxycyclohexanecarbonitrile. The individual enantiomers were separated by preparative chiral SFC using the following conditions to afford the two enantiomers:

Column Used: Chiral Technology AZ-H 2.1 X 25cm, 5uM.

Mobile phase: 29% / 71% Methanol/CO_2

Flow rate: 63 mL/Min

Wavelength: 220 nm

Peak 1: (1R,2R,5S)-2-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-hydroxycyclohexanecarbonitrile. LRMS (ESI) calc'd for $C_{20}H_{22}N_5O_2$ $[M+H]^+$: 364, found 364. ^1H NMR (600 MHz, $CDCl_3$): δ 7.86 (d, J = 6.0 Hz, 1H), 7.50 (d, J = 7.2 Hz, 2H), 7.41 (t, J = 7.2 Hz, 2H), 7.36 (t, J = 7.2 Hz, 2H), 6.80 (d, J = 6.0 Hz, 1H), 5.54 (s, 2H), 4.55 (s, 2H), 4.24-4.27 (m, 2H), 3.76 (t, J = 10.8 Hz, 1H), 2.44-2.50 (m, 1H), 2.37 (d, J = 13.2 Hz, 1H), 1.94-2.00 (m, 2H), 1.61-1.82 (m, 2H).

Peak 2: (1S,2S,5R)-2-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-hydroxycyclohexane carbonitrile. LRMS (ESI) calc'd for $C_{20}H_{22}N_5O_2$ $[M+H]^+$: 364, found 364. ^1H NMR (600 MHz, $CDCl_3$): δ 7.86 (d, J = 6.0 Hz, 1H), 7.50 (d, J = 7.2 Hz, 2H), 7.41 (t, J = 7.2 Hz, 2H), 7.36 (t, J = 7.2 Hz, 2H), 6.80 (d, J = 6.0 Hz, 1H), 5.54 (s, 2H), 4.55 (s, 2H), 4.24-4.27

(m, 2H), 3.76 (t, J = 10.8 Hz, 1H), 2.44-2.50 (m, 1H), 2.37 (d, J = 13.2 Hz, 1H), 1.94-2.00 (m, 2H), 1.61-1.82 (m, 2H).

Intermediate 10

5-bromo-2-(2,2,2-trifluoroethyl)isoindolin-1-one



I-10

Step 1: 4-bromo-2-(hydroxymethyl)-N-(2,2,2-trifluoroethyl)benzamide



I-10a

To a stirred suspension of aluminum chloride (8.14 g, 61.0 mmol) in CH_2Cl_2 at 0°C under argon was added 2,2,2-trifluoroethanamine (6.08 ml, 77 mmol). The reaction mixture was allowed to warm up to room temperature and stirred for 4 h. 5-bromoisobenzofuran-1(3H)-one (10.0 g, 46.9 mmol) was added to the reaction mixture, and heated at 80°C overnight. The reaction was carefully quenched with ice water (150 mL) and stirred until the ice was melted. The resulting mixture was diluted with CH_2Cl_2 (150 mL) and filtered through a pad of silica, eluting with additional CH_2Cl_2. The layers were separated, and the aqueous layer was extracted with CH_2Cl_2 (3 × 100 mL). The combined organic layers were dried over sodium sulfate and concentrated *in vacuo* to afford 4-bromo-2-(hydroxymethyl)-N-(2,2,2-trifluoroethyl)benzamide. LRMS (ESI) calc'd for $C_{10}H_{10}BrF_3NO_2$ $[M+H]^+$: 313, found 313.

Step 2: 5-bromo-2-(2,2,2-trifluoroethyl)isoindolin-1-one

To a stirred solution (cooled to 5°C) of 4-bromo-2-(hydroxymethyl)-N-(2,2,2-trifluoroethyl)benzamide (6.79 g, 21.8 mmol) in anhydrous THF (100 mL) and N-methyl-2-pyrrolidinone (40.0 mL) under argon was added a solution of isopropylmagnesium chloride (50 mL, 100 mmol) slowly to keep temperature under 10°C. After the addition was complete, the reaction mixture was stirred at a temperature below 10°C for 1 h, and then at room temperature for an additional hour. The reaction mixture was then cooled to 5°C and bis(dimethylamino)phosphoryl chloride (4.19 mL, 28.3 mmol) was added dropwise. The resulting reaction mixture was heated at reflux for 24 hr, then concentrated *in vacuo* to afford an oily residue that was purified by column chromatography on silica gel (hexanes/EtOAc: 2/1) to afford compound I-10. LRMS (ESI) calc'd for $C_{10}H_8BrF_3NO$ $[M+H]^+$: 294, found 294. ^1H NMR

(600 MHz, DMSO): δ 7.93 (d, *J* = 1.1Hz 1 H), 7.72 (d, *J* = 1.1 Hz, 1 H), 7.67-7.68 (s, 1 H), 4.58 (s, 2 H), 4.35 (q, 2 H).

Intermediate 11



I-11

Step 1,2: 2-[1-(3-Bromobenzyl)-1*H*-1,2,3-triazol-4-yl]propan-2-ol

To a solution of 1-bromo-3-(bromomethyl)benzene (5.0 g, 20 mmol) in DMSO (40 mL) was added sodium azide (1.3 g, 20 mmol). The resulting mixture was allowed to stir at ambient temperature for 18 hours before it was diluted with water and extracted with diethyl ether (2x). The combined organic extracts were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated *in vacuo*. The crude residue was dissolved in *t*-BuOH (65 mL) and water (39 mL) and to this mixture was added 2-methylbut-3-yn-2-ol (2.3 g, 27 mmol). Then a solution of copper (II) sulfate pentahydrate (0.26 g, 1.0 mmol) in water (10 mL) was added, followed by a solution of sodium ascorbate (0.83 g, 4.2 mmol) in water (8 mL). The resulting mixture was allowed to stir at ambient temperature for 2 hours and then was diluted with water and extracted with EtOAc (2x). The combined organic extracts were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated *in vacuo*. The residue was used without further purification. LRMS (ESI) calc'd for $C_{12}H_{15}BrN_3O$ $[M+H]^+$: 296, Found: 296.

Table 1. discloses Intermediate I-12 which was prepared in an analogous manner to that of Intermediate I-11, using 1-bromo-4-(bromomethyl)benzene as the starting material.

Table 1.

Inter-mediate	Structure	Compound Name	H^1 NMR
I-12		2-(1-(4-bromobenzyl)-1H-1,2,3-triazol-4-yl)propan-2-ol	($CDCl_3$, 400 MHz): δ 7.51 (d, *J* = 8.4 Hz, 2H), 7.34 (s, 1H), 7.15 (d, *J* = 8.4 Hz, 2H), 5.44 (s, 2H), 2.51 (brs, 1H), 1.61 (s, 6H)

Intermediates 13 and 14

1(*S* and *R*)-(4-Bromophenyl)-2,2,2-trifluoroethanol



I-13 and I-14

4'-Bromo-2,2,2-trifluoroacetophenone (3.00 mL, 19.8 mmol) was stirred in MeOH (66 mL) at 0 °C. Sodium borohydride (0.748 g, 19.8 mmol) was added and the mixture was allowed to warm to ambient temperature. The mixture was stirred for 3 hours, then quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was then washed with brine, dried over anhydrous $MgSO_4$, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (5% EtOAc/hexanes) to afford a racemic mixture of the title compounds. The racemic residue was resolved by Chiral SFC purification using the following method:

Column Used: Chiral Technology OJ-H 2.1 X 25cm, 5uM Column

Mobile Phase: eluting with 5% isopropyl alcohol/CO2)

Peak 1: (S or R)-1-(4-bromophenyl)-2,2,2-trifluoroethanol: ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.55 (d, 2H), 7.36 (d, 2H), 5.03 – 4.98 (m, 1H), 2.79 (br s, 1H).

Peak 2: (S or R)-1-(4-bromophenyl)-2,2,2-trifluoroethanol: ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.55 (d, 2H), 7.36 (d, 2H), 5.03 – 4.98 (m, 1H), 2.79 (br s, 1H).

Intermediate 15

N-(3-bromobenzyl)oxazole-5-carboxamide



I-15

Step 1: N-(3-bromobenzyl)oxazole-5-carboxamide

To a solution of (3-bromophenyl)methanamine (820 mg, 4.4 mmol) and oxazole-5-carboxylic acid (500 mg, 4.4 mmol) in DCM (50 mL), was added HOBt (1.2 g, 8.8 mmol), TEA (2.2 g, 22 mmol) and EDCI (1.7 g, 8.8 mmol). The resulting mixture was stirred at r.t. overnight, then partitioned between water and DCM. The organic phase was dried over $NaSO_4$, filtered and concentrated *in vacuo* to afford a residue that was purified by column chromatography on silica gel (1:1 pet ether/ EtOAc) to afford compound, I-15. ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.83 (s, 1H), 7.70 (s, 1H), 7.41 (d, J = 1.6 Hz, 1H), 7.37 (dt, J = 7.6 Hz, J = 1.6 Hz, 1H), 7.21-7.14 (m, 1H), 7.16 (t, J = 7.6 Hz, 1H), 6.57 (br, 1H), 4.53 (d, J = 6.0 Hz, 2H).

Table 2 discloses intermediates which were prepared in an analogous manner to that of Intermediate 15:

Table 2.

Inter-mediate	Structure	Compound name	NMR
I-16		N-(3-bromobenzyl)pyrimidine-2-carboxamide	^{1}H NMR (400 MHz, $CDCl_3$): δ 8.86 (d, J = 4.8 Hz, 2H), 8.33(br, 1H), 7.49 (t, J = 1.6 Hz, 1H), 7.43 (t, J = 5.2 Hz, 1H), 7.38 (dt, J = 5.2 Hz, J = 1.6 Hz, 1H), 7.29-7.27 (m, 1H), 7.19 (t, J = 7.6 Hz, 1H), 4.67 (d, J = 6.0 Hz, 2H).
I-17		2-(3-bromophenyl)-N-(1-methyl-1H-pyrazol-3-yl)acetamide	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.67 (br, 1H), 7.56 (s, 1H), 7.45-7.41 (m, 1H), 7.24-7.21(m, 3H), 6.64 (d, J = 2.4 Hz, 1H), 3.75(s, 3H), 3.66 (s, 2H).

Intermediate 18

tert-butyl 4-bromobenzylcarbamate



I-18

To a solution of (4-bromophenyl)methanamine (1.0 g, 5.4 mmol) in ethanol (20 mL) was added Boc_2O (2.0 g, 6.4 mmol). The resulting mixture was stirred overnight at room temperature. The solvent was removed *in vacuo* and the resulting residue was purified by column chromatography on silica gel (pet ether/EtOAc: 4/1) to afford tert-butyl 4-bromobenzylcarbamate. LRMS (ESI) calcd. for $C_{12}H_{17}BrNO_2$ $[M+H]^+$: 286, found 286. ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.44 (d, J = 6.0 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 4.85 (br s, 1H), 4.25 (d, J = 6.0 Hz, 2H), 1.45 (s, 9H).

Table 3 discloses intermediates that were prepared in an analogous manner to that of Intermediate 18:

Table 3.

Inter-	Structure	Compound Name	HNMR/ LRMS $[M+H]^+$

mediate			
I-19		tert-butyl 5-bromo-2-fluorobenzylcarbamate	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.44-7.42 (m, 1H), 7.35 -7.31 (m, 1H), 6.9 (d, J = 8.8 Hz, 1H), 4.95 (br, 1H), 4.31 (d, J = 5.6 Hz, 2H), 1.44 (s, 9H). LRMS calc'd. 304, found 304.
I-20		tert-butyl 3-bromo-5-fluorobenzylcarbamate	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.20 (s, 1H), 7.14 -7.11 (m, 1H), 6.93 (d, J = 9.2 Hz, 1H), 4.98 (br, 1H) ,4.27 (d, J = 5.6 Hz, 2H), 1.45 (s, 9H). LRMS calcd. 304, found 304

Intermediate 21

4-bromo-N-isopropylbenzenesulfonamide



I-21

To a solution of propan-2-amine (160 mg, 2.6 mmol) and DIPEA (780 mg, 6.0 mmol) in CH_2Cl_2 (7 mL) was added a solution of 4-bromobenzene-1-sulfonyl chloride (510 mg, 2.0 mmol) in CH_2Cl_2 (14 mL). The resulting reaction mixture was stirred at rt overnight, then was poured into water (20 mL), and extracted with CH_2Cl_2 (3 x 15 ml). The combined organic layers were concentrated *in vacuo* to afford a residue that was purified by column chromatography on silica (pet ether/EtOAc: 20/1) to give 4-bromo-N-isopropylbenzenesulfonamide. ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.75 – 7.72 (m, 2 H), 7.65 – 7.62 (m, 2 H), 4.43 (d, J = 7.52 Hz, 1 H), 3.49 – 3.44 (m, 1 H), 1.08 (d, J = 6.4 Hz, 6 H).

Table 4 discloses intermediates that were prepared in an analogous manner to that of Intermediate 21.

Table 4.

Inter-mediate	Structure	Compound Name	NMR
I-22		N-benzyl-4-bromobenzenesulfonamide	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.78 (d, J = 5.8 Hz, 2H), 7.70 (d, J = 5.8 Hz, 2H), 7.46-7.44 (m, 3H), 7.27-7.17 (m, 2H), 4.78-4.75 (m, 1H), 4.14 (d, J = 6 Hz, 2H)

I-23		4-bromo-N-(cyclopropylmethyl)benzenesulfonamide	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.65 (d, *J* = 5.6 Hz, 2H), 7.63(d, *J* = 5.6 Hz, 2H), 4.48-4.45 (m, 1H), 2.77-2.73 (m, 2H), 0.81-0.76 (m, 1H) 0.47-0.38 (m, 2H), 0.27-0.25 (m, 2H).
I-24		4-bromo-N-(2-methoxyethyl)benzenesulfonamide	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.72 (d, *J* = 5.8 Hz, 2H), 7.70 (d, *J* = 5.8 Hz, 2H), 4.48-4.45 (m, 1H), 3.49-3.84 (m,2H), 3.30 (s, 3H), 3.13-3.09 (m, 2 H).
I-25		4-bromo-N-cyclohexylbenzenesulfonamide	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.75-7.73 (m, 2H), 7.64-7.61 (m, 2H), 4.70 (d, *J* = 7.6 Hz, 1H), 3.17-3.09 (m, 1H), 1.75-1.72 (m, 2H), 1.64-1.59 (m, 2H), 1.52-1.48 (m, 1H), 1.24-1.14 (m, 2H).
I-26		1-((4-bromophenyl)sulfonyl) piperidine	^{1}H NMR (400 MHz $CDCl_3$): δ 7.66-7.63 (m, 2H), 7.61 – 7.58 (m, 2 H), 2.98-2.95 (m, 4H), 1.66-1.57 (m, 4H), 1.44-1.40 (m, 2H).
I-27		4-((4-bromophenyl)sulfonyl) morpholine	^{1}H NMR (400 MHz $CDCl_3$): δ 7.70-7.67 (m, 2H), 7.62-7.59 (m, 2H), 3.74-3.72 (m, 4H), 2.30-2.97 (m, 4H).

Intermediates 28 and 29

1-(3-bromobenzyl)-1H-1,2,3-triazole and 2-(3-bromobenzyl)-2H-1,2,3-triazole

 **I-28**  **I-29**

To a stirred solution of 1-bromo-3-(bromomethyl)benzene (5.0 g, 20.0 mmol) in acetone (200 ml) under N_2 was added 1H-1,2,3-triazole (2.1 g, 30.0 mmol) followed by K_2CO_3 (4.1 g, 30.0 mmol), and KI (0.16 g, 1.0 mmol). The reaction mixture was refluxed for 12 h, then it was diluted with H_2O (200 mL) and extracted with EtOAc (200 mL x 2). The combined organic layers were washed with *aq.* KOH (10%, 50 ml) followed by brine (200 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated *in vacuo* to afford a residue that was purified by column chromatograph on silica gel (petroleum ether / EtOAc: 50:1) to afford 1-(3-bromobenzyl)-1H-1,2,3-triazole, I-28, and 2-(3-bromobenzyl)-2H-1,2,3-triazole I-29.

I-28: ^{1}H NMR ($CDCl_3$ 400MHz): δ 7.70 (s, 1H) , 7.50 (t, *J* = 3.2Hz, 1H), 7.41 (d, *J* = 7.1Hz, 1H) , 7.22 (d, *J* =3.2Hz, 1H), 7.20-7.15 (m, 2H), 5.51(s, 2H).

I-29: ^{1}H NMR ($CDCl_3$ 400MHz): δ 7.63 (s, 2H) , 7.43 (d, *J* = 4.8Hz, 2H) , 7.20 (t, *J* = 3.4Hz, 2H), 5.56 (s, 2H).

Table 5 discloses intermediates that were prepared in an analogous manner to that of Intermediates 28 and 29.

Table 5.

Inter-mediate	Structure	Compound Name	NMR/ LRMS $[M+H]^+$
I-30		2-(4-bromobenzyl)-2H-1,2,3-triazole	^{1}HNMR ($CDCl_3$ 400MHz): δ 7.62 (s, 2H), 7.46 (d, *J* = 8.4 Hz, 2H), 7.17 (d, *J* = 8Hz, 2H), 5.55 (s, 2H).
I-31		1-(4-bromobenzyl)-1H-1,2,3-triazole	^{1}HNMR ($CDCl_3$ 400MHz): δ 7.66 (s, 1H), 7.41-7.45 (m, 3H), 7.07 (d, J = 6 Hz, 2H), 5.46 (s, 2H)
I-32		1-(3-bromobenzyl)-1H-1,2,4-triazole	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.08 (s, 1H), 7.96 (s, 1H), 7.46-7.44 (m, 1H), 7.37 (t, *J* = 1.7Hz, 1H), 7.22 (t, *J* = 7.8Hz, 1H), 7.16 (d, *J* = 7.7Hz, 1H), 5.29 (s, 2H). LRMS calc'd: 237, found: 237.
I-33		1-(3-bromobenzyl)-1H-pyrazole	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.56 (d, *J* = 1.7Hz, 1H), 7.43-7.40 (m, 2H), 7.33 (s, 1H), 7.20 (t, *J* = 7.8Hz, 1H), 7.12 (d, *J* = 7.8Hz, 1H), 6.30 (t, *J* = 2.0Hz, 1H), 5.29 (s, 2H). LRMS calc'd: 238, found: 238.
I-34		4-(3-bromobenzyl)-4H-1,2,4-triazole	^{1}H NMR (400 MHz, DMSO-d_6): δ 8.12 (s, 2H), 7.47-7.44 (m, 1H), 7.28 (t, *J* = 1.8Hz, 1H), 7.21-7.19 (m, 1H), 7.05-7.03 (m, 1H), 5.10 (s, 2H). LRMS calc'd: 237, found: 237
I-35		1-(3-bromobenzyl)-1H-imidazole	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.52 (s, 1H), 7.44-7.41 (m, 1H), 7.27-7.26 (m, 1H), 7.20 (t, *J* = 7.9Hz, 1H), 7.08 (t, *J* = 1.1Hz, 1H), 7.05-7.02 (m, 1H), 6.87 (t, *J* = 1.3Hz, 1H), 5.06 (s, 2H). LRMS calc'd: 238, found: 238

Intermediate 36

1-(3-bromobenzyl)-4-methyl-1H-1,2,3-triazole



I-36

Step 1: 1-(azidomethyl)-3-bromobenzene



I-36a

To a solution of 1-bromo-3-(bromomethyl)benzene (2.0 g, 8.0 mmol) in DMSO (50 mL) was added NaN_3 (0.65 g, 10.0 mmol). The resulting reaction mixture was stirred overnight at rt. The reaction was quenched with water (50 mL) and extracted with DCM (2x 50 mL). The combined organic layers were washed with brine (50 mL), then dried over Na_2SO_4, filtered and concentrated *in vacuo* to afford 1-(azidomethyl)-3-bromobenzene that was carried on without further purification.

Step 2: 1-(3-bromobenzyl)-4-methyl-1H-1,2,3-triazole

A mixture of 1-(azidomethyl)-3-bromobenzene (3.2 g, 15 mmol), trimethyl(prop-1-yn-1-yl)silane (1.6 mL,14 mmol) and Et_3N (2.2 mml, 4.5 mmol) in DMF (50 mL) was stirred at 100 ^oC overnight. The reaction mixture was cooled to rt, then *sat. aq.* NH_4Cl (25 mL) was added and extracted with EtOAc (50 mL x 2). The combined organic layers were washed with H_2O (50mL x 3), then dried over Na_2SO_4, and concentrated *in vacuo* to afford compound I-36. ^{1}HNMR ($CDCl_3$, 400MHz): δ 7.63 (s, 2H), 7.43 (d, J = 4.8Hz, 2H), 7.20 (t, J = 3.4Hz, 2H), 5.56 (s, 2H).

Intermediate 37

(4-bromophenyl)(pyrrolidin-1-yl)methanone



I-37

To a suspension of 4-bromobenzoic acid (150 mg, 0.75 mmol) in DCM (7.5 mL) were added pyrrolidine (53 mg, 0.75 mmol), HOBT (110 mg, 0.78 mmol), and Et_3N (190 mg, 1.9 mmol) successively at room temperature, then to the mixture was added EDCI (150 mg, 0.78 mmol) in portions. The resulting mixture was stirred overnight, then was poured into water and washed with dilute *aq.* HCl (5 mL), *sat. aq.* $NaHCO_3$ (15 mL) and brine (10 mL). The organic layer was dried over Na_2SO_4, filtered then concentrated *in vacuo* to afford the crude product which was purified by preparative TLC (petroleum ether / EtOAc: 3:1) to afford comound I-37. LRMS ESI calcd. for $C_{11}H_{13}BrNO$ $[M+H]^+$: 254, found: 254. ^{1}HNMR (400 MHz, $CDCl_3$): δ 7.46 (d, J = 8.4 Hz, 2 H), 7.33 (d, J = 8.4 Hz, 2 H), 3.55 (t, J =6.8 Hz, 2 H), 3.33 (t, J =6.4 Hz, 2 H), 1.92-1.77 (m, 4H).

Table 5 discloses an intermediate that was prepared in analogous manner to that of compound, I-37.

Table 5.

Inter-mediate	Structure	Compound Name	LRMS $[M+H]^+$
38		(4-bromo-2-methylphenyl)(pyrrolidin-1-yl)methanone	Calc'd: 268, found: 268

Intermediate 39

4-bromo-N,N,2-trimethylbenzamide



I-39

A solution of 4-bromo-2-methylbenzoic acid (2.15 g, 10.00 mmol, 1.00 equiv) and thionyl chloride (3.6 g, 30.25 mmol, 3.00 equiv) was heated at 80 °C for 3 h. The excess thionyl chloride was removed under reduced pressure, and the resulting residue was dissolved in dichloromethane (50 mL) and cooled to 0 °C (ice/water bath). Dimethylamine (gas) was bubbled to the reaction solution for 5 min. The resulting solution was stirred at 20 °C for 10 min, then was concentrated *in vacuo*, and diluted with ethyl acetate (100 mL). The reaction mixture was washed successively with aqueous sodium hydroxide (1 N, 20 mL), water (20 mL) and brine (20 mL). The organic layer was dried over sodium sulfate, filtered and concentrated *in vacuo* to afford 4-bromo-2-methyl-*N,N,*dimethylbenzamide. ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.40–7.39 (m, 1H), 7.36 (dd, J = 1.51 Hz, 8.03 Hz, 1H), 7.06 (d, J = 8.03 Hz, 1H), 3.13 (s, 3H), 2.84 (s, 3H), 2.28 (s, 3H).

Table 6 discloses an intermediate that was prepared in an analogous manner to that of Intermediate 39.

Table 6.

Inter-mediate	Structure	Compound Name	LRMS/NMR

I-40		(4-bromo-2-methylphenyl)(morpholino)methanone	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.42-7.37 (m, 2H), 7.06 (d, *J* = 8.0 Hz, 1H), 3.84-3.78 (m, 4H), 3.76-3.60 (m, 2H), 3.26-3.24 (m, 2H), 2.32 (s, 3H)

Intermediate 41

4-chloro-2-cyclopropyl-N,N-dimethylbenzamide



I-41

Into a 25-mL schlenk tube purged and maintained with an inert atmosphere of nitrogen, were added 2-bromo-4-chloro-*N*,*N*-dimethylbenzamide (0.26 g, 1.00 mmol), cyclopropylboronic acid (0.13 g, 1.50 mmol), toluene (5 mL), water (0.25 mL), tricyclohexylphosphine (14 mg, 0.05 mmol), palladium(II) acetate (22.4 mg, 0.10 mmol), and potassium phosphate (0.85 g, 4.00 mmol). The resulting mixture was stirred for 3 h at 100 °C in an oil bath, then was cooled down to 20 °C, and diluted with ethyl acetate (100 mL), washed with water (2 x 20 mL) and brine (2 x 20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo* to afford a residue that was purified by chromatography (5%-10% ethyl acetate/ petroleum ether) to afford compound I-41. ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.18-7.03 (m, 2H), 6.85 (s, 1H), 3.14 (s, 3H), 2.87 (s, 3H), 1.91-1.82 (m, 1H), 1.00-0.90 (m, 2H), 0.88-0.64 (m, 2H).

Intermediate 42

(±) 1-(3-bromophenyl)ethanol



I-42

To a solution of 1-(3-bromophenyl)ethanone (1.0 g, 5.0 mmol) in EtOH (15 mL) was added $NaBH_4$ (470 mg, 12 mmol). The mixture was stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo* to dryness, and the resulting residue was purified by chromatography on silica gel (hexanes / EtOAc: 5 / 1) to afford (±)1-(3-bromophenyl)ethanol. LRMS (ESI) calcd. For $C_8H_{10}BrO$ $[M+H]^+$ 201, found 201.^{1}H NMR ($CDCl_3$, 400MHz): δ 7.51-

7.50 (m, 1H), 7.39-7.36 (m, 1H), 7.26-7.24 (m, 1H), 7.21-7.17 (m, 1H), 4.84-4.79 (m, 1H), 2.35 (s, 1H), 1.45 (d, J = 6.48 Hz, 3H).

Intermediate 43

4-(3-bromobenzyl)morpholine



I-43

To a suspension of 1-bromo-3-bromomethyl-benzene (530 mg, 2.1 mmol) in THF (10 mL) was added morpholine (200 mg, 1.8 mmol) and Et_3N (350 mg, 3.5 mmol). The resulting suspension was stirred at room temperature for 8 hour. When the LCMS showed the reaction was complete, water (35 mL) was added, and the mixture was extracted with EtOAc (50 mL), dried over sodium sulfate, filtered and concentrated *in vacuo*. The residue was purified by preparative TLC (petroleum ether / EtOAc: 5/1) to afford compound, I-43. MS (ESI) calcd. For $C_{11}H_{15}BrNO$ $[M+H]^+$ 255, found 255. ^1H NMR ($CDCl_3$, 400MHz): δ 7.51 (s, 1H), 7.40 (d, *J* = 8 Hz, 1H), 7.29 (d, *J* = 8 Hz, 1H), 7.19 (t, J = 8 Hz, 1H), 3.66 (m, 4H), 3.47 (s, 2H), 2.41 (m, 4H).

Intermediate 44

N-(3-bromobenzyl)-2,2,2-trifluoroethanamine



I-44

A suspension of 1,3-dibromo-benzene (500 mg, 2 mmol) in 2,2,2-Trifluoro-ethylamine (790 mg, 8 mmol) was stirred at 40-50 °C for 10 hour. When LCMS showed the reaction was complete, the mixture was concentrated *in vacuo* to afford compound I-44. LRMS (ESI) calc'd. For $C_{11}H_{15}BrNO$ $[M+H]^+$ 268, found 268.

Table 7 discloses an intermediate that was prepared in an analogous manner to that of I-44.

Table 7.

Inter-mediate	Structure	Compound Name	NMR/LRMS $[M+H]^+$
I-45		N-(4-bromobenzyl)-2,2,2-trifluoroethanamine	^1H NMR (CDCl3, 400MHz): δ 7.43 (d, *J* = 8.4 Hz, 2H), 7.19 (d, *J* = 8.4 Hz, 2H), 3.83 (m, 2H), 3.13 (q, *J* = 9.6 Hz, 2H). LRMS calc'd: 268, found: 268

Intermediate 46

(R)-N-(1-(4-bromophenyl)ethyl)-2,2,2-trifluoroethanamine



I-46

Step 1: (*R*)-*N*-(1-(4-bromophenyl)ethyl)-2,2,2-trifluoroacetamide

To a solution of (*R*)-1-(4-bromophenyl)ethanamine (3.00 g, 15.0 mmol) in CH_2Cl_2 (70 mL) was added TFAA (3.78 g, 18.0 mmol) at 0 °C. The resulting reaction mixture was stirred for 1 h at 20 °C, then quenched by the addition of water. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to afford (*R*)-*N*-(1-(4-bromophenyl)ethyl)-2,2,2-trifluoroacetamide. ^{1}H NMR (300 MHz, $CDCl_3$): δ 7.51 (d, *J* = 8.4 Hz, 2H), 7.20 (d, *J* = 8.4 Hz, 2H), 6.40 (s, br, 1H), 5.15–5.05 (m, 1H), 1.57 (d, *J* = 6.9 Hz, 3H).

Step 2: (R)-N-(1-(4-bromophenyl)ethyl)-2,2,2-trifluoroethanamine

To a stirred solution of (*R*)-*N*-(1-(4-bromophenyl)ethyl)-2,2,2-trifluoroacetamide (1.00 g, 3.38 mmol) in THF (20 mL) was added borane dimethylsulfide complex (2M in THF, 8.4 mL, 17 mMol). The resulting solution was stirred for 4 h at 75 °C. The mixture was poured carefully into an ice/water (50 mL) mixture and extracted with EtOAc (40 mL x 2). The combined organic layers were dried over sodium sulfate, filtered and concentrated *in vacuo* to afford compound, I-46. ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.53 (d, *J* = 8.4 Hz, 2H), 7.22 (d, *J* = 8.4 Hz, 2H), 6.44 (s, br, 1H), 5.16–5.09 (m, 1H), 1.60 (d, *J* = 7.2 Hz, 3H).

Table 8 discloses an intermediate that was prepared in a similar manner to that described for compound I-46.

Table 8.

Inter-mediate	Structure	Compound Name	NMR
I-47		(S)-N-(1-(4-bromophenyl)ethyl)-2,2,2-trifluoroethanamine	^{1}H NMR (400 MHz, $CDCl_3$): δ 7.53 (d, *J* = 8.4 Hz, 2H), 7.22 (d, *J* = 8.4 Hz, 2H), 6.44 (s, br, 1H), 5.16–5.09 (m, 1H), 1.60 (d, *J* = 7.2 Hz, 3H).

Intermediate 48

5-bromo-2-methylisoindoline



I-48

Into an 100-mL round-bottom flask was placed 5-bromo-2,3-dihydro-1*H*-isoindole (1.00 g, 5.05 mmol), formaldehyde (0.23 g, 40% in water, 7.60 mmol), sodium borohydride (0.29 g, 7.60 mmol) and methanol (50 mL). The resulting solution was stirred for 1 h at 15 °C, then extracted with dichloromethane (3 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and was concentrated *in vacuo* to afford a residue that was purified by silica gel column chromatography with ethyl acetate/petroleum ether (1:1) to afford compound I-48. MS (ESI) calc'd for: $C_9H_{10}BrN$ $[M + H]^+$: 212, found 212.

Intermediate 49

5-bromo-2-ethylisoindoline



I-49

Step 1: 1-(5-bromoisoindolin-2-yl)ethanone



I-49a

Into a 50-mL three necked flask were placed 5-bromoisoindoline hydrochloride (0.234 g, 1.00 mmol), acetic acid (4 mL) and acetic anhydride (0.31 g, 3.00 mmol). The mixture was stirred at 20 °C for 2 h then diluted with ethyl acetate (50 mL). The solution was washed with water (3 x 15 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo* to afford a residue that was purified by silica gel column chromatography (2%-50% ethyl acetate in petroleum ether) to afford compound I-49a. ^{1}H NMR (400 MHz, CD_3OD) δ 7.54 (d, J = 4.8 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.27 (dd, J = 4.8, 8.0 Hz, 1H), 4.88 (d, J = 16.4 Hz, 2H), 4.72 (d, J = 16.4 Hz, 2H), 2.18 (s, 3H).

Step 2: 5-bromo-2-ethylisoindoline

Into a 50-mL three necked flask, were placed compound I-49a (0.17 g, 0.71 mmol), tetrahydrofuran (10 mL) and borane dimethylsulfite complex (0.35 mL, 10 M in tetrahydrofuran, 3.5 mmol). The solution was heated at reflux for 2 h, then was cooled to 20 °C and water (3 mL) was carefully added dropwise. The resulting mixture was concentrated *in vacuo* and diluted with ethyl acetate (50 mL). The solution was washed with water (15 mL) and brine (15 mL) respectively, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo* to afford compound I-49. ^{1}H NMR (400 MHz, $CDCl_3$) δ7.44–7.38 (m, 2H), 7.11 (d, J = 8.0 Hz, 1H), 4.52 (d, J = 14.0 Hz, 1H), 4.49 (d, J = 14.0 Hz, 1H), 4.16 (d, J = 14.0 Hz, 1H), 4.13 (d, J = 14.0 Hz, 1H), 3.12 (q, J = 7.2 Hz, 2H), 1.30 (t, J = 7.2 Hz, 3H).

Table 9 discloses intermediates that were prepared in a manner analogous to that described for compound I-49.

Table 9.

Inter-mediate	Structure	Compound Name	Spectral Data
I-50		5-Bromo-2-isobutylisoindoline	^{1}H NMR (400 MHz, $CDCl_3$) δ 7.41 (d, J = 8.1 Hz, 1H), 7.35 (s, 1H), 7.07 (d, J = 8.1 Hz, 1H), 4.50 (q, J = 9.3 Hz, 2H), 4.14 (q, J = 10.2 Hz, 2H), 2.87 (q, J = 5.4 Hz, 2H), 2.40-2.35 (m, 1H), 1.03 (d, J = 6.9 Hz, 6H).
I-51		5-Bromo-2-(cyclopropylmethyl)isoindoline	^{1}H NMR (300 MHz, DMSO-d_6) δ7.52 (s, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.25 (d, J = 8.1 Hz, 1H), 4.40–4.20 (m, 4H), 2.87 (d, J = 6.9 Hz, 2H), 1.19–1.10 (m, 1H), 0.53-0.47 (m, 2H), 0.26-0.20 (m, 2H).
I-52		5-Bromo-2-(2,2,2-trifluoroethyl)isoindoline	^{1}H NMR (400 Hz, $CDCl_3$) δ 7.49-7.45 (m, 2H), 7.10 (d, J = 4.4 Hz, 1H), 4.13-4.25 (m, 4H), 3.36 (q, J = 5.6 Hz, 2H).

Intermediate 53

5-bromo-2-isopropylisoindoline



I-53

Into an 100-mL round-bottom flask was placed a solution of 5-bromo-2,3-dihydro-1*H*-isoindole hydrochloride (2.00 g, 8.53 mmol, 1.00 equiv) in *N,N*-dimethylformamide (50 mL). Sodium hydride (0.85 g, 60% in mineral oil, 21.32 mmol) was added carefully and the resulting reaction mixture was stirred for 45 min at 20 °C. 2-Iodopropane (2.17 g, 12.77 mmol) was added dropwise at the same temperature then the resulting solution was stirred for 16 h at 50 °C in an oil bath. The reaction was cooled down to ambient temperature then quenched carefully by water (80 mL) addition. The resulting mixture was extracted with ethyl acetate (3 x 40 mL). The organic layers were combined, washed with water (50 mL) and brine (50 mL) respectively, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo* to afford compound I-53 as a brown solid. MS (ESI) calc'd for: $C_{11}H_{15}BrN$ $[M + H]^+$: 240, found: 240; ^1H NMR (300 MHz, $CDCl_3$) δ 7.46-7.32 (m, 2H), 7.07 (d, J = 7.8 Hz, 1H), 4.92 (d, J = 7.8 Hz, 4H), 2.79-2.71 (m, 1H), 1.19 (d, J = 6.3 Hz, 6H).

Intermediate 54

(R)-N-((S)-1-(3-bromophenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide



I-54

Step 1: (R,E)-N-(3-bromobenzylidene)-2-methylpropane-2-sulfinamide



I-54a

To a suspension of 3-bromobenzaldehyde (2.00 g, 10.8 mmol) and (S)-2-methylpropane-2-sulfinamide (2.90 g, 21.6 mmol) in THF (50 mL) was added titanium ethoxide (3.10 g, 10.8 mmol). The mixture was heated to reflux for 5 h, then it was cooled to room temperature and quenched by the addition of water (30 mL). The resulting mixture was filtered, and the filtrate was extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (30 mL x 2) dried over $NaSO_4$, filtered and concentrated *in vacuo* to afford a residue that was purified by column chromatography on silica gel (petroleum ether: EtOAc = 40:1 to 10:1) to

give compound (R,E)-N-(3-bromobenzylidene)-2-methylpropane-2-sulfinamide. LRMS (ESI) calc'd. for $C_{11}H_{15}BrNOS$ $[M+H]^+$: 288, found: 288. ^1H NMR (400 MHz, $CDCl_3$): δ 8.51 (s, 1H), 8.00 (s, 1H), 7.72 (d, *J* = 8.0 Hz, 1H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.34 (t, *J* = 8.0 Hz, 1H), 1.25 (s, 9H).

Step 2: (R)-N-((S)-1-(3-bromophenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide

To a suspension of (R,E)-N-(3-bromobenzylidene)-2-methylpropane-2-sulfinamide (150 mg, 0.52 mmol) and TBAF (210 mg, 1 mmol) in THF (15 mL) was added $TMSCF_3$ (0.84 mL, 1.7 mmol) dropwise at -55°C, and the resulting mixture was stirred for 1 h. The reaction was quenched by the addition of *aq.* NH_4Cl and extracted with EtOAc (15 mL x 2). The combined organic layers were washed with brine (15 mL x 2), dried over Na_2SO_4, filtered and concentrated *in vacuo* to afford a residue that was purified by *prep.* TLC (silica gel, eluted by petroleum ether : EtOAc =10:1) to give compound (R)-N-((S)-1-(3-bromophenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide. LRMS (ESI) calc'd. For $C_{12}H_{16}BrF_3NOS$ $[M+H]^+$ 358, found 358. ^1H NMR (400 MHz, $CDCl_3$): δ 7.56 (br s, 1H), 7.53 (d, *J* = 8.0 Hz, 1H), 7.37 (d, *J* = 8.0 Hz, 1H), 7.28 (t, *J* = 8.0 Hz, 1H), 4.80-4.74 (m, 1H), 3.62 (d, *J* = 6.4 Hz, 1H), 1.25 (s, 9H).

Table 10 discloses intermediates that were prepare in an analogous manner to that described for Intermediate 54, and in some cases using (R)-2-methylpropane-2-sulfinamide to afford the alternative diastereomer:

Table 10.

Inter-mediate	Structure	Compound Name	LRMS $[M+H]^+$
I-55		(S)-N-((R)-1-(3-bromophenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide	Calc'd: 358, found: 358
I-56		(S)-N-((R)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide	Calc'd: 358, found: 358
I-57		(R)-N-((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide	Calc'd 358, found 358

Intermediates 58 and 59

1-(4-bromophenyl)-2,2,2-trifluoroethanamine (racemic)



I-58 and I-59

To a solution of 1-(4-bromophenyl)-2,2,2-trifluoroethanone (1.00 g, 3.95 mmol) in toluene (14 mL) at rt was added a solution of lithium bis(trimethylsilyl)amide in THF (4.35 mL, 4.35 mmol) dropwise. The reaction was stirred at rt for 15 min, then BH_3·THF (7.90 mL, 7.90 mmol) was added and stirred for an additional 20 min. The reaction was cooled to 0 °C, and was carefully quenched with aqueous sodium hydroxide (2M; 5.93 mL, 11.9 mmol) over approximately 5 min. The resulting mixture was stirred at rt for 90 min, and then the layers were separated. The organic layer was washed with 1N NaOH, dried over sodium sulfate, filtered and concentrated *in vacuo* to afford racemic 1-(4-bromophenyl)-2,2,2-trifluoroethanamine.

Chiral SFC conditions:

Column Used: Chiralpak AZ-H, 21x250 mm

UV wavelength: 220 nm

Flow Rate: 70 ml/min

Modifier: MeOH (7%)

Peak 1: (R)-1-(4-bromophenyl)-2,2,2-trifluoroethanamine; LRMS (ESI) calc'd for $C_8H_8BrF_3N$ $[M+H]^+$: 254, found: 254.

Peak 2: (S)-1-(4-bromophenyl)-2,2,2-trifluoroethanamine; LRMS (ESI) calc'd for $C_8H_8BrF_3N[M+H]^+$: 254; found: 254.

Intermediate 60

N-(5-bromo-2-(N,N-dimethylsulfamoyl)benzyl)acetamide



I-60

Step 1: N-(3-bromobenzyl)acetamide



I-60a

A mixture of (3-bromophenyl)methanamine (5.4 g, 29 mmol), AcCl (2.74 g, 29 mmol) and Et_3N (5.86 g, 58 mmol) in DCM (100 mL) was stirred at rt for 3 h, then it was quenched with water (20 mL) and extracted with DCM (3 x 20 mL). The combined organic layers were concentrated *in vacuo*. The residue was recrystallized from hexanes/EtOAc (10/1: 55 mL) to afford I-60a. ^1H NMR ($CDCl_3$ 400 MHz): δ 7.40-7.36 (m, 2H), 7.2-7.15 (m, 2H), 6.01 (br s, 1H), 4.37 (d, J = 6 Hz, 2H), 2.01 (s, 3H).

Step 2: 2-(acetamidomethyl)-4-bromobenzene-1-sulfonyl chloride



I-60b

A mixture of compound I-60a (0.45 g, 2 mmol) in $ClSO_3H$ (1.64 g, 14 mmol) was stirred at rt for 2 h. The reaction mixture was quenched by careful addition of water (20 mL) and then extracted with DCM (20 mL x 3). The combined organic layers were concentrated *in vacuo,* and the resulting residue was triturated with DCM/Hex (1/25, 100 mL) to afford compound I-60b after filtration, which was used for the next step without further purification.

Step 3: 2 N-(5-bromo-2-(N,N-dimethylsulfamoyl)benzyl)acetamide

To a solution of compound I-60b (100 mg, 0.3 mmol) in DCM (1 mL) was added dimethylamine hydrochloride (50 mg, 0.6 mmol) and pyridine (0.13 g, 1.5 mmol). The reaction mixture was stirred at rt overnight, then concentrated *in vacuo*. The resulting residue was diluted with DCM (20 mL). The DCM solution was washed with H_2O (2 x 20 mL) and brine (20 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified by preparative TLC to afford compound I-60. ^1H NMR ($CDCl_3$, 400 MHz): δ 7.81 (s, 1H), 7.67 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 8.6 Hz, 1H), 6.43 (br s, 1H), 4.63 (d, J = 6.6 Hz, 2H), 2.81 (s, 6H), 1.97 (s, 3H).

Intermediate 61

5-bromo-2-(tert-butyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide



I-61

Step 1: 4-bromo-N-(tert-butyl)-2-methylbenzenesulfonamide



I-61a

To a solution of 4-bromo-2-methylbenzene-1-sulfonyl chloride (2.0 g, 7.4 mmol) in CH_2Cl_2 (15 mL) was added a solution of 2-methylpropan-2- amine (0.65 g, 8.9 mmol) and triethylamine (0.9 g, 8.9 mmol) in CH_2Cl_2 (30 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 2 h and then rt for 16 hours. The mixture was washed with 0.1 M HCl (15 mL) and saturated aqueous $NaHCO_3$ (15 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated *in vacuo* to afford compound I-61a. ^{1}H NMR (400 MHz, DMSO-d6) δ 7.78 (d, *J* = 8.4 Hz, 1H), 7.63 (d, *J* = 1.6 Hz, 1H), 7.59-7.56 (m, 2H), 2.57 (s, 3H), 1.09 (s, 9H).

Step 2: 5-bromo-2-(tert-butyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide



1-61b

A mixture of H_5IO_6 (5.9 g, 26 mmol) in acetonitrile(50 mL) was stirred at RT for 1 h, then CrO_3 (33 mg, 0.33 mmol) was added followed by acetic anhydride (2.7 g, 26 mmol). The resulting orange solution was cooled to 0 °C, and to it was added compound I-61a (1.0 g, 3.3 mmol). After stirring at 0 °C for 15 min, the reaction was allowed to warm to rt and stirred for 16 hours. The solvent was removed *in vacuo*, and the residue was extracted with EtOAc (100 mL). The ethyl acetate solution was washed with saturated aqueous $NaHCO_3$ (40 mL) and brine, and dried over Na_2SO_4. After filtration and concentration *in vacuo*, the residue was purified by column chromatography on silica gel (petroleum ether/EtOAc = 20:1) to afford compound I-61b. ^{1}H NMR (400 MHz, DMSO-d6) δ 8.82-8.14 (m, 3H), 1.66 (s, 9H).

Step 3: 5-bromo-2-(tert-butyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide

To a solution of compound I-61b (0.20 g, 0.63 mmol) in THF (4 mL), was added $BH_3.Me_2S$ (240 mg, 3 mmol). The reaction mixture was refluxed for 16 hours. After being cooled to RT, the reaction was quenched with 2M HCl (15 mL), then extracted with EtOAc (2 x

50 mL). The combined extracts were washed with brine, dried over Na_2SO_4, filtered and concentrated *in vacuo*. The resulting residue was purified by preparative TLC to afford compound I-61. ^{1}H NMR (400 MHz, DMSO-d6) δ 7.83-7.56 (m, 3H), 4.55 (s, 2H), 1.46 (s, 9H).

Alternatively, Step 3 above can be conducted using BH_3-THF complex as the reducing agent (and heating to ~75 °C) to effect the carbonyl reduction (as described for Intermediate 61, Step 2).

Table 11 includes intermediates that were prepared in an analogous manner to that disclosed for Intermediate 61.

Table 11.

Inter-mediate	Structure	Compound Name	NMR
I-62		5-bromo-2-methyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide	^{1}H NMR ($CDCl_3$, 400MHz): δ 7.63-7.60 (m, 2H), 7.5 (s, 1H), 4.25 (s, 2H), 2.89 (s, 3H).

Intermediate 63

5-bromo-2-ethyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide



I-63

Step 1: 4-bromo-N-ethyl-2-methylbenzenesulfonamide



I-63a

Into a 100-mL 3-necked round-bottom flask were placed a solution of 4-bromo-2-methylbenzene-1-sulfonyl chloride (3.0 g, 9.7 mmol, 1.00 equiv) in dichloromethane (30 mL), ethanamine (700 mg, 15.5 mmol, 1.60 equiv) and DIPEA (4.32 g, 29.1 mmol, 3.0 equiv). The resulting solution was stirred for 0.5 h at 25 °C. The mixture was washed with water (10 ml), dried over sodium sulfate, filtered and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (5:1 petroleum ether/ethyl acetate) to afford compound I-63-a. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 7.47-7.51 (m, 2H), 7.84 (d, J = 8.4 Hz, 1H), 2.99-3.06 (m, 2H), 2.66 (s, 3H), 1.13 (t, J = 2.4 Hz, 3H).

Step 2: 5-bromo-2-ethylbenzo[d]isothiazol-3(2H)-one 1,1-dioxide


I-63b

To a solution of 4-bromo-N-ethyl-2-methylbenzene-1-sulfonamide (1.00 g, 3.59 mmol, 1.00 equiv) in 1,2-dichloroethane (10 mL) was added iodobenzene diacetate (3.50 g, 10.9 mmol, 3.00 equiv) and I_2 (900 mg, 3.54 mmol). The resulting solution was stirred for 16 h at 60 °C. The mixture was washed with water (100 mL), and aqueous sodium sulfite (100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated *in vacuo*. Column chromatography of the resulting residue on silica gel (5:1 petroleum ether/ethyl acetate) gave compound I-63b. ^{1}H NMR (300 MHz, $CDCl_3$) δ: 7.70-7.79 (m, 1H), 7.97 (m, 1H), 8.18 (s, 1H), 3.84 (q, J = 7.2 Hz, 2H), 1.45 (t, J = 7.6 Hz, 3H).

Step 3: 5-bromo-2-ethyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide

To a solution of I-63b (80 mg, 0.28 mmol) in tetrahydrofuran (5 mL) was added BH_3-$S(Me)_2$ (2M in THF, 0.70 mL, 1.4 mMol). The resulting solution was stirred for 4 h at 70°C and then quenched by the addition of ice water (30 mL). The mixture was then extracted with ethyl acetate (3 x 30 mL), and the combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to give crude I-63. MS (ESI) calc'd for $C_9H_{11}BrNO_2S$ $[M+H]^+$: 276, found 276. ^{1}H NMR (300 MHz, $CDCl_3$) δ ppm: 7.77 (s, 2H), 7.57 (s, 1H), 4.34 (s, 2H), 3.21-3.41 (m, 2H), 1.38 (t, J = 7.2 Hz, 3H).

The intermediates described in Table 12 were prepared in an analogous manner to that disclosed for Intermediate 63.

Table 12.

Inter-mediate	Structure	Compound Name	LRMS $[M+H]^+$
I-64		5-bromo-2-isobutyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide	Calc'd: 304, found: 304
I-65		5-bromo-2-(cyclopropylmethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide	Calc'd: 302, found: 302
I-66		5-bromo-2-(cyclopentylmethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide	Calc'd 330, found: 330

Intermediate 67

5-bromo-2-(2,2,2-trifluoroethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide



I-67

Step 1: 4-bromo-2-methyl-N-(2,2,2-trifluoroethyl)benzenesulfonamide



I-63a

Formation of compound I-67a was conducted in an analogous manner as described in Step I of the process for making I-63a.

Step 2: 5-bromo-2-(2,2,2-trifluoroethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide



I-67a

A mixture of periodic acid (1.12 g, 4.91 mmol), compound I-63a (163 mg, 0.491 mmol), chromium trioxide (9.8 mg, 0.098 mmol) in acetonitrile (5 mL) was heated to reflux at 83 °C for 2 h. The reaction mixture was concentrated *in vacuo* to remove the acetonitrile. Water was then added, and the mixture was extracted with EtOAc (x 3). The combined organic layers were washed with saturated aqueous $NaHCO_3$, followed by aq. $Na_2S_2O_3$ and brine. The organic layer was dried over Na_2SO_4, filtered and concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (5-15% EtOAc/Hexanes) to afford I-67a. ^1H NMR ($CDCl_3$, 600MHz): δ 8.24 (d, J = 1.2 Hz, 1H), 8.04 (dd, J = 8.1, 1.8 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 4.30 (q, J = 8.4 Hz, 2H).

Step 3: 5-bromo-2-(2,2,2-trifluoroethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide

To a mixture of compound I-67a (515 mg, 1.50 mmol) in THF (10 mL) was added 1M BH_3·THF (15.0 mL, 15.0 mmol) and the reaction was heated in a sealed tube at 75 °C overnight. The reaction was then cooled to rt and quenched by careful addition of the reaction to a mixture of ice water and DCM. The resulting biphasic mixture was stirred for 2 hours, then extracted with DCM (x 3). The combined organic layers were dried over Na_2SO_4, filtered and

concentrated *in vacuo*. The resulting material was purified by silica gel chromatography (EtOAc/hexanes: 5-30%) to afford impure desired product. The product was repurified by silica gel chromatography (EtOAc/hexanes: 0-20%), to afford compound I-67. ^{1}H NMR ($CDCl_3$, 600MHz): δ 7.69 (br s, 2H), 7.58 (br s, 1H), 4.53 (s, 2H), 3.82 (q, J = 9.0 Hz, 2H).

Intermediate 68

5-bromo-2-(3-hydroxy-2,2-dimethylpropyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide



I-68

Step 1: 5-bromo-2-(3-hydroxy-2,2-dimethylpropyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide



I-68a

To a stirred solution of 5-bromo-2,3-dihydro-1,2-benzothiazole-1,1,3-trione (0.10 g, 0.38 mmol,) in *N*-methyl-2-pyrrolidone (3 mL) was added 3-bromo-2,2-dimethylpropan-1-ol (0.19 g, 1.2 mmol) followed by cesium carbonate (0.37 g, 1.1 mmol). The resulting reaction mixture was stirred for 16 h at 130 °C. The reaction was cooled down to ambient temperature and quenched by the addition of water (10 mL). The resulting mixture was extracted with ethyl acetate (2 x 20 mL). The organic layers were combined, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo* to afford a residue that was purified directly by silica gel column chromatography (ethyl acetate/petroleum ether: 1/1) to afford compound I-68a. LRMS (ESI) calc'd for $C_{12}H_{15}BrNO_4S$ $[M + H]^+$: 348, found: 348.

Step 2: 5-Bromo-2-(3-hydroxy-2,2-dimethylpropyl)-2,3-dihydro-1,2-benzothiazole-1,1-dione

To a stirred solution of 5-bromo-2-(3-hydroxy-2,2-dimethylpropyl)-2,3-dihydro-1,2-benzothiazole-1,1,3-trione (0.20 g, 0.57 mmol) in tetrahydrofuran (5.0 mL) was added a solution of borane dimethylsulfide (1.40 mL, 2.0 M in tetrahydrofuran, 2.8 mmol). The resulting solution was stirred for 2 h at 75 °C. The reaction was quenched by the careful addition of water/ice (10

mL). The resulting mixture was extracted with ethyl acetate (2 x 30 mL). The organic layers were combined, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo* to afford a residue that was purified directly by silica gel column chromatography (ethyl acetate/petroleum ether: 1/1) to afford compound I-68. LRMS (ESI) calc'd for $C_{12}H_{17}BrNO_3S$ $[M + H]^+$: 334, found 334.

Table 13 discloses an intermediate that was prepared in using similar procedures as decribed above for Intermediate I-68.

Table 13.

Inter-mediate	Structure	Compound Name	LRMS $[M+H]^+$
69		5-bromo-2-isopropyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide	Calc'd: 290, found: 290

Intermediate 70

5-bromo-2-(2-methoxyethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide



I-70

To a stirred solution of 5-bromo-2,3-dihydro-1,2-benzothiazole-1,1-dione (0.20 g, 0.81 mmol) in *N*,*N*-dimethylformamide (5 mL) was added 1-bromo-2-methoxyethane (0.13 g, 0.96 mmol) and cesium carbonate (0.39 g, 1.2 mmol). The reaction mixture was stirred for 4 h at 50 °C, then was quenched by water (20 mL). The mixture was extracted with ethyl acetate (2 x 30 mL), the organic layers were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated *in vacuo* to afford a residue that was purified by silica gel column chromatography with petroleum ethyl acetate /ether (1/1) to afford compound I-70. MS (EI) calc'd for $C_{10}H_{12}BrNO_3S$ $[M+H]^+$: 306, found 306.

Table 14 discloses an intermediate prepared in using similar procedures as described for intermediate I-70.

Table 14.

Inter-mediate	Structure	Compound Name	LRMS $[M+H]^+$
I-71		5-bromo-2-(2-hydroxyethyl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide	Calc'd: 292, found: 292

Intermediate 72

5-bromo-2-(4-hydroxy-2-methylbutan-2-yl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide



I-72

Step 1: Ethyl 3-(4-bromo-2-methylphenylsulfonamido)-3-methylbutanoate



I-72a

To 4-bromo-2-methylbenzene-1-sulfonyl chloride (2.00 g, 7.42 mmol) in dichloromethane (40 mL) was added ethyl 3-amino-3-methylbutanoate hydrochloride (1.62 g, 8.92 mmol) and triethylamine (1.88 g, 18.6 mmol). The resulting solution was stirred for 4 h at ambient temperature, then concentrated *in vacuo*. The resulting residue purified by silica gel column chromatography (ethyl acetate/ petroleum ether: 1/1) to afford compound I-72a.

Step 2: ethyl 3-(5-bromo-1,1-dioxido-3-oxobenzo[d]isothiazol-2(3H)-yl)-3-methylbutanoate



I-72b

To ethyl 3-(4-bromo-2-methylphenylsulfonamido)-3-methylbutanoate (0.50 g, 1.32 mmol) in acetonitrile (100 mL) was added periodic acid (2.40 g, 10.5 mmol) and chromium trioxide (26 mg, 0.26 mmol). The resulting mixture was stirred for 4 h at ambient temperature. The solids were removed by filtration, and the filtrate was concentrated *in vacuo* to afford a residue that was purified by silica gel column chromatography (petroleum ether/ethyl acetate: 1/1) to afford compound I-72b. ^{1}H NMR (300 MHz, $CDCl_3$) δ 8.15 (d, J = 1.8 Hz, 1H), 7.96 (dd, J = 1.8, 8.1 Hz, 1H), 7.71 (d, J = 8.1 Hz, 1H), 4.08 (q, J = 7.2 Hz, 2H), 3.12 (s, 2H), 1.88 (s, 6H), 1.12 (t, J = 7.2 Hz, 3H).

Step 3: <u>5-bromo-2-(4-hydroxy-2-methylbutan-2-yl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide</u>

To compound I-71b (0.20 g, 0.51 mmol) in tetrahydrofuran (5 mL) was added borane-methyl sulfide complex (0.25 mL, 10 M in tetrahydrofuran, 2.50 mmol). The resulting solution was stirred for 16 h at 50 °C, and carefully quenched by ice-water (10 mL). The mixture was extracted with ethyl acetate (3 x 30 mL), and the combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo*, and the resulting residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether: 1/1) to afford compound I-72. LRMS (ESI) calc'd for $C_{12}H_{17}BrNO_3S$ $[M + H]^+$: 334, found: 334.

Intermediate 73

5-bromo-2,3-dihydrobenzo[*b*]thiophene 1,1-dioxide



I-73

To a solution of 5-bromo-benzo[*b*]thiophene 1,1-dioxide (1.00 g, 4.08 mmol) in ethanol (14 mL) at 0 °C, sodium borohydride (193 mg, 5.10 mmol) was added. The resulting reaction mixture was warmed to room temperature and stirred overnight. The reaction mixture was then cooled to 0 °C, and quenched with 1N HCl. The mixture was diluted with ethyl acetate (25 mL), the layers were separated, and the aqeous layer was extracted with ethyl acetate (3 x 25 mL). The

combined organic layers were washed with brine, dried over Na_2SO_4, and concentrated *in vacuo*. The crude oil was purified by column chromatography on silica gel (Hexanes/EtOAc: 5:1) to give compound I-73. ^{1}H NMR (500 MHz, $CDCl_3$): δ 7.62 – 7.53 (m, 2 H), 7.51 (s, 1 H), 3.55 – 3.45 (m, 2 H), 3.39 – 3.29 (m, 2 H).

Intermediate 74

1-((4-bromobenzyl)sulfonyl)pyrrolidine



I-74

Step 1: Sodium (4-bromophenyl)methanesulfonate



I-74a

To a boiling solution of 1-bromo-4-(bromomethyl)benzene (200 g, 0.8 mol) in EtOH (500 mL) was added a solution of sodium sulfite (101 g, 0.80 mol) in H_2O (500 ml) over 60 min. The resulting reaction mixture was stirred at refluxing for 2 h, then the mixture was cooled to 0°C, and stirred for 30 min. The mixture was filtered, and the solid was washed with EtOH, and dried *in vacuo* to afford compound I-74a. ^{1}H NMR (300 MHz, D_2O) δ: 7.50 (d, 2H), 7.20 (d, 2H), 4.05 (s, 2H).

Step 2: (4-bromophenyl)methanesulfonyl chloride



I-74b

To a vigorously stirred suspension of sodium (4-bromophenyl)methanesulfonate (167 g, 0.611 mol) in 650 mL DMF at -10°C was added thionyl dichloride (162 mL, 2.23 mol) drop-wise. The resulting reaction solution was stirred at rt for 2 h then was poured into ice with vigorous stirring. The mixture was filtered, and the resulting solid was dissolved in EtOAc, then washed with H_2O and brine, dried over Na_2SO_4, filtered and concentrated to give compound I-74b. ^{1}H NMR (300 MHz, $CDCl_3$) δ: 7.66 (d, 2H), 7.39 (d, 2H), 4.87 (s, 2H).

Step 3: 1-((4-bromobenzyl)sulfonyl)pyrrolidine

To a stirred mixture of potassium carbonate (74.8 g, 0.542 mol) in DCM (70mL) and H_2O (220 mL) at -10 °C was added pyrrolidine (21.2 g, 0.298 mol) in portions, and the resulting mixture was stirred for 20 min. Then (4-bromophenyl)methanesulfonyl chloride (73.0 g, 0.271 mol) in DCM (400 mL)was added drop-wise. The resultant mixture was stirred for 1h at

RT. The organic phase was separated, washed with H_2O, brine, dried over Na_2SO_4, and concentrated. The residue was recrystallized from 5% EtOAc/petroleum ether to give compound I-74. ^1H NMR (300 MHz, CDCl3) δ: 7.52 (d, 2H), 7.25 (d, 2H), 4.20 (s,2H), 3.20-3.30 (m, 4H), 1.80-1.92 (m, 4H); LRMS found: 328 $[M+23]^+$.

Intermediate 75

(±) 4-(3-bromophenyl)-2,2,4-trimethyl-1,3-dioxolane



I-75

Step 1: 1-bromo-3-(prop-1-en-2-yl)benzene



I-75a

To a suspension of Ph_3PMeBr (21.4 g , 60.0 mmol) in THF (500 mL) was added t-BuOK (6.72 g, 60.0 mmol) at 0°C. The resulting mixture was stirred at rt for 1 h. To the mixture was added 1-(4-bromophenyl)ethanone (10.0 g, 50.0 mmol) dropwise at 0 °C, then was stirred for 24 h. H_2O (300 mL) was added, and the mixture was extracted with EtOAc (300 mL x 2). The combined organic layers were washed with brine (300 mL), dried over Na_2SO_4, filtered and concentrated to a residue that was purified by column chromatography on silica gel (Hexanes/EtOAc: 20:1) to afford (±) 1-bromo-4- (prop-1-en-2-yl)benzene, I-75a.

Step 2: (racemic) 2-(3-bromophenyl)propane-1,2-diol



I-75b

To a solution of compound I-75a (10.0 g, 50.7 mmol) at 0°C was added a mixture of $K_2O_8O_4 \cdot 2H_2O$ (930 mg, 2.5 mmol), $K_3Fe(CN)_6$ (83 g, 230 mmol) and K_2CO_3 (21 g, 150 mmol) in t-BuOH (300 mL) and H_2O (300 mL). The reaction was quenched by the addition of aqueous saturated $Na_2S_2O_3$ (200 mL) and extracted with EtOAc (500 mL). The organic layer was washed with brine, dried over Na_2SO_4, filtered and concentrated *in vacuo* to afford racemate of I-75b.

Step 3: (racemic) 4-(3-bromophenyl)-2,2,4-trimethyl-1,3-dioxolane

A suspension of 2-(4-bromophenyl)propane-1,2-diol (6.0 g, 26 mmol), 2,2-dimethoxypropane(6 mL), and TsOH (1.1 g, 6.5 mmol) in toluene (100 mL) was stirred overnight at rt. The mixture was quenched with H_2O and extracted with EtOAc. The organic layer was washed with brine, dried over Na_2SO_4 and concentrated *in vacuo* to afford (racemic) I-75. ^1H NMR ($CDCl_3$, 400 MHz): δ 7.56 (s, 1H) , 7.56-7.20 (m, 3H), 4.08-4.06 (m, 2H) , 1.59-1.39 (m, 6H), 1.39 (d, J = 5.2 Hz, 3H).

Intermediate 76

4-bromo-2-(hydroxymethyl)benzenesulfonamide



I-76

Step 1: 4-bromo-2-methylbenzenesulfonamide



I-76a

Chlorosulfonic acid (63 g, 540 mmol) was added slowly to a cold solution (0°C) of 1-bromo-3-methylbenzene (10 g, 58 mmol) in $CHCl_3$ (100 mL). The reaction was allowed to stir for 2 hours at 0°C. The reaction mixture was poured carefully into ice water (400 mL) and extracted with EtOAc (500 mL). The layers were separated and the organic layer was washed with brine, dried over $NaSO_4$, filtered and concentrated *in vacuo*. The crude product was dissolved in THF (100 mL) and cooled to 0°C, then to the solution was added NH_3/H_2O (25%, 150 ml). The mixture was stirred at the same temperature for 4 hours. The reaction was extracted with EtOAc (200 mL x 2), and the combined organic layers were washed with water (2 x 200 mL) and brine (100 mL), dried over $NaSO_4$, filtered and concentrated *in vacuo* to afford 4-bromo-2-methylbenzenesulfonamide. ^1H NMR (400 MHz, DMSO-d6) δ 7.76 (d, J = 8.4 Hz, 1H), 7.64 (s, 1H), 7.59 (dd, J = 8.4, 2.0 Hz, 1H), 7.48 (brs, 2H), 2.58 (s, 3H).

Step 2: N-((4-bromo-2-methylphenyl)sulfonyl)acetamide



I-76b

To a solution of I-76a (7.0 g, 28 mmol) in pyridine(70 mL) was added Ac_2O (5.7 g, 56 mmol) followed by DMAP (1.0 g, 8.4 mmol). The reaction mixture was stirred for 16 hours at rt, the quenched with saturated aqueous NH_4Cl and H_2O. The resulting mixture was extracted with EtOAc (200 mL x 2). The combined organic layers were washed with 1M HCl (30 mL) and brine (50 mL), dried over Na_2SO_4, filtered and concentrated *in vacuo* to afford a residue that was recrystallized from EtOAc to afford compound I-76b. ^{1}H NMR (400 MHz, DMSO-d6) δ12.26 (br s, 1H), 7.85 (d, *J* = 8.4 Hz, 1H), 7.69-7.63 (m, 2H), 2.57 (s, 3H), 1.95 (s, 3H).

Step 3: 4-bromo-2-(hydroxymethyl)benzenesulfonamide

$KMnO_4$ (2.7 g, 17 mmol) was added to a solution of compound I-76b (0.50 g, 1.7 mmol) in aqueous NaOH (1 M, 24 mL) and the reaction was allowed to proceed at 80°C with stirring for 16 hours. The reaction was quenched with acetone. The resulting insoluble material was remove by filtration, and the filtrate was diluted with H_2O, and acidified to pH = 3 using 1M HCl. The mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine, dried over Na_2SO_4, filtered and concentrated *in vacuo* to afford 2-(N-acetylsulfamoyl)-5-bromobenzoic acid which was carried on to the reduction without further purification. To a solution of 5-bromo-2-sulfamoylbenzoic acid (0.14 g, 0.53 mmol) in THF (5 mL) was added $BH_3.Me_2S$ (160 mg, 2.1 mmol). The reaction mixture was refluxed for 16 hours, cooled to rt, then carefully quenched with *aq.* HCl (2 M) to pH = 3. The resulting mixture was extracted with EtOAc (2 x 50mL). The combined organic layers were washed with brine, dried over Na_2SO_4, filtered and concentrated *in vacuo*. The residue was purified by preparative TLC to afford I-76. ^{1}H NMR (400 MHz, DMSO-d6) δ 7.87-7.85 (m, 1H), 7.72 (d, *J* = 8.4 Hz, 1H),7.63 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.29 (s, 2H), 5.56 (t, *J* = 5.6 Hz, 1H), 4.85 (d, *J* = 5.6 Hz, 2H).

Intermediate 77

4-(benzyloxy)-2-(5-chloro-2-(methylsulfonyl)phenyl)butan-2-ol



I-77

Step 1: (2-bromo-4-chlorophenyl)(methyl)sulfane



I-77a

A solution of 2-bromo-4-chloro-1-fluorobenzene (2.5 mL, 20.52 mmol) and sodium thiomethoxide (1.453 g, 20.72 mmol) in DMF (20 mL) was stirred at 100 °C for 2 h. The reaction mixture was added to water (20 mL) with stirring, and the aqueous mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated *in vacuo* to afford a oily residue that was purified by column chromatography on silica gel (hexanes/EtOAc: 20/1) to afford compound I-77a as a colorless oil. ^{1}H NMR (600 MHz, DMSO): δ 7.74 (d, *J* = 8.6, 2.3 Hz, 1 H), 7.49 (dd, *J* = 8.6, 2.3 Hz, 1 H), 7.28 (d, *J* = 8.6 Hz, 1 H), 2.51 (m, 3 H).

Step 2: 4-(benzyloxy)-2-(5-chloro-2-(methylthio)phenyl)butan-2-ol



I-77b

To a THF solution of isopropylmagnesium chloride-lithium chloride complex (1.0 M) (2.43 mL, 3.16 mmol) in a oven dried vial was added (2-bromo-4-chlorophenyl)(methyl)sulfane (500 mg, 2.11 mmol; dried by passing through a plug of neat magnesium sulfate) dropwise under argon at 0°C. The ice bath was removed and the vial was allowed to warm to room temperature and stirred for 2 h. 4-(benzyloxy)butan-2-ol (1.125 g, 6.31 mmol) was added dropwise into the cooled reaction mixture. The resulting reaction was allowed to stir at room temperature overnight, then was concentrated *in vacuo* to afford an oily residue that was purified by column chromatography on silica gel (hexanes/EtOAc: 10/1) to afford compound I-77b. ^{1}H NMR (600 MHz, DMSO-d6): δ 7.55 (d, *J* = 2.4 Hz, 1 H), 7.27-7.20 (m, 5 H), 7.18 (d, *J* = 7.4 Hz, 2 H), 5.23 (s, 1 H), 4.29 (s, 2 H), 3.43-3.39 (m, 1H), 3.17-3.12 (m, 1 H), 2.40 (s, 3 H), 2.55-2.50 (m, 1 H); 2.16-2.12 (m, 1 H), 1.55 (s, 3 H).

Step 3: 4-(benzyloxy)-2-(5-chloro-2-(methylsulfonyl)phenyl)butan-2-ol

To a solution of 4-(benzyloxy)-2-(5-chloro-2-(methylthio)phenyl)butan-2-ol (297 mg, 0.88 mmol) in CH_2Cl_2 (7 mL) cooled in an ice bath was added meta-chloroperoxybenzoic acid (380 mg, 2.20 mmol). After stirring at room temperature overnight, the reaction mixture was diluted with CH_2Cl_2 (5 mL) and washed with saturated sodium bicarbonate solution, dried over sodium sulfate, filtered and concentrated *in vacuo* to afford an oily residue that was purified by column chromatography on silica gel (hexanes/EtOAc: 20-30%) to give I-77 as a colorless oil. LRMS (ESI) calc'd for $C_{18}H_{22}ClO_4S[M+H]^+$: 369, found 369. ^1H NMR (600 MHz, DMSO-d6): δ 8.08 (d, *J* = 8.7 Hz, 1 H), 7.65 (d, *J* = 2.2 Hz, 1 H), 7.54 (dd, *J* = 8.7, 2.2 Hz, 1 H), 7.24-7.25 (m, 3 H), 7.16 (d, *J* = 7.5 Hz, 2 H), 5.47 (s, 1 H), 4.29-4.30 (m, 2 H), 3.46-3.43 (dt, *J* = 9.7, 6.8 Hz, 1 H), 3.37-3.33 (dt, *J* = 9.7, 6.8 Hz, 1 H), 3.32 (s, 3 H), 2.43-2.38 (dt, *J* = 14.0, 6.8 Hz, 1 H), 2.18-2.15 (dt, *J* = 14.0, 6.8 Hz, 1 H), 1.60 (s, 3 H).

Table 15 discloses an intermediate which was prepared in analogous manner to that of Intermediate 77:

Table 15.

Inter-mediate	Structure	Compound Name	LRMS $[M+H]^+$
I-78		1-((tert-butyldimethylsilyl)oxy)-2-(5-chloro-2-(methylsulfonyl)phenyl)propan-2-ol	Calc'd. 380, found 380.

Intermediate 79

6-chloro-4-hydroxy-4-(hydroxymethyl)thiochroman 1,1-dioxide



I-79

Step 1: 6-chloro-4-hydroxy-4-((isopropoxydimethylsilyl)methyl)thiochroman 1,1-dioxide



I-79a

A three-necked round-bottom flask was charged with magnesium turnings (71.1 mg, 2.93 mmol) that were dried under a rapid stream of N_2 with a heat gun. After cooling to room temperature, the flow rate of N_2 was reduced, and 1 mL of a solution of 6-chloro-4-hydroxy-4-((isopropoxydimethylsilyl)methyl)thiochroman 1,1-dioxide (470 mg, 2.82 mmol) in dry THF (3.5 mL) and two drops of 1,2-dibromoethane (2.0 μL, 0.022 mmol) were added. The mixture was stirred at room temperature and within a few min an exothermic reaction started. The remaining solution was added slowly at room temperature. After the addition was complete, the reaction mixture was stirred at room temperature, and gradually the solution turned gray in color. The mixture was cooled to 0°C, and a solution of 6-chlorothiochroman-4-one 1,1-dioxide (500 mg, 2.168 mmol) in THF (2.0 mL) was added dropwise at 0°C, then warmed to room temperature overnight (an orange solution formed). The resulting mixture was quenched with ammonium chloride solution (10% aqueous) and extracted with ethyl acetate (3 x 5 mL). The combined organic layers were washed with brine (3 x 10 mL), dried over sodium sulfate, filtered and concentrated *in vacuo* to afford compound I-79a that was carried on without further purification.

Step 2: 6-chloro-4-hydroxy-4-(hydroxymethyl)thiochroman 1,1-dioxide

To a crude mixture of I-79a (392 mg, 1.08 mmol), potassium fluoride (62.7 mg, 1.08 mmol) in THF (0.5 mL) and methanol (0.5 mL) was added hydrogen perioxide (30%; 0.29 mL, 3.24 mmol) in one portion at room temperature. The resulting cloudy solution was kept to maintain stirring under 50°C and at room temperature for 2 h. The reaction was quenched with aqueous sodium thiosulfate solution, extracted with ethyl acetate (3 x 5mL), and concentrated to afford a residue that was purified by column chromatography on silica gel (hexanes/EtOAc: 0-100%) to give compound I-79. ^{1}H NMR (600 MHz, DMSO-d6): δ 7.74 (d, J = 8.5 Hz, 1 H), 7.65 (d, J = 2.2 Hz, 1 H), 7.58 (dd, J = 8.5, 2.2 Hz, 1 H), 5.10 (t, J = 5.8 Hz, 1 H), 3.68-3.62 (m, 2 H), 3.54-3.50 (ddd, J = 14.2, 8.3, 2.8 Hz, 1 H), 3.46-3.42 (dd, J = 11.3, 5.4 Hz, 1 H), 2.62-2.56 (ddd, J = 14.8, 8.3, 2.8 Hz, 1 H), 2.36-2.28 (m, 1 H) (note: could not assign one hydroxyl proton; likely due to overlap with solvent peaks).

Intermediate 80

methyl 5-bromo-2,3-dihydro-1H-indene-2-carboxylate



I-80

Step 1: methyl 6-bromo-1-oxo-2,3-dihydro-1H-indene-2-carboxylate



I-80a

Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 5-bromo-2,3-dihydro-1*H*-inden-1-one (1.00 g, 4.74 mmol, 1.00 equiv) in tetrahydrofuran (15 mL). Sodium hydride (0.38 g, 60% in mineral oil, 9.48 mmol) was added followed by dimethyl carbonate (0.90 g, 10.00 mmol). The resulting mixture was stirred for 30 min at 50 °C then quenched by the addition of hydrochloric acid (20 mL, 1 M). The resulting mixture was extracted with ethyl acetate (2 x 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo* to afford compound I-80a. LRMS (ESI) calc'd for $C_{11}H_{10}BrO_3$ $[M + H]^+$: 269, 271(1:1), found 269, 271 (1:1).

Step 2: methyl 5-bromo-2,3-dihydro-1H-indene-2-carboxylate

Into a 25-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of compound I-80a (0.70 g, 2.6 mmol) in trifluoroacetic acid (10 mL). Triethylsilane (4 mL) was added dropwise at 0 °C, and the resulting solution was stirred for 18 h at 10 °C. The reaction mixture was concentrated *in vacuo* and the resulting residue was diluted with ethyl acetate (50 mL) and washed with water (100 mL). The organic layer was concentrated *in vacuo* to afford compound I-80. GCMS (EI) calc'd for $C_{11}H_{11}BrO_2$ $[M]^+$: 254, found 254.

Intermediate 81

1-([3-bromo-5-[(methylsulfanyl)methyl]phenyl]methyl)-1H-1,2,3-triazole



I-81

Step 1: 1-bromo-3,5-bis(bromomethyl)benzene



I-81a

To a stirred solution of 1-bromo-3,5-dimethylbenzene (5.00 g, 27.0 mmol) in acetonitrile (80 mL) was added AIBN (0.045 g, 0.27 mmol) and N-bromosuccinimide (7.20 g, 40.5 mmol). The reaction mixture was stirred for 1 h at 80 °C and then quenched by the addition of aqueous ammonium chloride (300 mL). The resulting solution was extracted with ethyl acetate (100 mL x 3). The organic layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo* to afford a residue that was purified by silica gel column chromatography (ethyl acetate/petroleum ether: 1/100) to afford compound I-81a. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.70 (s, 2H), 7.64 (s, 1H), 4.70 (s, 4H).

Step 2: (3-bromo-5-(bromomethyl)benzyl)(methyl)sulfane



I-81b

Compound I-81a (0.500 g, 1.46 mmol), (methylsulfanyl)sodium (0.102 g, 1.46 mmol, 1.00 equiv), and ethanol (10 mL) were combined, and the resulting solution was stirred for 1 h at 60 °C. The reaction mixture was concentrated *in vacuo* to afford a residue that was used for the next step without any further purification.

Step 3: 1-([3-bromo-5-[(methylsulfanyl)methyl]phenyl]methyl)-1H-1,2,3-triazole

To a stirred solution of compound I-81b (0.500 g, 1.61 mmol) in acetonitrile (15 mL) was added 1H-1,2,3-triazole (0.220 g, 3.19 mmol) and potassium carbonate (0.442 g, 3.20 mmol). The reaction mixture was stirred for 1 h at 25 °C. The reaction was then quenched by the addition of water (30 mL), and the resulting solution was extracted with ethyl acetate (50 mL x 3). The organic layers were combined, washed with water (3 x 10 mL), dried over sodium sulfate, filtered and concentrated *in vacuo* to afford a residue that was purified by silica gel chromatography (ethyl acetate/petroleum ether: 1:2) to give compound I-81. ^{1}H NMR (400 MHz, DMSO): δ 8.24 (s, 1H), 7.77 (s, 1H), 7.49 (s, 1H), 7.39 (s, 1H), 7.23 (s, 1H), 5.64 (s, 2H), 1.93 (s, 3H).

Intermediate 82


I-82

1,1'-((5-bromo-1,3-phenylene)bis(methylene))bis(1H-pyrazole)

Step 1: 1-bromo-3,5-bis(bromomethyl)benzene (alternate synthesis)


I-82a

1-bromo-3,5-dimethylbenzene (5.00 g, 27.0 mmol), *N*-bromosuccinimide (7.20 g, 40.5 mmol), AIBN (0.045g, 0.27 mmol) and acetonitrile (80 mL) were combined in a flask under a nitrogen atmosphere. The resulting solution was stirred for 1 h at 80 °C, then diluted with aqueous ammonium chloride (50 mL) solution, and then extracted with dichloromethane (3 x 50 mL). The combined organic layers were concentrated *in vacuo* to afford a residue that was purfied directly by silica gel column chromtagrophy (petroleum ether) to afford compound I-82a.

Step 2: 1,1'-((5-bromo-1,3-phenylene)bis(methylene))bis(1H-pyrazole)

To a mixture of 1*H*-pyrazole (1.80 g, 26.4 mmol) in acetonitrile (120 mL) was added potassium carbonate (3.60 g, 26.1 mmol). The resulting mixture was stirred for 1 h at 25 °C, then 1-bromo-3,5-bis(bromomethyl)benzene (3.00 g, 8.75 mmol, 1.00 equiv) was added, and the solution was stirred for 16 h at 25 °C. The reaction was quenched by the addition of aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate (3 x 150 mL). The organic layers were combined, dried over sodium sulfate, filtered and concentrated *in vacuo* to give crude product that was applied directly to a silica gel column and eluted with ethyl acetate/petroleum (1/1) to afford compound I-82. LRMS (ESI) calc'd for $C_{14}H_{14}BrN_4$ [M + 1]$^+$: 317, found 317.

Intermediate 83

4-Hydroxycyclohex-1-ene-1-carbonitrile


I-83

Step 1: 4-Oxocyclohex-1-ene-1-carbonitrile


I-83a

In a sealed tube, {[(3E)-4-methoxybuta-1,3-dien-2-yl]oxy}(trimethyl)silane (5.65 mL, 29.0 mmol) and acrylonitrile (1.91 mL, 29.0 mmol) were combined in benzene (9.67 mL), heated to reflux, and allowed to stir for 16 hours. The reaction mixture was then cooled to ambient

temperature and the volatiles were removed *in vacuo* (23 °C water bath). The residue was stirred into a mixture of aqueous HCl (1N; 29.0 mL, 29.0 mmol) and THF (9.7 mL). After being stirred at ambient temperature for 3 hours, the reaction mixture was extracted with diethyl ether. The organic layer was washed with de-ionized water (2x), brine, dried over anhydrous Na_2SO_4, filtered and concentrated *in vacuo* (23 °C water bath). The residue was purified by MPLC on silica gel (using a gradient elution of 0-50% hexanes/acetone). Desired fractions were identified, combined and concentrated *in vacuo* (23 °C water bath) to afford compound I-83a. ^{1}H NMR (600 MHz, $CDCl_3$): δ 6.68 (tt, *J* = 4.0, 1.5, 1H), 3.05 (dt, *J* = 4.3, 2.2, 2H), 2.71 (tq, *J* = 6.9, 1.9, 2H), 2.57 (t, *J* = 6.9 2H).

Step 2: 4-Hydroxycyclohex-1-ene-1-carbonitrile

To a stirred solution of 4-oxocyclohex-1-ene-1-carbonitrile (170 mg, 1.40 mmol) in MeOH (2.3 mL) at -78 °C was added cerium (III) chloride (484 mg, 1.96 mmol) in MeOH (4.7 mL). The resulting mixture was allowed to stir for 5 minutes at -78 °C before $NaBH_4$ (48 mg, 1.3 mmol) was added in one portion. The mixture was stirred for 20 minutes and then allowed to warm to ambient temperature. After being stirred for 30 minutes, the reaction mixture was diluted with water and extracted with diethyl ether (3x). The combined organic extracts were washed with brine, dried over anhydrous Na_2SO_4, filtered, and concentrated *in vacuo* (maintaining the water bath at 23 °C) to afford compound I-83. ^{1}H NMR (600 MHz, $CDCl_3$): δ 6.50 (tt, *J* = 3.9, 1.8, 1H), 4.03-3.98 (m, 1H), 3.50 – 3.42 (qd, *J* = 11.4, 4.5, 1H), 2.50 (br d, *J* = 19.2, 1H), 2.46–2.38 (m, 1H), 2.33–2.23 (m, 1H), 2.21–2.13 (m, 1H), 1.90–1.84 (m, 1H), 1.76–1.67 (m, 1H).

Intermediate 84

4-bromo-2-(hydroxymethyl)benzenesulfonamide



I-84

Step 1: 8-methylene-1,4-dioxaspiro[4.5]decane



I-84a

To a suspension of PPh_3CH_3Br (17.2 g, 48.0 mmol) in THF (100 ml) was added t-BuONa (3.7 g, 38 mmol) at rt. The reaction mixture was stirred for 3 h at the same temperature, then to this mixture was added a solution of 1,4-dioxaspiro[4.5]decan-8-one (3.0 g, 19 mmol) in THF (50 mL). The reaction was stirred at rt for 5 h, then was quenched by saturated aqueous NH_4Cl (10 mL). The resulting mixture was extracted with CH_2Cl_2 (3x 10 mL) and the combined organic layers were concentrated *in vacuo* to afford a residue that was purified by column

chromatography on silica gel (hexanes/EtOAc: 10/1) to give compound I-84a. ^{1}H NMR ($CDCl_3$, 400MHz): δ 4.65 (s, 2H), 3.96 (s, 4H), 2.27 (t, J = 6.5 Hz, 4H), 1.69 (t, J = 6.5 Hz, 4H).

Step 2: Spiro[2.5]octan-6-one ethylene ketone



I-84b

To a solution of 8-methylene-1,4-dioxaspiro[4.5]decane (10 g, 65 mmol) and CH_2I_2 (56 g, 210 mmol) in THF (100 mL) was added $Zn(Et)_2$ (1 M, 110 mL, 110 mmol) under nitrogen at rt, and the mixture was stirred for 5 h at the same temperature. The reaction was quenched by careful addition of aqueous HCl (2M; 150 mL), then was extracted with CH_2Cl_2 (3 x 20 mL). The organic layer was dried over $MgSO_4$, filtered and concentrated *in vacuo* to afford a residue that was purified by column chromatography on silica gel (hexanes/EtOAc: 30/1) to afford compound I-84b. ^{1}H NMR ($CDCl_3$, 400MHz): δ 3.96 (s, 4H), 1.69 (t, *J* = 6.4 Hz, 4H), 1.42 (t, *J* = 6.4 Hz, 4H), 0.27 (s, 4H).

Step 3: Spiro[2.5]octan-6-one



I-84c

To a solution of I-84b (3.00 g, 17.9 mmol) in THF (100 mL) was added HCl (1M; 100 mL), and the mixture was stirred at rt overnight. The reaction mixture was diluted with petroleum ether. The layers were separated and the organic layer was concentrated *in vacuo* to afford a residue that was purified by column chromatography on silica gel (hexanes/EtOAc: 10/1) to afford I-84c. ^{1}H NMR ($CDCl_3$, 400MHz): δ 2.39 (t, *J* = 6.4 Hz, 4H), 1.65 (t, *J* = 6.4 Hz, 4H), 0.46 (s, 4H).

Step 4: 6-oxospiro[2.5]octane-5-carbonitrile



I-84d

To a solution of $NH(i\text{-}Pr)_2$ (1.2 g, 12 mmol) in THF (10 mL) was added n-BuLi (5 mL, 11.5 mmol) under nitrogen at -78°C. The resulting mixture was stirred at 0 °C for 30 min, then to the reaction was added a solution of I-84c (1.3 g, 10 mmol) in THF (10 mL) at -78°C. After stirring at this temperature for 30 min, this mixture was added to a solution of TsCN (3.7 g, 20 mmol) in THF (10 mL) at -78°C, and stirred for 30 min. The reaction was quenched carefully with concentrated ammonium hydroxide (10 mL), and the mixture was warmed to rt then

acidified with 1M HCl. The mixture was extracted with EtOAc (2 x 20 mL). The combined organic layers were concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (hexanes/EtOAc: 10/1) to afford compound I-84d. ^{1}H NMR ($CDCl_3$, 400MHz): δ 3.46-3.42 (m, 1H), 2.46-2.40 (m, 1H), 2.33-2.26 (m, 1H), 2.19-2.13 (m, 1H), 1.94-1.83 (m, 1H), 1.59-1.53 (m, 1H), 1.26-1.17 (m, 1H), 0.54-0.44 (m, 2H), 0.36-0.33 (m,2H).

Step 5: (racemic trans)-6-hydroxyspiro[2.5]octane-5-carbonitrile



I-84e

A mixture of compound I-84e (3.0 g, 20 mmol) and $LiBH_4$ (1.8 g, 80 mmol) in THF (100 mL) was stirred at rt overnight. The mixture was quenched by the careful addition of aqueous HCl (1M; 40 mL) and extracted with DCM (3 x 15 mL). The combined organic layers were concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (hexanes/ EtOAc: 5 / 1) to afford (racemic trans)-6-hydroxyspiro[2.5]octane-5-carbonitrile (I-84e) as a yellow oil. ^{1}H NMR ($CDCl_3$, 400MHz): δ 4.46-4.24 (m, 1H), 3.72 (brs, 1H), 3.54-3.46 (m, 1H), 2.29-2.18 (m, 3H), 2.12-1.68 (m, 3H), 1.08-0.95 (m, 1H), 0.88-0.81 (m, 1H), 0.8-0.73 (m, 2H).

Step 6: Spiro[2.5]oct-5-ene-6-carbonitrile

To a solution of (racemic trans)-6-hydroxyspiro[2.5]octane-5-carbonitrile(I-84e) (1.7 g, 11 mmol) and DIPEA (2.9 g, 22 mmol) in DCM (60 mL) was added MsCl (1.5 g, 12 mmol), and the mixture was stirred at rt for 3 h. DBU (6.9 g, 45 mmol) was added, and the resulting mixture was stirred at rt overnight. After being diluted with water, the mixture was extracted with EtOAc (3 x 20 mL), and the resulting organic layer was washed with aqueous HCl (1 M; 20 mL), saturated aqueous $NaHCO_3$ (20 mL) and brine. The organic layer was dried over $MgSO_4$, filtered and was concentrated *in vacuo* to afford a residue that was purified by column chromatography on silica gel (hexanes/EtOAc: 80/1) to afford spiro[2.5]oct-5-ene-6-carbonitrile I-84. ^{1}H NMR ($CDCl_3$, 400MHz): δ 6.70-6.68 (m, 1H), 2.31-2.35 (m, 2H), 2.08-2.04 (m, 2H), 1.43 -1.4 (m, 2H), 0.44-0.34 (m, 4H).

Example 1

(*cis*)-2-{3-[(4-Fluorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl}cyclohexanecarbonitrile (racemate)



1-1

Step 1: cis-2-(4-(Benzyloxy)-3-((4-fluorophenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile (racemic)



1-a

A vial was charged with (*cis*)-2-[3-amino-4-(benzyloxy)-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl]cyclohexanecarbonitrile (Intermediate I-2; 24 mg; 0.069 mmol), di-tert-butyl(2',4',6'-triisopropyl-3,4,5,6-tetramethyl-[1,1'-biphenyl]-2-yl)phosphine (20 mg, 0.041 mmol), $Pd_2(dba)_3$ (13 mg, 0.014 mmol), and potassium acetate (17 mg, 0.17 mmol). 2-propanol (0.75 mL) and 4-bromofluorobenzene (19 μL, 0.17 mmol) were added and the mixture was sparged with N_2. The vial was then sealed and heated at 85 °C for 2.5 hours. The reaction was cooled to room temperature, diluted with EtOAc (30 mL), and washed with water (10 mL) followed by brine (10 mL). The organic layer was dried over Na_2SO_4, filtered, and concentrated *in vacuo* to afford a residue that was purified by silica gel chromatography (0 to 100% EtOAc/hexanes) followed by further purification by preparatory thin layer chromatography (20% acetone/hexanes) to afford compound 1-a (racemic). LRMS (ESI) calc'd for $C_{26}H_{25}FN_5O$ $[M+H]^+$: 442, found 442.

Step 2: (*cis*)-2-{3-[(4-fluorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl}cyclohexanecarbonitrile (racemate)

To a solution of 1-a (racemic) (25 mg, 0.057 mmol) in EtOAc (2 mL) under nitrogen was added 10% Pd/C (10 mg). The reaction was placed under an atmosphere of H_2 (balloon) and stirred vigorously at room temperature for 2 hours. The balloon of H_2 was removed and EtOH (2 mL) and MeOH (2 mL) were added. The mixture was sonicated for several minutes and then the catalyst was removed by filtration. The filtrate was concentrated *in vacuo* and the residue was purified by mass triggered reverse phase HPLC (C-18; acetonitrile/water containing 0.1% TFA). Lyophilization of the product containing fractions afforded compound 1-1 (racemate). LRMS (ESI) calc'd for $C_{19}H_{19}FN_5O$ $[M+H]^+$: 352, found 352. ^1H NMR (600 MHz, DMSO-d_6): δ 11.06 (d, J = 5.4 Hz, 1H), 8.00 (s, 1H), 7.74 (m, 2H), 7.17 (m, 1H), 7.02 (m, 2H), 6.59 (d, J = 7.2 Hz,

1H), 4.58 (m, 1H), 3.43 (m, 1H), 2.21 (m, 1H), 1.99 (m, 1H), 1.82-1.90 (m, 3H), 1.66 (m, 1H), 1.45-1.58 (m, 2H).

Example 2

(*trans*)-2-{3-[(4-fluorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl}cyclohexanecarbonitrile (racemate)



2-1

Step 1: trans-2-(4-(benzyloxy)-3-((4-fluorophenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile (racemic)



2-a

A vial was charged with (*trans*)-2-[3-amino-4-(benzyloxy)-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl]cyclohexanecarbonitrile (Intermediate 3; 36 mg; 0.104 mmol), di-tert-butyl(2',4',6'-triisopropyl-3,4,5,6-tetramethyl-[1,1'-biphenyl]-2-yl)phosphine (30 mg, 0.062 mmol), $Pd_2(dba)_3$ (19 mg, 0.021 mmol), and potassium acetate (25 mg, 0.26 mmol). 2-propanol (1.0 mL) and 4-bromofluorobenzene (28 μL, 0.26 mmol) were added and the mixture was sparged with N_2. The vial was then sealed and heated at 85 °C for 2.5 hours. The reaction was cooled to room temperature, diluted with EtOAc (30 mL), and washed with water (10 mL) and brine (10 mL). The organic layer was dried over Na_2SO_4, filtered, and concentrated *in vacuo*. Purification of the residue by silica gel chromatography (0 to 100% EtOAc/hexanes) afforded 2-a (racemic). LRMS (ESI) calc'd for $C_{26}H_{25}FN_5O$ $[M+H]^+$: 442, found 442.

Step 2: (*trans*)-2-{3-[(4-fluorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl}cyclohexanecarbonitrile (racemate)

To a solution of 2-a (racemic) (45.1 mg, 0.057 mmol) in EtOAc (4 mL) was added EtOH (1 mL) and 10% Pd/C (10 mg). The reaction was placed under an atmosphere of H_2 (balloon) and stirred vigorously at room temperature for 2 hours. The balloon of H_2 was then removed and the catalyst was removed by filtration. The filtrate was concentrated *in vacuo* and the residue was purified by mass triggered reverse phase HPLC (C-18; acetonitrile/water containing 0.1%

TFA). Lyophilization of the fractions containing desired product afforded 2-1 (racemate). LRMS (ESI) calc'd for $C_{19}H_{19}FN_5O$ $[M+H]^+$: 352, found 352. ^1H NMR (600 MHz, DMSO-d_6): δ 11.05 (d, J = 5.4 Hz, 1H), 8.07 (s, 1H), 7.66 (m, 2H), 7.18 (dd, J = 7.2, 6.0 Hz, 1H), 7.09 (m, 2H), 6.63 (d, J = 7.2 Hz, 1H), 4.64 (m, 1H), 3.28 (m, 1H), 2.15 (m, 1H), 1.68-1.87 (m, 5H), 1.45 (m, 1H), 1.33 (m, 1H).

Example 3

(1*R*,2*R*)-2-{3-[(2-fluoropyridin-4-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl}cyclohexanecarbonitrile



3-1

Step 1: (1R,2R)-2-(4-(benzyloxy)-3-((2-fluoropyridin-4-yl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile



3-a

A vial was charged with (1*R*,2*R*)-2-[3-amino-4-(benzyloxy)-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl]cyclohexanecarbonitrile (Intermediate I-4; 28.5 mg; 0.082 mmol), di-tert-butyl(2',4',6'-triisopropyl-3,4,5,6-tetramethyl-[1,1'-biphenyl]-2-yl)phosphine (23.7 mg, 0.049 mmol), $Pd_2(dba)_3$ (15.0 mg, 0.016 mmol), 4-bromo-2-fluoropyridine (36.1 mg, 0.205 mmol), and potassium acetate (20.1 mg, 0.205 mmol). 2-propanol (1.0 mL) was added and the mixture was sparged with N_2. The vial was then sealed and heated at 85 °C for 2.5 hours. The reaction was cooled to room temperature, diluted with EtOAc (30 mL), and washed with water (10 mL) and brine (10 mL). The organic layer was dried over Na_2SO_4, filtered, and concentrated *in vacuo*. Purification of the residue by silica gel chromatography (0 to 100% EtOAc/hexanes) followed by further purification by preparatory thin layer chromatography (25% acetone/hexanes) afforded compound 3-a. LRMS (ESI) calc'd for $C_{25}H_{24}FN_6O$ $[M+H]^+$: 443, found 443. ^1H NMR (600 MHz, $CDCl_3$): δ 7.97 (d, J = 5.4 Hz, 1H), 7.93 (d, J = 6.0 Hz, 1H), 7.62 (s, 1H), 7.50 (d, J = 7.2 Hz, 2H), 7.45 (t, J = 7.2 Hz, 2H), 7.40 (t, J = 7.2 Hz, 1H), 7.28 (s, 1H), 6.91 (d, J = 6.6 Hz, 1H),

6.85 (d, J = 5.4 Hz, 1H), 5.56 (s, 2H), 4.33 (m, 1H), 3.29 (m, 1H), 2.37 (m, 1H), 1.98-2.10 (m, 3H), 1.91 (m, 1H), 1.80 (m, 1H), 1.41-1.55 (m, 2H).

Step 2: (1*R*,2*R*)-2-{3-[(2-fluoropyridin-4-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl}cyclohexanecarbonitrile

To a solution of 3-a (32.6 mg, 0.074 mmol) in EtOAc (3 mL) was added EtOH (0.5 mL) and 10% Pd/C (10 mg). The reaction was placed under an atmosphere of H_2 (balloon) and stirred vigorously at room temperature for 2 hours. The balloon of H_2 was then removed and the catalyst was removed by filtration. The filtrate was concentrated and the residue was purified on a Biotage 10g silica gel column with 0 to 10% MeOH/CH_2Cl_2 to afford 3-1. LRMS (ESI) calc'd for $C_{18}H_{18}FN_6O$ $[M+H]^+$: 353, found 353. ^1H NMR (600 MHz, DMSO-d_6): δ 11.2 (s, 1H), 8.99 (s, 1H), 7.93 (d, J =6.0 Hz, 1H), 7.50 (d, J = 6.0 Hz, 1H), 7.36 (s, 1H), 7.23 (m, 1H), 6.69 (d, J = 7.2 Hz, 1H), 4.72 (m, 1H), 3.30 (m, 1H), 2.16 (m, 1H), 1.67-1.92 (m, 5H), 1.46 (m, 1H), 1.34 (m, 1H).

Table 16 discloses Examples that were prepared in analogy to Example 3, starting with the appropriate enantiopure trans-2-[3-amino-4-(benzyloxy)-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl]cyclohexanecarbonitrile (Intermediates I-4 *or* I-5).

Table 16.

Example	Structure	Compound Name	LRMS $[M+H]^+$
3-2		(1*S*,2*S*)-2-{3-[(2-fluoropyridin-4-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 353, found 353
3-3		(1R,2R)-2-(4-oxo-3-((4-((pyrrolidin-1-ylsulfonyl)methyl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 481, found 481
3-4		(1*R*,2*R*)-2-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd 412, found 412

3-5		(1*S*,2*S*)-2-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd 412, found 412
3-6		4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)-N,N-dimethylbenzenesulfonamide	Calc'd 441, found 441
3-7		4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)benzenesulfonamide	Calc'd 413, found 413
3-8		(1S,2S)-2-[4-oxo-3-({4-[(1R or 1S))-2,2,2-trifluoro-1-hydroxyethyl]phenyl}amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile	Calc'd 432, found 432
3-9		(1S,2S)-2-[4-oxo-3-({4-[(1S)-2,2,2-trifluoro-1-hydroxyethyl]phenyl}amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile	Calc'd 432, found 432
3-10		(1S,2S)-2-(4-oxo-3-{[1-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-isoindol-5-yl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd 471, found 471

3-11		2-[3-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-N-(1-methyl-1H-pyrazol-3-yl)acetamide	Calc'd 471, found 471
3-12		N-[3-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]-1,3-oxazole-5-carboxamide	Calc'd 458, found 458
3-13		N-[3-({1-[(1R,2R)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]-1,3-oxazole-5-carboxamide	Calc'd 458, found 458
3-14		N-[3-({1-[(1R,2R)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]pyrimidine-2-carboxamide	Calc'd 469, found 469
3-15		2-[3-({1-[(1R,2R)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-N-(1-methyl-1H-pyrazol-3-yl)acetamide	Calc'd 471, found 471
3-16		tert-butyl [3-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]carbamate	Calc'd 463, found 463

3-17		N-[3-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]pyrimidine-2-carboxamide	Calc'd 469, found 469
3-18		4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)-N-(1-methylethyl)benzenesulfonamide	Calc'd: 455, found 455
3-19		N-benzyl-4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)benzenesulfonamide	Calc'd: 503, found 503
3-20		4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)-N-(cyclopropylmethyl)benzenesulfonamide	Calc'd: 467, found 467
3-21		4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)-N-(2-methoxyethyl)benzenesulfonamide	Calc'd: 471, found 471
3-22		4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)-N-cyclohexylbenzenesulfonamide	Calc'd: 495, found 495

3-23		(1S,2S)-2-(4-oxo-3-{[4-(piperidin-1-ylsulfonyl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 481, found 481
3-24		(1S,2S)-2-(3-{[4-(morpholin-4-ylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 483, found 483
3-25		(1S,2S)-2-[4-oxo-3-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile	Calc'd: 334, found 334
3-26		(1S,2S)-2-(4-oxo-3-{[3-(1H-1,2,3-triazol-1-ylmethyl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 415, found 415
3-27		(1S,2S)-2-(3-{[3-methyl-4-(pyrrolidin-1-ylcarbonyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd 445, found 445
3-28		(1S,2S)-2-(4-oxo-3-{[3-(2H-1,2,3-triazol-2-ylmethyl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 415, found 415

3-29		N-[4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]-1,3-oxazole-5-carboxamide	Calc'd 458, found 458
3-30		N-[4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]pyrimidine-2-carboxamide	Calc'd 469, found 469
3-31		(1S,2S)-2-(3-{[3-(1-hydroxyethyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 378, found 378
3-32		tert-butyl [4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]carbamate	Calc'd 463, found 463
3-33		(1S,2S)-2-(3-{[3-(morpholin-4-ylmethyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 433, found 433
3-34		(1S,2S)-2-[3-({3-[(dimethylamino)methyl]phenyl}amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile	Calc'd: 391, found 391

3-35		tert-butyl [5-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)-2-fluorobenzyl]carbamate	Calc'd 481, found 425 (M-*t*Bu)
3-36		tert-butyl [3-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)-5-fluorobenzyl]carbamate	Calc'd 481, found 425 (M-*t*Bu)
3-37		(1S,2S)-2-[3-({3-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]phenyl}amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile	Calc'd: 429, found 429
3-38		(1S,2S)-2-(4-oxo-3-{[3-(2,2,4-trimethyl-1,3-dioxolan-4-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 448, found 448
3-39		(1S,2S)-2-{4-oxo-3-[(3-{[(2,2,2-trifluoroethyl)amino]methyl}phenyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 445, found 445
3-40		N-[5-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)-2-(dimethylsulfamoyl)benzyl]acetamide	Calc'd: 512, found 512

3-41		N-{(1S)-1-[3-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-2,2,2-trifluoroethyl}-2-methylpropane-2-sulfinamide	Calc'd: 535, found 535
3-42		N-{(1R)-1-[3-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-2,2,2-trifluoroethyl}-2-methylpropane-2-sulfinamide	Calc'd: 535, found 535
3-43		(1S,2S)-2-(4-oxo-3-{[3-(1H-pyrazol-1-ylmethyl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 414, found 414
3-44		(1S,2S)-2-(4-oxo-3-{[4-(pyrrolidin-1-ylcarbonyl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 431, found 431
3-45		(1S,2S)-2-(4-oxo-3-{[4-(2H-1,2,3-triazol-2-ylmethyl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 415, found 415
3-46		(1S,2S)-2-(4-oxo-3-{[4-(1H-1,2,3-triazol-1-ylmethyl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd 415, found 415

3-47		(1S,2S)-2-(3-{[3-(1H-imidazol-1-ylmethyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 414, found 414
3-48		(1S,2S)-2-(3-{[4-hydroxy-4-(hydroxymethyl)-1,1-dioxido-3,4-dihydro-2H-thiochromen-6-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 484, found 484
3-49		(1S,2S)-2-{3-[(2-methyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd 439, found 439
3-50		(1S,2S)-2-(4-oxo-3-{[3-(1H-1,2,4-triazol-1-ylmethyl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 415, found 415
3-51		(1S,2S)-2-(4-oxo-3-{[3-(4H-1,2,4-triazol-4-ylmethyl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 415, found 415
3-52		(1S,2S)-2-{3-[(4-{[4-(1-hydroxy-1-methylethyl)-1H-1,2,3-triazol-1-yl]methyl}phenyl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 473, found 473

3-53		(1S,2S)-2-{3-[(2-tert-butyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 481, found 425 (M-*t*Bu)
3-54		(1S,2S)-2-{3-[(1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 425, found 425
3-55		N-{(1S)-1-[4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-2,2,2-trifluoroethyl}-2-methylpropane-2-sulfinamide	Calc'd: 535, found 535
3-56		N-{(1R)-1-[4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-2,2,2-trifluoroethyl}-2-methylpropane-2-sulfinamide	Calc'd: 535, found 535
3-57		(1S,2S)-2-{4-oxo-3-[(4-{[(2,2,2-trifluoroethyl)amino]methyl}phenyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 445, found: 445

3-58		(1S,2S)-2-(3-{[1,1-dioxido-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 507, found 507
3-59		(1S,2S)-2-{3-[(1,1-dioxido-2,3-dihydro-1-benzothiophen-5-yl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 424, found 424
3-60		(1S,2S)-2-{3-[(2-ethyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 453, found 453
3-61		(1S,2S)-2-(4-oxo-3-{[2-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-isoindol-5-yl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 457, found 457
3-62		(1S,2S)-2-(3-{[2-(2-methylpropyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 481, found 481

3-63		(1S,2S)-2-(3-{[2-(cyclopropylmethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 479, found 479
3-64		(1S,2S)-2-{3-[(2-methyl-2,3-dihydro-1H-isoindol-5-yl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 389, found 389
3-65		(1S,2S)-2-(3-{[2-(cyclopentylmethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 507, found 507
3-66		(1S,2S)-2-{4-oxo-3-[(4-{(1R)-1-[(2,2,2-trifluoroethyl)amino]ethyl}phenyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 459, found 459
3-67		4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)-N,N,2-trimethylbenzamide	Calc'd 419, found 419

3-68		(1S,2S)-2-(3-{[3-methyl-4-(morpholin-4-ylcarbonyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 461, found 461
3-69		4-({1-[(1S,2S)-2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)-2-cyclopropyl-N,N-dimethylbenzamide	Calc'd: 445, found 445
3-70		(1S,2S)-2-(3-{[4-(2,2-difluoro-1-hydroxyethyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile (mix of diastereomers)	Calc'd: 414, found 414
[1]The following two examples, 3-71 and 3-72 were separated by chiral-prep HPLC with the following conditions: column: chiralpak AD-H, 0.46 x 15 cm, 5µm mobile phase: ethanol and hexane (0.1% triethlamine) (55% hexane; 15 min run time); detector: UV 254/220 nm.			
[1]3-71		(1S,2S)-2-[4-oxo-3-({4-[(2S or R)-pyrrolidin-2-yl]phenyl}amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile	Calc'd: 403, found 403
[1]3-72		(1S,2S)-2-[4-oxo-3-({4-[(2R or S)-pyrrolidin-2-yl]phenyl}amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile	Calc'd 403, found 403

3-73		(1S,2S)-2-{4-oxo-3-[(4-{(1S)-1-[(2,2,2-trifluoroethyl)amino]ethyl}phenyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 459, found 459
3-74		(1S,2S)-2-(3-{[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 417, found 417
3-75		(1S,2S)-2-(3-{[2-(2-methylpropyl)-2,3-dihydro-1H-isoindol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 431, found 431
3-76		(1S,2S)-2-{3-[(2-ethyl-2,3-dihydro-1H-isoindol-5-yl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 403, found 403
3-77		(1S,2S)-2-(3-{[2-(cyclopropylmethyl)-2,3-dihydro-1H-isoindol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 429 found 429

3-78		(1S,2S)-2-[3-({3-[(methylsulfanyl)methyl]-5-(1H-1,2,3-triazol-1-ylmethyl)phenyl}amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile	Calc'd: 475, found 475
3-79		(1S,2S)-2-(3-{[2-(1-methylethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 467, found 467
3-80		(1S,2S)-2-(3-{[2-(2-hydroxyethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 469, found 469
3-81		(1S,2S)-2-(3-{[2-(3-hydroxy-1,1-dimethylpropyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 511, found 511
3-82		(1S,2S)-2-(3-{[2-(3-hydroxy-2,2-dimethylpropyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 511, found 511

3-83		(1S,2S)-2-(3-{[2-(2-methoxyethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 483, found 483
3-84		(1S,2S)-2-{3-[(3-{[4-(1-hydroxy-1-methylethyl)-1H-1,2,3-triazol-1-yl]methyl}phenyl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile	Calc'd: 473, found 473
3-85		(1S,2S)-2-(3-{[3-(1-hydroxy-2-methoxy-1-methylethyl)-4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 500, found 500
3-86		(1S,2S)-2-(3-{[3-(1,3-dihydroxy-1-methylpropyl)-4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 500, found 500
3-87		(1S,2S)-2-(3-{[3-(1,2-dihydroxy-1-methylethyl)-4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd : 486, found 486
3-88		(1S,2S,5R)-5-hydroxy-2-(4-oxo-3-((4-(trifluoromethyl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 508, found 508

3-89		(1R,2R,5S)-5-hydroxy-2-(4-oxo-3-((4-(trifluoromethyl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 418, found 418
3-90		(1S,2S,5R)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-hydroxycyclohexanecarbonitrile	Calc'd: 384, found 384
3-91		(1S,2S)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd : 368, found 368
3-92		(1S,2S)-2-{3-[(2-fluoropyridin-4-yl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclopentanecarbonitrile	Calc'd: 339, found 339
3-93		(1R,2S)-2-{3-[(2-fluoropyridin-4-yl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclopentanecarbonitrile	Calc'd: 339, found 339
3-94		(1S,2S)-2-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile	Calc'd: 398, found 398
3-95		(1R,2S)-2-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile	Calc'd: 427, found 427

3-96		4-({1-[(1S,2S)-2-cyanocyclopentyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)-N,N-dimethylbenzenesulfonamide	Calc'd: 398, found 398
3-97		(1S,2S)-2-(4-oxo-3-{[1-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-isoindol-5-yl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile	Calc'd: for 457, found 457
3-98		(1S,2S)-2-(4-oxo-3-{[4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile (mix of diastereomers)	Calc'd: 418, found 418
3-99		4-({1-[(1S,2S)-2-cyanocyclopentyl]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl}amino)benzenesulfonamide	Calc'd: 399, found 399
3-100		(1S,2R)-2-{3-[(2-tert-butyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclopentanecarbonitrile	Calc'd: 467, found 467
3-101		(1S,2R)-2-(3-{[1,1-dioxido-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile	Calc'd: 493, found 493
3-102		(1S,2R)-2-{3-[(2-methyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclopentanecarbonitrile	Calc'd: 425, found 425

3-103		(1S,2S)-2-[3-({4-[(1R or 1S)-1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclopentanecarbonitrile	Calc'd: 417, found 417
3-104		(1S,2S)-2-[3-({4-[(1S or 1R)-1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclopentanecarbonitrile	Calc'd: 417, found 417

Example 3-5

(1*S*,2*S*)-2-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl)cyclohexanecarbonitrile



3-5

Step 1: (1S,2S)-2-(4-(Benzyloxy)-3-((4-(methylsulfonyl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile



3-5a

A mixture of (1S,2S)-2-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile (Intermediate I-5; 6.24 g, 18.0 mmol), 1-bromo-4-(methylsulfonyl)benzene (8.44 g, 35.9 mmol), $Pd_2(dba)_3$ (1.64 g, 1.80 mmol) and 2-di-*t*-butylphosphino-3,4,5,6-tetramethyl-2',4',6'-tri-*i*-propylbiphenyl (tetramethyl-tBu-Xphos; 2.59 g, 5.38 mmol) in 2-Propanol (70 mL) was placed in a vial and sealed. The mixture was flushed with argon for 10 min, then was heated at 85 °C for 2 hour. The reaction mixture was cooled

and diluted with EtOAc, filtered through celite, with the resulting filtrate concentrated *in vacuo*. The resulting residue was purified by silica gel chromatography (0-80% EtOAc/hexanes), to give compound 3-5a. LRMS (ESI) calc'd for $C_{27}H_{28}N_5O_3S$ [M+H]: 502; found 502.

Step 2: (1S,2S)-2-(4-(benzyloxy)-3-((4-(methylsulfonyl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile

Compound 3-5a (8.58 g, 17.1 mmol) and Pd/C (10%; 0.85 g, 0.80 mmol) were combined in a flask and placed under nitrogen. Ethyl acetate (100 mL) and THF (100 mL) was added, and the mixture was evacuated *in vacuo* and back-filled with H_2 (3 times). The reaction mixure was stirred at rt under hydrogen (balloon pressure) overnight. The catalyst was removed by filtration of the reaction mixture through celite rinsing with EtOAc. The resulting filtrate was concentrated *in vacuo* to afford a residue that was purified by silica gel chromatography (0-6%MeOH/DCM) to afford a solid that was triturated with MeOH to afford compound 3-5. LRMS (ESI) calc'd for $C_{20}H_{22}N_5O_3S$ $[M+H]^+$: 412, found 412. ^1H NMR (600 MHz, DMSO-d_6): δ 11.1 (s, 1H), 8.66 (s, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 9.0 Hz, 2H), 7.22 (m, 1H), 6.68 (d, J = 7.2 Hz, 1H), 4.70 (m, 1H), 3.35 (m, 1H), 3.10 (s, 3H), 2.16 (m, 1H), 1.68-1.91 (m, 5H), 1.46 (m, 1H), 1.33 (m, 1H).

Table 17 discloses intermedieates utilized in synthesis of compounds of Example 4. Intermediates I-85 through I-87 were made using procedures analogous to those utilized in the making of intermediates I-8 and I-9.

Table 17.

Inter-mediate	Structure	Compound Name	LRMS $[M+H]^+$
I-85		racemic-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-hydroxycyclohexanecarbonitrile	Calc'd: 384, found 384
I-86		(1S,2S,5R)-5-hydroxy-2-(4-oxo-3-((4-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 434, found 434

I-87		(1S,2S,5R)-2-(3-((4-chloro-3-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-hydroxycyclohexanecarbonitrile	Calc'd: 402, found 402

Example 4

(1R,2R,5S)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(((S)-1-cyclopropylethyl)amino)cyclohexanecarbonitrile (4-1)

(1S,2S,5R)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(((S)-1-cyclopropylethyl)amino)cyclohexanecarbonitrile (4-2)

(1R,2R,5R)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(((S)-1-cyclopropylethyl)amino)cyclohexanecarbonitrile (4-3)

(1S,2S,5S)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(((S)-1-cyclopropylethyl)amino)cyclohexanecarbonitrile (4-4)


4-1


4-2


4-3


4-4

Step 1: (1R,2R)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-oxocyclohexanecarbonitrile and (1S,2S)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-oxocyclohexanecarbonitrile


4-a


4-b

To a solution of I-85 [(1S,2S,5R) and (1R,2R,5S)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-hydroxycyclohexanecarbonitrile] (racemic, 77 mg, 0.20 mmol) in DMSO (2.0 mL) was added IBX (stabilized, 45% by weight; 312 mg, 0.502 mmol), and the mixtue was heated at 50 °C for 3h. The mixture was cooled to rt, stir with sat $Na_2S_2O_3$ and sat $NaHCO_3$ for 30 min, extracted with ethyl acetate, wash organic with brine, dried over Na2SO4, filtered and concentrated *in vacuo*. The crude ketone, (4-a and 4-b) was used for next step without purification.

Step 2: Title Compounds 4-1, 4-2, 4-3 and 4-4

$NaCNBH_4$ (28.8 mg, 0.458 mmol) was added to a mixture of the crude ketone from previous step (70 mg, 0.183 mmol), (s)-1-cyclopropylethylamine (150 µl, 1.47 mmol), and acetic acid (84 uL, 1.47 mmol) in MeOH/THF. The mixture was stirred at rt for 3h, diluted with EtOAc and sat. NaHCO3. The organic layer was separated, washed with brine, dried over Na2SO4, and concentrated. The residue was purified by flash chormatography (dry loading, 0-20% MeOH/DCM) to give two mixtures, each containing two diastereomers. The two mixtures was submitted separately to chiral separation to give 4 diasteromers:

Column Used: Phenomenex Lux-4 IC 2.1 X 25cm, 5uM.

Mobile phase: 39% / 61% MeOH/CO_2 (with 0.25% dimethylamine modifier).

Flow rate: 62 mL/Min, 7 min run time

Wavelength: 220 nm.

Diastereomer 1; Example 4-1: (1S,2S,5R)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(((S)-1-cyclopropylethyl)amino)cyclohexanecarbonitrile. LRMS (ESI) calc'd for $C_{24}H_{28}ClN_6O$ $[M+H]^+$: 451, found 451. ^1H NMR (600 MHz, Acetone-d_6): δ 10.1 (s, 1H), 8.09 (s, 1H), 7.78 (d, J = 7.8 Hz, 2H), 7.27-7.29 (m, 3H), 6.60 (d, J = 7.2 Hz, 1H), 4.64 (td, J = 12, and 3.6 Hz, 1H), 3.96 (t, J = 12Hz, 1H), 3.33 (d, J = 21 Hz, 1H), 2.50-2.58 (m, 1H), 2.16-2.30 (m, 2H), 1.87-2.08 (m, 3H), 1.60-1.68 (m, 2H), 1.17 (s, 3H), 0.70-0.80 (m, 1H), 0.50-0.58 (m, 1H), 0.34-0.46 (m, 2H), 0.18-0.23 (m, 1H).

Diastereomer 2; Example 4-2: (1R,2R,5S)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(((S)-1-cyclopropylethyl)amino)cyclohexanecarbonitrile LRMS (ESI) calc'd for $C_{24}H_{28}ClN_6O$ $[M+H]^+$: 451, found 451.

Diastereomer 3; Example 4-3: (1S,2S,5S)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(((S)-1-cyclopropylethyl)amino)cyclohexanecarbonitrile LRMS (ESI) calc'd for $C_{24}H_{28}ClN_6O$ $[M+H]^+$: 451, found 451.

Diastereomer 4; Example 4-4: (1R,2R,5R)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(((S)-1-cyclopropylethyl)amino)cyclohexanecarbonitrile LRMS (ESI) calc'd for $C_{24}H_{28}ClN_6O$ $[M+H]^+$: 451, found 451. ^1H NMR (600 MHz, Acetone-d_6): δ 10.1 (s, 1H), 8.09 (s, 1H), 7.74 (d, J = 9.0 Hz, 2H), 7.27-7.29 (m, 3H), 6.62 (d, J = 7.2 Hz, 1H), 4.64-4.69 (m, 1H), 3.59 (t, J = 10.2 Hz, 1H), 3.00-3.12 (m, 1H), 2.49-2.56 (m, 1H), 2.05-2.26 (m, 5H), 1.26-1.70 (m, 3H), 1.16 (s, 3H), 0.70-0.80 (m, 1H), 0.40-0.49 (m, 2H), 0.24-0.38 (m, 1H), 0.10-0.17 (m, 1H).

Example 5

(1S,2S,5R)-2-(3-((4-chloro-3-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(dimethylamino)cyclohexanecarbonitrile (5-1) and (1S,2S,5S)-2-(3-((4-chloro-3-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(dimethylamino)cyclohexanecarbonitrile (5-2)



5-1



5-2

Step1: (1S,2S)-2-(3-((4-chloro-3-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-oxocyclohexanecarbonitrile



5-a

To a solution of (1S,2S,5R)-2-(3-((4-chloro-3-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-hydroxycyclohexanecarbonitrile (I-87) (0.55 g, 1.4 mmol) in DMSO (14 mL) was added IBX (stablized, 45% by weight; 2.1 g, 3.4 mmol). The mixture was heated at 50°C and held for 2.5 hours. The reaction was cooled to room temperature, diluted with a mixture of water (70 mL), aqueous sodium thiosulphate (15 mL) and aquesous sodium bicarbonate (15 mL), and vigorously stirred for 20 minutes. The reaction mixture was extracted with EtOAc (50 mL). The organic layer was washed with water (15 mL) and brine (15 mL) then

dried over Na_2SO_4 and concentrated *in vacuo* affording compound 5-a. LRMS (ESI) calc'd for $C_{19}H_{16}ClFN_5O_2$ $[M+H]^+$: 400, found 400.

Step 2: (1S,2S,5R)-2-(3-((4-chloro-3-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(dimethylamino)cyclohexanecarbonitrile (5-1) and (1S,2S,5S)-2-(3-((4-chloro-3-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(dimethylamino)cyclohexanecarbonitrile (5-2)

To a suspension of compound 5-a (0.18 g, 0.45 mmol) in a mixture of THF (2.3 mL) and MeOH (2.3 mL) was added dimethylamine (0.16 g, 3.6 mmol) and acetic acid (0.21 mL, 3.6 mmol). The reaction mixture was stirred at room temperature for 15 minutes then sodium cyanoborohydride (0.71 g, 1.1 mmol) was added and the reaction mixture was allowed to stir for an additional 18 hours at room temperature. The reaction mixture was concentrated *in vacuo* to afford a residue that was purified by column chromatography on silica gel (DCM/MeOH).

The first eluting peak gave pure Example 5-1. LRMS (ESI) calc'd for $C_{21}H_{23}ClFN_6O$ $[M+H]^+$: 429, found 429. ^1H NMR (600 MHz, DMSO) δ 11.10 (d, J = 5.6, 1H), 8.47 (s, 1H), 7.84 – 7.78 (m, 1H), 7.43 – 7.36 (m, 2H), 7.24 – 7.19 (m, 1H), 6.61 (d, J = 7.4, 1H), 4.80 – 4.74 (m, 1H), 3.59 – 3.52 (m, 1H), 2.43 – 2.35 (m, 1H), 2.19 (s, 6H), 2.14 – 2.10 (m, 2H), 2.06 – 1.99 (m, 1H), 1.90 – 1.82 (m, 1H), 1.68 – 1.61 (m, 1H), 1.61 – 1.53 (m, 1H).

The second eluting peak was further purified by reverse phase HPLC (C-18; acetonitrile/water containing 0.1% TFA). Fractions containing desired product were diluted with EtOAc, washed with saturated $NaHCO_3$, dried over Na_2SO_4, filtered, and concentrated *in vacuo* to afford Example 5-2. LRMS (ESI) calc'd for $C_{21}H_{23}ClFN_6O$ $[M+H]^+$: 429, found 429. ^1H NMR (600 MHz, DMSO) δ 11.10 (d, J = 5.7, 1H), 8.44 (s, 1H), 7.80 (dd, J = 12.4, 2.5, 1H), 7.49 (dd, J = 8.8, 2.3, 1H), 7.38 (t, J = 8.7, 1H), 7.21 (dd, J = 7.2, 6.0, 1H), 6.64 (d, J = 7.3, 1H), 4.75 – 4.67 (m, 1H), 3.46 – 3.39 (m, 1H), 2.48 – 2.42 (m, 1H), 2.23 – 2.15 (m, 7H), 1.94 – 1.89 (m, 2H), 1.86 – 1.80 (m, 1H), 1.77 – 1.69 (m, 1H), 1.54 – 1.44 (m, 1H).

Table 18 contains Examples 5-3 through 5-28 that were prepared in an analogous fashion to that of Examples 5-1 and 5-2 starting with the appropriately substituted hydroxy-containing intermediate and amine through sequential oxidation and reductive amination reactions.

Table 18.

Example	Structure	Compound Name	LRMS $[M+H]^+$
5-3		(1S,2S,5R)-5-(azetidin-1-yl)-2-(3-((4-chloro-3-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 441, found 441

5-4		(1S,2S,5S)-5-(azetidin-1-yl)-2-(3-((4-chloro-3-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 441, found 441
5-5		(1S,2S,5R)-2-(3-((4-chloro-3-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(((S)-1-cyclopropylethyl)amino)cyclohexanecarbonitrile	Calc'd: 469, found 469
5-6		(1S,2S,5S)-2-(3-((4-chloro-3-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(((S)-1-cyclopropylethyl)amino)cyclohexanecarbonitrile	Calc'd: 469, found 469
5-7		(1S,2S,5R)-5-(azetidin-1-yl)-2-(4-oxo-3-((4-(trifluoromethyl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 457, found 457
5-8		(1S,2S,5S)-5-(azetidin-1-yl)-2-(4-oxo-3-((4-(trifluoromethyl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 457, found 457
5-9		(1R,2R,5S)-5-(azetidin-1-yl)-2-(4-oxo-3-((4-(trifluoromethyl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 457, found 457

5-10		(1R,2R,5R)-5-(azetidin-1-yl)-2-(4-oxo-3-((4-(trifluoromethyl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 457, found 457
5-11		(1S,2S,5R)-5-(((S)-1-cyclopropylethyl)amino)-2-(4-oxo-3-((4-(trifluoromethyl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 485, found 485
5-12		(1S,2S,5S)-5-(((S)-1-cyclopropylethyl)amino)-2-(4-oxo-3-((4-(trifluoromethyl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 485, found 485
5-13		(1R,2R,5S)-5-(((S)-1-cyclopropylethyl)amino)-2-(4-oxo-3-((4-(trifluoromethyl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 485, found 485
5-14		(1R,2R,5R)-5-(((S)-1-cyclopropylethyl)amino)-2-(4-oxo-3-((4-(trifluoromethyl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 485, found 485

5-15		(1S,2S,5R)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(dimethylamino)cyclohexanecarbonitrile	Calc'd: 411, found 411
5-16		(1S,2S,5S)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(dimethylamino)cyclohexanecarbonitrile	Calc'd: 411, found 411
5-17		(1S,2S,5R)-5-(azetidin-1-yl)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 423, found 423
5-18		(1S,2S,5S)-5-(azetidin-1-yl)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 423, found 423
5-19		(1S,2S,5R)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(3-hydroxyazetidin-1-yl)cyclohexanecarbonitrile	Calc'd: 439, found 439

5-20		(1S,2S,5S)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(3-hydroxyazetidin-1-yl)cyclohexanecarbonitrile	Calc'd: 439, found 439
5-21		(1S,2S,5R)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(3-hydroxy-3-methylazetidin-1-yl)cyclohexanecarbonitrile	Calc'd: 453, found 453
5-22		(1S,2S,5S)-2-(3-((4-chlorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)-5-(3-hydroxy-3-methylazetidin-1-yl)cyclohexanecarbonitrile	Calc'd: 453, found 453
5-23		(1S,2S,5R)-5-(azetidin-1-yl)-2-(4-oxo-3-((4-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 473, found 473
5-24		(1S,2S,5S)-5-(azetidin-1-yl)-2-(4-oxo-3-((4-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 473, found 473

5-25		(1S,2S,5R)-5-(dimethylamino)-2-(4-oxo-3-((4-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 461, found 461
5-26		(1S,2S,5S)-5-(dimethylamino)-2-(4-oxo-3-((4-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 461, found 461
5-27		(1S,2S,5R)-5-(((S)-1-cyclopropylethyl)amino)-2-(4-oxo-3-((4-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 501, found
5-28		(1S,2S,5S)-5-(((S)-1-cyclopropylethyl)amino)-2-(4-oxo-3-((4-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 501, found 501

Example 6

(1R,2R)-2-(3-((3-(aminomethyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile



6-1

To a flask containing Example 3-16 (0.29 g, 0.63 mmol) was added HCl-MeOH solution, and the resulting mixture was stirred for 16 hours. After concentration, (1R,2R)-2-(3-((3-(aminomethyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile (HCl salt) was obtained. LRMS (ESI) calc'd. for $C_{20}H_{23}N_6O$ $[M+H]^+$ 363, found 363. ^1H NMR (400 MHz, DMSO-*d6*): δ 11.12 (d, *J* = 5.6 Hz, 1H), 8.41 (br, 3H), 8.15 (s, 1H), 7.78-7.76 (m, 1H), 7.55 (s, 1H), 7.34-7.30 (m, 1H), 7.27-7.19 (m, 1H), 6.99-6.95 (m, 1H), 6.66 (d, *J* = 7.2 Hz, 1H), 4.69-4.63 (m, 1H),3.98 (d, *J* = 5.2 Hz, 2H), 2.70-2.64 (m, 1H), 2.18-2.15 (m, 1H), 1.91-1.88 (m, 2H), 1.79-1.73 (m, 3H), 1.69-1.33 (m, 2H).

Table 19 contains Examples that were prepared in an analogous manner to that of Example 6.

Table 19.

Example	Structure	Compound Name	LRMS $[M+H]^+$
6-2		(1S,2S)-2-(3-((3-(aminomethyl)-4-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 381, found 381.
6-3		(1S,2S)-2-(3-((3-(aminomethyl)-5-fluorophenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 381, found 381

6-4		(1S,2S)-2-(3-((3-(aminomethyl)-4-(methylsulfonyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 441, found 441
6-5		(1S,2S)-2-(3-((4-(aminomethyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 363, found 363

Example 7

(1S,2S)-2-(3-((3-((S)-1-amino-2,2,2-trifluoroethyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrileecarbonitrile



7-1

To a solution of HCl in EtOAc (1 M, 1.5 mL) was added (R)-N-((S)-1-(3-((4-(benzyloxy)-1-((1S,2S)-2-cyanocyclohexyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)phenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide (12 mg, 0.02 mmol), and the resulting mixture was stirred at rt overnight. After concentration *in vacuo*, the resulting residue was purified by *prep.* HPLC (Instrument: YMC-Actus, Column: Triart C18 150 x 30 mm; 5μm, Mobile phase A: water, Mobile phase B: acetonitrile) to afford compound 8-1. LRMS (ESI) calc'd. for $C_{21}H_{22}F_3N_6O$ $[M+H]^+$: 431, found 431.

Table 20 discloses compound examples that were prepared in an analogous manner to Example 7.

Table 20.

Example	Structure	Compound Name	LRMS $[M+H]^+$

7-2		(1S,2S)-2-[3-({3-[(1R)-1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile	Calc'd: 431, found 431
7-3		(1S,2S)-2-[3-({4-[(1R)-1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile	Calc'd 431, found 431
7-4		(1S,2S)-2-[3-({4-[(1S)-1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile	Calc'd 431, found 431

Example 8

2-(aminomethyl)-4-((1-((1S,2S)-2-cyanocyclohexyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N,N-dimethylbenzenesulfonamide



8-1

A mixture of Example 3-40; 10 mg, 0.02 mmol) in *aq*. HCl (1 M, 10 mL) was refluxed for 4 h. After removal of solvent, the residue was purified by *prep.* HPLC to afford 2-(aminomethyl)-4-((1-((1S,2S)-2-cyanocyclohexyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N,N-dimethylbenzenesulfonamide. LRMS (ESI) calcd. For $C_{22}H_{28}N_7O_3S$ $[M+H]^+$ 470, found 470.

Example 9

(*S or R*)-2-(1-(3-(4-(1-Amino-2,2-difluoroethyl)phenylamino)-4-oxo-4,5-dihydropyrazolo[4,3-*c*]pyridin-1-yl)cyclohexyl)acetonitrile and
(*R or S*)-2-(1-(3-(4-(1-amino(-2,2-difluoroethyl)phenylamino)-4-oxo-4,5-dihydropyrazolo[4,3-*c*]pyridin-1-yl)cyclohexyl)acetonitrile



9-1



9-2

Step 1: 1-(4-bromophenyl)-2,2-difluoroethanone



9-a

Into an 100-mL 3-necked round-bottom flask was added a solution of 1,4-dibromobenzene (0.23 g, 0.99 mmol) in tetrahydrofuran (50 mL). The solution was placed under nitrogen and cooled to -78 °C. *n*-Butyllithium (0.4 mL, 2.5 M) was added dropwise, and the resulting solution was stirred for 30 min at the same temperature. Ethyl 2,2-difluoroacetate (0.14 g, 1.10 mmol) was added dropwise to the mixture and the resulting solution was stirred for an additional 1 h at -78 °C. The reaction was quenched by the careful addition of hydrochloric acid (2 mL, 1 M). The mixture was extracted with ethyl acetate (2 x 10 mL), and the organic layers were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated *in vacuo* to afford 1-(4-bromophenyl) 2,2-difluoroethan-1-one. GCMS calc'd for $C_8H_5BrF_2O$ $[M]^+$: 234; found 234.

Step 2: (1S,2S)-2-(4-(benzyloxy)-3-((4-(2,2-difluoroacetyl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile



9-b

Into an 100-mL round-bottom flask were placed (1*S*, 2*S*)-2-[3-amino-4-(benzyloxy)-1*H*-pyrazolo[4,3-*c*]pyridin-1-yl]cyclohexane-1-carbonitrile, Intermediate I-7, (0.50 g, 1.44 mmol), 1-(4-bromophenyl) 2,2-difluoroethan-1-one (0.67 g, 2.87 mmol), *tris*(dibenzylideneacetone)dipalladium(0) (0.33 g, 0.36 mmol), di-*tert*-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (0.45 g, 1.00 mmol), potassium acetate (0.28 g, 2.85 mmol) and isopropanol (50 mL). The resulting mixture was stirred for 16 h at 80 °C. The mixture was filtered and the filtrate was concentrated *in vacuo*. The resulting residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether: 1:10) to afford compound 10-b. LRMS (ESI) calc'd for $C_{28}H_{26}F_2N_5O_2$ $[M + H]^+$: 502, found 502.

Step 3: N-(1-(4-((4-(benzyloxy)-1-((1S,2S)-2-cyanocyclohexyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)phenyl)-2,2-difluoroethyl)-2-methylpropane-2-sulfinamide (diastereomers mixture)



9-c

Into an 100-mL round-bottom flask purged nitrogen were placed compound 9-b (0.25 g, 0.50 mmol), 2-methylpropane-2-sulfinamide (0.12 g, 0.99 mmol), titanium isopropoxide (0.28 g, 1.00 mmol) and tetrahydrofuran (40 mL). The mixture was stirred for 4 h at 80 °C and cooled down to ambient temperature. Sodium borohydride (93 mg, 1.5 mmol) was added portionwise. The mixture was stirred for 3 h at ambient temperature and quenched by water (50 mL). The solids were filtered off and the resulting filtrate was extracted with ethyl acetate (3 x

100 mL). The combined organic layers were combined, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo* to afford the 9-c as a mixture of diastereomers. MS.(ESI) calc'd for $C_{32}H_{37}F_2N_6O_2S$ $[M + H]^+$: 607, found 607.

Step 4: (*S or R*)-2-(1-(3-(4-(1-Amino-2,2-difluoroethyl)phenylamino)-4-oxo-4,5- dihydropyrazolo[4,3-*c*]pyridin-1-yl)cyclohexyl)acetonitrile and (*R or S*)-2-(1-(3-(4-(1-amino(-2,2-difluoroethyl)phenylamino)-4-oxo-4,5-dihydropyrazolo[4,3-*c*]pyridin-1-yl)cyclohexyl)acetonitrile

Into a 50-mL round-bottom flask were placed 9-c (0.25 g, 0.50 mmol), 10% palladium on carbon (0.20 g), ethyl acetate (20 mL), and hydrochloric acid (1 mL, 1 M). The resulting mixture was stirred for 5 h at ambient temperature under hydrogen (2 atm). The solid was removed by filtration. The filtrate was adjusted to pH = 8 with saturated aqeous sodium carbonate, and the mixture was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, dried over sodium sulfate and filtered. The filtrate was concentrated *in vacuo* to afford (1*S*,2*S*)-2-(3-[[4-(1-amino-2,2-difluoroethyl)phenyl]amino]-4-oxo-1*H*,4*H*,5*H*-pyrazolo[4,3-*c*]pyridin-1-yl)cyclohexane-1-carbonitrile (mixture of diastereomers). The solid was purified by Chiral-Prep-HPLC with the following conditions: column, Chiralpak IA, 2 x 25 cm, 5 μm; mobile phase, hexane and ethanol (hold 40.0% ethanol in 30 min); detector, UV 254/220 nm. This affords (*S or R*)-2-(1-(3-(4-(1-amino-2,2-difluoroethyl)phenylamino)-4-oxo-4,5-dihydropyrazolo[4,3-c]pyridin-1-yl)cyclohexyl)acetonitrile (9-1). LRMS (ESI) calc'd for $C_{21}H_{23}F_2N_6O$ $[M + H]^+$: 413, found 413; ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.10 (d, J = 5.6 Hz, 1H), 8.07 (s, 1H), 7.64 (d, J = 8.8 Hz, 2H), 7.33 (d, J = 8.8 Hz, 2H), 7.24-7.21 (m, 1H), 5.93 (d, J = 4.4 Hz, 1H), 4.81-4.61 (m, 1H), 4.12-3.95 (m, 1H), 3.33 (d, J = 11.2 Hz, 1H), 2.21 (d, J = 11.2 Hz, 3H), 1.91-1.75 (m, 5H), 1.77-1.33 (m, 3H); and (*R or S*)-2-(1-(3-(4-(1-amino(-2,2-difluoroethyl)phenylamino)-4-oxo-4,5-dihydropyrazolo[4,3-*c*]pyridin-1-yl)cyclohexyl)acetonitrile (9-2). LRMS (ESI) calc'd for $C_{21}H_{23}F_2N_6O$ $[M + H]^+$: 413, found 413; ^{1}H NMR (400 MHz, DMSO-d_6) δ: 11.09 (d, J = 5.6 Hz, 1H), 8.07 (s, 1H), 7.64 (d, J = 8.8 Hz, 2H), 7.33 (d, J = 8.8 Hz, 2H), 7.24-7.21 (m, 1H), 5.93 (d, J = 4.4 Hz, 1H), 4.72-4.65 (m, 1H), 4.06-4.01 (m, 1H), 3.33 (d, J = 11.2 Hz, 1H), 2.20 (d, J = 11.8 Hz, 2H), 1.91-1.75 (m, 5H), 1.87-1.33 (m, 4H).

Table 21 reveals compounds that were prepared in similar procedures as decribed above in Example 9, using dimethylamine instead of 2-methylpropane-2-sulfinamide. (1*S*,2*S*)-2-(3-(4-((*S or R*)-1-(Dimethylamino)-2,2,2-trifluoroethyl)phenylamino)-4-oxo-4,5-dihydropyrazolo[4,3-

c]pyridin-1-yl)cyclohexanecarbonitrile and (1*S*,2*S*)-2-(3-(4-((*R or S*)-1-(dimethylamino)-2,2,2-trifluoroethyl)phenylamino)-4-oxo-4,5-dihydropyrazolo[4,3-*c*]pyridin-1-yl)cyclohexanecarbonitrile were separated from racemic (1*S*,2*S*)-2-(3-(4-(1-(dimethylamino)-2,2,2-trifluoroethyl)phenylamino)-4-oxo-4,5-dihydropyrazolo[4,3-*c*]pyridin-1-yl)cyclohexanecarbonitrile in chiral HPLC conditions: column, Chiralpak AD-H, 2 x 25cm; mobile phase, ethanol and hexane (hold 85.0% hexane in 40 min); detector, UV 254/220 nm.

Table 21.

Example	Structure	Compound Name	LRMS $[M+H]^+$
9-3		(1*S*,2*S*)-2-(3-(4-((*S or R*)-1-(Dimethylamino)-2,2,2-trifluoroethyl)phenylamino) -4-oxo-4,5-dihydropyrazolo[4,3-*c*]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 459, found 459
9-4		(1*S*,2*S*)-2-(3-(4-((*R*)-1-(Dimethylamino)-2,2,2-trifluoroethyl)phenylamino) -4-oxo-4,5-dihydropyrazolo[4,3-*c*]pyridin-1-yl)cyclohexanecarbonitrile	Calc'd: 459, found 459

Example 10

Racemic-(1S,2S)-2-(3-((4-(2,2-difluoro-1-hydroxyethyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile



10-1

Step 1: (1S,2S)-2-(4-(benzyloxy)-3-((4-(2,2-difluoro-1-hydroxyethyl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile (mixture of diastereomers)



10-a

Into an 100-mL round bottom flask was placed a solution of 9-b (0.13 g, 0.26 mmol, 1.00 equiv) in methanol (10 mL). Sodium borohydride (30 mg, 0.79 mmol, 3.00 equiv.) was added portionwise, and the resulting mixture was stirred for 3 h at ambient temperature. Water (20 mL) was added to the reaction and the mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo* to give racemic mixture of compound 10-a. LRMS (ESI) calc'd: for $C_{28}H_{28}F_2N_5O_2$ $[M + H]^+$: 504, found 504.

Step 2: (1S,2S)-2-(3-((4-(2,2-difluoro-1-hydroxyethyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile (mixture of diastereomers)

Deprotection was proceeded in a similar procedure as decribed above for Examples 3-8 and 3-9 to afford a diastereomeric mixture of 10-1. LRMS(ESI) calc'd for $C_{22}H_{22}F_2N_5O_2$ $[M + H]^+$: 414, found 414; ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.10 (d, J = 5.6 Hz, 1H), 8.10 (s, 1H), 7.66 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 7.24-7.21 (m, 1H), 6.68 (d, J = 7.2 Hz, 1H), 6.11-5.82 (m, 2H), 4.72-4.64 (m, 2H), 3.38-3.35 (m, 1H), 2.20 (d, J = 10.0 Hz, 2H), 1.95-1.13 (m, 6H).

Example 11

(1S,2S)-2-(3-((3-(1,2-dihydroxypropan-2-yl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile (mixture of diastereomers)



11-1

To a suspension of (*1S,2S*)-2-{4-Oxo-3-[3-(2,2,4-trimethyl-[1,3]dioxolan-4-yl)-phenylamino]-4,5-dihydro-pyrazolo[4,3-c]pyridin-1-yl}- cyclohexanecarbonitrile

(diastereomeric mixture of Example 3-38; 10 mg, 0.022 mmol) in THF (1 mL) was added HCl (0.4 mL). The resulting suspension was stirred at room temperature for 8 hour. The mixture was concentrated *in vacuo*, and the resulting residue was purified by *prep.* HPLC (method below) to afford compound 11-1 (mixture of diastereomers). LRMS (ESI) calcd. for $C_{22}H_{25}N_5O_3$ $[M + H]^+$ 408, found 408.

Instrument: Gilson 215
Column: ASB C18 5u 150*25mm
Mobile phase A: Water (0.01mol/L ammonium bicarbonate)
Mobile phaseB: Acetonitrile(neutral)

Example 12

(1S,2S)-2-(3-(isoindolin-5-ylamino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile (TFA salt)



12-1

To a stirred solution of tert-butyl 5-((4-(benzyloxy)-1-((1S,2S)-2-cyanocyclohexyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)isoindoline-2-carboxylate prepared in an analogous manner as described for EXAMPLE 3-16, (35 mg, 0.062 mmol) in DCM (0.5 ml) was added TFA (0.5 ml). The resulting solution was stirred at rt for approximately 3 hr. The reaction was concentrated to afford a crude residue that was taken up into MeOH (2 mL) and was purified by mass triggered reverse phase HPLC to afford. Lyophyllization of the product fractions affords compound 12-1 as a TFA salt. LRMS calc'd for $C_{21}H_{23}N_6O$ $[M+H]^+$: 375; found: 375. ^{1}HNMR (600 MHz, DMSO-d6): δ 11.07 (d, J = 5.4 Hz, 1H), 9.24 (br s, 2H), 8.19 (s, 1H), 7.67 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.28 (d, J = 7.8 Hz, 1H), 7.20 (t, J = 7.8 Hz, 1H), 6.65 (d, J = 7.2 Hz, 1H), 4.66 (dt, J = 10.8, 4.2 Hz, 1H), 4.47 (br t, J = 4.8 Hz, 2H), 4.41 (br t, J = 5.4 Hz, 2H), 3.31 (m overlapping with water peak, 1H) 2.16 (br d, J = 10.8 Hz, 1H), 1.86-1.71 (m, 4H), 1.47 (br q, J = 12.6 Hz, 1H), 1.32 (br q, J = 13.2 Hz, 1H).

Example 13-1

5-((1-((1S,2S)-2-Cyanocyclohexyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-indene-2-carboxylic acid (mixture of diastereomers)



13-1

Step 1: Methyl 5-((4-(benzyloxy)-1-((1S,2S)-2-cyanocyclohexyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-indene-2-carboxylate (mixture of diastereomers)



13-a

Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, were placed Intermediate I-3 (0.80 g, 2.30 mmol), Intermediate I-80 (0.70 g, 2.74 mmol), di-*tert*-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (0.70 g, 1.65 mmol), *tris*(dibenzylideneacetone)dipalladium(0)-chloroform (0.70 g, 0.68 mmol), potassium acetate (0.30 g, 3.06 mmol) and isopropanol (20 mL). The resulting mixture was stirred for 6 h at 80 °C then was cooled and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether: 1/3) to afford compound 13-a (mixture of diastereomers): LRMS (ESI) calc'd for $C_{31}H_{32}N_5O_3$ $[M + H]^+$: 522, found 522.

Step 2: 5-((4-(Benzyloxy)-1-((1S,2S)-2-cyanocyclohexyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-indene-2-carboxylic acid (mixture of diastereomers)



13-b

Into a 25-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen were placed 13-a (mixture of diastereomers; 0.15 g, 0.29 mmol), methanol (10 mL), sodium hydroxide (50 mg, 1.25 mmol, 4.31 equiv) and water (10 mL). The resulting mixture was stirred for 3 h at 15 °C, then was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated *in vacuo* to afford 13-b (mixture of diastereomers). LRMS (ESI) calc'd for $C_{30}H_{30}N_5O_3$ $[M + H]^+$: 508, found 508.

Step 3: 5-((1-((1S,2S)-2-cyanocyclohexyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-2,3-dihydro-1H-indene-2-carboxylic acid (mixture of diastereomers)

Deprotection was similar to that described for EXAMPLE 3 to afford 5-(1-((1*S*,2*S*)-2-cyanocyclohexyl)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-*c*]pyridin-3-ylamino)-2,3-dihydro-1*H*-indene-2-carboxylic acid (mixture of diastereomers) was obtained: MS (ESI) calc'd for $C_{23}H_{24}N_5O_3$ $[M + H]^+$: 418, found 418; ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.04 (br s, 1H), 7.95 (br s, 1H), 7.47 (s, 1H), 7.41 (d, J = 10.8 Hz, 1H), 7.21 (d, J = 10.0 Hz, 1H), 7.11 (d, J = 10.8 Hz, 1H), 6.66 (d, J = 10.0 Hz, 1H), 4.71-4.62 (m, 1H), 3.14-3.04 (m, 4H), 2.27-2.14 (m, 1H), 1.89-1.75 (m, 5H), 1.64-1.38 (m, 3H).

Example 14

Racemic-trans 6-(3-((4-(methylsulfonyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile



14-1

Step 1: cis and trans- 6-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile (racemic)


14-a


14-b

A mixture of spiro[2.5]oct-5-ene-6-carbonitrile (Intermediate I-84 ; 1.38 g, 10.4 mmol), DBU (0.32 g, 2.2 mmol) and 4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-3-amine (Intermediate 1-1; 0.25 g, 1.1 mmol) in EtOH (4 mL) was stirred in 100°C in sealed-vessel for 7 days. After removal of the solvent *in vacuo*, the residue was purified by column chromatography on silica gel (Hex: EtOAc = 5:1) to give the individual cis/trans isomers of 6-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile (racemic).

Trans isomer: ^{1}H NMR ($CDCl_3$, 400MHz): δ 7.48 (d, *J* = 6.4Hz, 1H), 7.11-6.96 (m, 5 H), 6.43 (d, *J* = 6.2 Hz, 1H), 5.14 (s, 2H), 4.11 (br, 2H), 3.92-3.85 (m, 1H), 3.05-2.98 (m, 1H), 1.93-1.77 (m, 2H), 1.66-1.55 (m, 2H), 1.07-1.02 (m, 1H), 0.69-0.66 (m, 1H), 0.16-0.10 (m, 2H), 0.03-0.00 (m, 2H).

Cis isomer: ^{1}H NMR ($CDCl_3$, 400MHz): δ 7.76 (d, J=6.4 Hz, 1H), 7.42-7.4 (m, 2H), 7.35-7.25 (m, 3H), 6.78 (d, *J* = 6.4 Hz, 1H), 5.46 (s, 2H), 4.42 (br, 2H), 4.31-4.26 (m, 1H), 3.31-3.27 (m, 1H), 2.71-2.61 (m, 1H), 2.14-2.06 (m, 2H), 1.85-1.78 (m, 1H), 1.57-1.46 (m, 1H), 1.33-1.21 (m, 1H), 0.81-0.72 (m, 2H), 0.56-0.52 (m, 1H), 0.34-0.31 (m, 2H).

Step 2: racemic-trans-6-(4-(benzyloxy)-3-((4-(methylsulfonyl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile


14-c

To a suspension of *trans*-6-(3-amino-4-(benzyloxy)-1H-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile (racemic; 50 mg, 0.13 mmol) and KOAc (34 mg, 0.34 mmol) in *i*-PrOH (0.5 ml) was added $Pd_2(dba)_3$ (27 mg, 0.03 mmol), *t*BuXPhos (34 mg, 0.08 mmol) and 1-bromo-4-(methylsulfonyl)benzene (40 mg, 0.16 mmol) under a nitrogen atmosphere. The

resulting suspension was heated to 105°C using microwave reactor for 1 h, then cooled to room temperature and filtered. The filtrate was purified by *prep.* TLC (silica gel, Hex:EtOAc = 1:1) to afford racemic-trans-6-(4-(benzyloxy)-3-((4-(methylsulfonyl)phenyl)amino)-1H-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile, 14-c. ^{1}H NMR ($CDCl_3$, 400MHz): δ 7.95 (d, *J* = 6 Hz, 1H), 7.89-7.87 (m, 2 H), 7.63-7.59 (m, 3H), 7.55-7.53 (m, 2H), 7.48-7.4 (m, 3H), 6.94 (d, *J* = 6 Hz, 1H), 5.6 (s, 2H), 4.45-4.38 (m, 1H), 3.52-3.45 (m, 1H), 3.03 (s, 3H), 2.37-2.23 (m, 2H), 2.11-2.01 (m, 2H), 1.51-1.47 (m, 1H), 1.14-1.08 (m, 1H), 0.59-0.47 (m, 4H). LRMS calc'd for $C_{29}H_{30}N_5O_3S$ $[M+H]^+$: 528; found 528.

Step 3: Racemic-trans 6-(3-((4-(methylsulfonyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile

A mixture of racemic 14-c (37 mg, 0.07 mmol) and Pd/C (10 mg) in THF/EtOAc (1 mL, 1/1) was stirred at rt under H_2 (15 psi) overnight. The catalyst was removed by filtration, and the fitrate was concentrated *in vacuo*. The residue was washed with MeOH followed by THF to give Racemic-trans 6-(3-((4-(methylsulfonyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile, 14-1. LRMS (ESI) calc'd. for $C_{22}H_{25}N_5O_3S$ $[M+H]^+$: 438; found 438.^{1}H NMR (DMSO-*d6*, 400MHz): δ 11.18 (s, 1H), 8.72 (s, 1 H), 7.88-7.79 (m, 4H), 7.32-7.24 (m, 1H), 6.73 (d, *J* = 7.3 Hz, 1H), 4.90-4.79 (m, 1H), 3.49-3.42 (m, 1H), 3.14 (s, 3H), 2.31-2.24 (m, 1H), 2.04-1.91 (m, 3H), 1.44-1.41 (m, 1H), 1.00-0.98 (m, 1H), 0.50-0.36 (m, 4H).

Table 23 discloses compounds that were prepared in an analogous manner to that described for Example 14, using the appropriate intermediates.

Table 23

Example	Structure	Compound Name	LRMS $[M+H]^+$
14-2		4-((1-((5S,6S)-5-cyanospiro[2.5]octan-6-yl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N,N-dimethylbenzenesulfonamide	Calc'd. 467, found 467

14-3		Racemic-cis-6-(3-((4-(methylsulfonyl)phenyl)amino)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile	Calc'd. 438, found 438

BIOLOGICAL ASSAYS

Jak Biochemical HTRF Assay Protocol

The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain for each enzyme (Invitrogen JAK1 #M4290, JAK2 #M4290, JAK3 #M4290, Tyk2 #M4290) in an HTRF format biochemical assay. The reactions employed a common peptide substrate, LCB-EQEDEPEGDYFEWLW-NH2 (in-house). The basic assay protocol is as follows: First, 250 nL of diluted compounds in DMSO were dispensed into the wells of a dry 384-well Black plate (Greiner #781076) using a Labcyte Echo 555 acoustic dispenser. Subsequent reagent additions employed an Agilent Bravo. Next, 18 μL of 1.11X enzyme and 1.11X substrate in 1X assay buffer (Invitrogen kinase buffer # PV3189, 2 mM DTT, 0.05% BSA) were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate. After equilibration, 2 μL of 10X ATP in 1X assay buffer was added to initiate the kinase reaction and the plates were shaken and then incubated at room temperature for 120 minutes. At the end of the incubation, 20 μL of 2X stop buffer (streptavidin-Dylight 650 (Thermo #84547B/100mL), Eu-tagged pY20 antibody (Perkin Elmer #AD0067), EDTA, HEPES, and Triton) was added to quench the reaction. Plates were shaken and centrifuged and then incubated 60 minutes at room temperature and then read on a Perkin Elmer Envision (λ_{ex} = 337 nm, λ_{em} = 665 and 615 nm, TRF delay time = 20 μs). HTRF signal = 10,000 * 665 nm reading / 615 nm reading. After normalization to untreated controls, the percent inhibition of the HTRF signal at each compound concentration was calculated. The plot of percent inhibition versus the log of compound concentration was fit with a 4-parameter dose response equation to calculate IC_{50} values.

Final reaction conditions were:

Enzyme	[E] (nM)	[S] (μM)	[ATP] (μM)	[Eu-pY20] (nM)	[SA-Dylight] (nM)
JAK1	1.405	0.75	31.8	9	312.5
JAK2	0.052	0.75	8.5	9	312.5
JAK3	0.031	0.75	2.9	9	312.5
Tyk2	2.612	0.75	6.9	9	312.5

Compound concentrations tested were 1496, 499, 175, 49.9, 18.7, 6.2, 2.1, 0.75, 0.24, 0.075, and 0.0125 nM, with 1.25% residual DMSO.

BIOLOGICAL DATA

Examples of the instant invention were evaluated in JAK1 and JAK2 *in vitro* binding assays. The following table tabulates the biological data disclosed for the instant invention as JAK1 IC_{50} and JAK2 IC_{50} values.

Example	JAK1 IC_{50}	JAK2 IC_{50}
1-1	2.5	36
2-1	0.56	7.5
3-1	18	97
3-2	0.40	5.4
3-3	6.1	21
3-4	9.4	16
3-5	0.12	0.83
3-6	0.11	0.33
3-7	0.11	0.85
3-8	0.13	0.82
3-9	0.081	0.54
3-10	0.12	0.43
3-11	0.41	3.3
3-12	0.31	2.3
3-13	14	25
3-14	38	68
3-15	14	30
3-16	1.4	3.3
3-17	0.91	5.8
3-18	0.12	0.37
3-19	0.21	1.2
3-20	0.13	0.60
3-21	0.17	0.79
3-22	0.40	1.2

3-23	0.31	0.48
3-24	0.15	0.47
3-25	0.45	3.2
3-26	0.10	0.49
3-27	0.13	0.20
3-28	1.0	0.93
3-29	0.32	1.5
3-30	0.29	2.0
3-31	0.46	1.7
3-32	0.45	1.5
3-33	1.3	1.7
3-34	1.1	1.1
3-35	3.2	4.7
3-36	2.3	3.8
3-37	0.18	2.1
3-38	5.0	16
3-39	0.64	1.8
3-40	0.10	0.79
3-41	1.6	29
3-42	0.46	13
3-43	1.4	1.7
3-44	1.4	4.8
3-45	0.37	0.42
3-46	0.095	0.34
3-47	0.78	2.2
3-48	18	18
3-49	0.026	0.29
3-50	0.50	1.3
3-51	0.25	1.2
3-52	0.16	0.41
3-53	0.039	0.19
3-54	0.051	0.62

3-55	0.52	1.5
3-56	0.31	0.54
3-57	0.20	0.53
3-58	0.050	0.58
3-59	0.062	0.71
3-60	0.044	0.41
3-61	0.55	1.1
3-62	0.083	0.41
3-63	0.066	0.54
3-64	0.39	1.6
3-65	0.12	0.65
3-66	0.20	0.32
3-67	0.34	0.43
3-68	0.47	0.28
3-69	2.1	5.7
3-70	0.14	0.61
3-71	0.27	0.54
3-72	0.45	0.50
3-73	0.26	0.45
3-74	0.14	0.29
3-75	0.28	0.68
3-76	0.41	2.1
3-77	0.52	2.3
3-78	2.0	4.4
3-79	0.071	0.48
3-80	0.079	0.92
3-81	0.055	0.23
3-82	0.11	0.85
3-83	0.066	0.55
3-84	0.52	2.6
3-85	3.0	4.2
3-86	2.8	7.6

3-87	0.25	0.95
3-88	0.48	4.1
3-89	9.8	117
3-90	0.28	7.3
3-91	0.45	10.3
3-92	0.64	5.7
3-93	12	48
3-94	0.12	0.69
3-95	4.7	16
3-96	0.11	0.30
3-97	0.082	0.44
3-98	0.075	0.53
3-99	0.090	0.51
3-100	0.043	0.28
3-101	0.056	0.50
3-102	0.051	0.66
3-103	0.28	0.70
3-104	0.22	0.59
4-1	5.3	122
4-2	84	>1500
4-3	0.30	13
4-4	7.8	525
5-1	1.5	19
5-2	0.60	14
5-3	1.7	40
5-4	1.7	31
5-5	7.1	113
5-6	1.3	55
5-7	1.4	60
5-8	0.88	22
5-9	25	660
5-10	37	940

5-11	3.0	106
5-12	1.2	70
5-13	97	>1500
5-14	9.4	580
5-15	0.28	11
5-16	0.34	11
5-17	0.83	33
5-18	0.54	13
5-19	0.11	2.5
5-20	0.14	3.0
5-21	0.35	6.5
5-22	0.24	4.0
5-23	0.88	31
5-24	0.88	31
5-25	0.96	22
5-26	0.33	7
5-27	3.7	233
5-28	0.50	37
6-1	1.5	5.2
6-2	0.75	2.3
6-3	1.4	2.3
6-4	1.0	2.9
6-5	0.46	0.82
7-1	0.61	1.5
7-2	0.26	2.2
7-3	0.12	0.37
7-4	0.11	0.41
8-1	0.78	1.6
9-1	0.19	0.47
9-2	0.22	0.51
9-3	0.16	0.39
9-4	0.11	0.25

10-1	0.14	0.61
11-1	2.5	4.0
12-1	0.31	0.86
13-1	0.47	3.4
14-1	1.1	4.4
14-2	0.80	2.2
14-3	3.7	4.8

CLAIMS:

1. A compound of formula I or a pharmaceutically acceptable salt, or a stereoisimer thereof:



I

A is selected from aryl and heteroaryl;
n is 0, 1, 2, 3, or 4;
m is 0, 1, 2, 3, or 4;
p is 0, 1, 2, 3, or 4;
R^1 is selected from:
halogen,
Oxo (=O),
C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{1-10} heteroalkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{2-10} alkenyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
aryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{3-8} cycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
heteroaryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
(C_{1-10})heteroalkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
C_{3-8} cycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
aryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
heteroaryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
C_{0-10} alkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
(C_{1-10})heteroalkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{3-8} cycloalkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
aryl C_{0-10} alkylaminoamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
heteroaryl C_{0-10} alkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
(C_{3-8})heterocycloalkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{0-10} alkylsulfonylC_{0-10} alkyl,
C_{1-10} heteroalkylsulfonylC_{0-10} alkyl,

(C_{3-8})cycloalkylC_{0-10}alkylsulfonylC_{0-10} alkyl,
(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfonylC_{0-10} alkyl,
heteroarylC_{0-10} alkylsulfonylC_{0-10} alkyl,
arylC_{0-10} alkylsulfonylC_{0-10} alkyl,
C_{1-10} alkylsulfamoylC_{0-10} alkyl,
C_{1-10} heteroalkylsulfamoylC_{0-10} alkyl,
(C_{3-8})cycloalkylC_{0-10} alkylsulfamoylC_{0-10} alkyl,
(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfamoylC_{0-10} alkyl,
heteroarylC_{0-10} alkylsulfamoylC_{0-10} alkyl,
arylC_{0-10} alkylsulfamoylC_{0-10} alkyl,
$(C_{0-10}$ alkyl$)_{1-2}$ amino,
$-CO_2(C_{0-10}$ alkyl),
$-(C_{0-10}$ alkyl$)CO_2H$,
$-SO_2NH_2$,
$-SO_2NH(C_{1-10}$ alkyl)
$-SO_2N(C_{0-10}$ alkyl$)_2$,
$-SO_2CF_3$,
$-SO_2CF_2H$,
C_{1-10} alkylsulfinylC_{0-10} alkyl,
C_{1-10} heteroalkylsulfinylC_{0-10}alkyl,
(C_{3-8})cycloalkylC_{0-10}alkylsulfinylC_{0-10}alkyl,
(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfinylC_{0-10}alkyl,
heteroarylC_{0-10} alkylsulfinylC_{0-10}alkyl,
arylC_{0-10}alkylsulfinylC_{0-10}alkyl,
C_{0-10} alkylsulfinylaminoC_{0-10} alkyl,
C_{1-4}acylamino C_{0-10} alkyl,
hydroxy,
$-(C_{1-10}$ alkyl)OH,
$-C_{0-10}$ alkylalkoxy,
cyano,
$(C_{1-6}$alkyl)cyano, and
C_{1-6}haloalkyl;

R^2 is selected from:
halogen,
Oxo (=O),
C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{3-8} cycloalkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{0-10} alkylaminoC_{0-10} alkyl,
(C_{1-10})heteroalkylaminoC_{0-10}alkyl,
C_{3-8} cycloalkyl C_{0-10} alkylaminoC_{0-10} alkyl,
aryl C_{0-10} alkylaminoC_{0-10} alkyl,
heteroaryl C_{0-10} alkylaminoC_{0-10} alkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkylaminoC_{0-10} alkyl,
C_{1-10} alkylsulfonyl,
(C_{3-8})cycloalkylC_{0-10}alkylsulfonyl,
(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfonyl,
(C_{0-10} alkyl)$_{1-2}$ amino,
-CO_2(C_{0-10} alkyl),
-(C_{0-10} alkyl)CO_2H,
-SO_2CF_3,
-SO_2CF_2H,
C_{1-10} alkylsulfinyl,
hydroxy,
-(C_{1-10} alkyl)OH,
-C_{0-10} alkylalkoxy,
cyano,
(C_{1-6}alkyl)cyano, and
C_{1-6}haloalkyl, and
wherein two R^2 may optionally join together with the ring atoms to which they are attached and form a 3 to 6 membered ring; and

wherein R^1 and R^2 are each optionally substituted with 1, 2, 3, or 4 R^3 substituents;

R^3 is independently selected from:
halogen,
C_{1-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, and
C_{1-10} heteroalkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{2-10} alkenyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
aryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{3-8} cycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
heteroaryl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
((C_{0-10})alkyl)$_{1-2}$aminocarbonyloxy,
aryl (C_{0-10})alkylaminocarbonyloxy,
-CO_2(C_{0-10} alkyl),
-(C_{0-10} alkyl)CO_2H,

Oxo (=O),
$-SO_2NH_2$,
$-SO_2NH(C_{1-10}$ alkyl)
$-SO_2N(C_{0-10}$ alkyl$)_2$,
$-SO_2CF_3$,
$-SO_2CF_2H$,
C_{1-10} alkylsulfinyl,
amino,
$(C_{0-10}$ alkyl$)_{1-2}$ amino,
$-(oxy)_{0-1}(carbonyl)_{0-1}N(C_{0-10}$ alkyl$)_{1-2}$
hydroxy,
$(C_{1-10}$ alkyl)OH,
C_{1-10} alkoxy,
$(C_{1-10}$ alkyl)cyano,
cyano, and
C_{1-6}haloalkyl; and

R^3 is optionally substituted with 1, 2, or 3 R^4 substituents selected from hydrogen, hydroxy, (C_{1-6})alkyl, (C_{1-6})alkoxy, $(C_{1-10}$ alkyl)OH, halogen, CO_2H, $-(C_{0-6})$alkylCN, $-O(C=O)C_1-C_6$ alkyl, NO_2, trifluoromethoxy, trifluoroethoxy, trifluoromethyl, trifluoroethyl, $-N-C(O)O(C_{0-6})$alkyl, C_{1-10} alkylsulfonyl, oxo (O=), aminosulfonyl, $-SO_2NH_2$, $-SO_2NH(C_{1-10}$ alkyl), $-SO_2N(C_{0-10}$ alkyl$)_2$,$-SO_2C_{1-6}$alkyl, $-SO_2CF_3$, $-SO_2CF_2H$, $-C_{1-10}$ alkylsulfinyl, $-O_{(0-1)}(C_{1-10})$haloalkyl, amino$(C_{1-6}$alkyl$)_{0-2}$ and NH_2.

2. A compound of claim 1, wherein R^1 is selected from: halogen, Oxo (=O), C_{1-10} alkyl$(oxy)_{0-1}(carbonyl)_{0-1}C_{0-10}$ alkyl, C_{1-10} heteroalkyl$(oxy)_{0-1}(carbonyl)_{0-1}C_{0-10}$ alkyl, aryl C_{0-10} alkyl$(oxy)_{0-1}(carbonyl)_{0-1}C_{0-10}$ alkyl, C_{3-8} cycloalkyl C_{0-10} alkyl$(oxy)_{0-1}(carbonyl)_{0-1}C_{0-10}$ alkyl, heteroaryl C_{0-10} alkyl$(oxy)_{0-1}(carbonyl)_{0-1}C_{0-10}$ alkyl, (C_{3-8})heterocycloalkyl C_{0-10} alkyl$(oxy)_{0-1}(carbonyl)_{0-1}C_{0-10}$ alkyl, C_{0-10} alkyl$(oxy)_{0-1}(carbonyl)_{0-1}$aminoC$_{0-10}$ alkyl, heteroaryl C_{0-10} alkyl$(oxy)_{0-1}(carbonyl)_{0-1}$aminoC$_{0-10}$ alkyl, C_{0-10} alkylamino$(oxy)_{0-1}(carbonyl)_{0-1}C_{0-10}$ alkyl, heteroaryl C_{0-10} alkylamino$(oxy)_{0-1}(carbonyl)_{0-1}C_{0-10}$ alkyl, C_{0-10} alkylsulfonylC$_{0-10}$ alkyl, (C_{3-8})cycloheteroalkylC$_{0-10}$alkylsulfonylC$_{0-10}$ alkyl, C_{1-10} alkylsulfamoylC$_{0-10}$ alkyl, (C_{3-8})cycloalkylC$_{0-10}$ alkylsulfamoylC$_{0-10}$ alkyl, (C_{3-8})cycloheteroalkylC$_{0-10}$alkylsulfamoylC$_{0-10}$alkyl, arylC$_{0-10}$ alkylsulfamoylC$_{0-10}$ alkyl, $-(C_{0-10}$ alkyl$)CO_2H$, $-SO_2NH_2$, $-SO_2NH(C_{1-10}$ alkyl), $-SO_2N(C_{0-10}$ alkyl$)_2$, C_{0-10} alkylsulfinylaminoC$_{0-10}$ alkyl, $-(C_{1-10}$ alkyl)OH, $-C_{0-10}$ alkylalkoxy, and C_{1-6}haloalkyl;
wherein R^1 is optionally substituted with 1, 2, 3, or 4 R^3 substituents.

3. A compound of claim 2, wherein A is selected from phenyl, pyridinyl, 2,3-dihydro-1*H*-isoindolyl, thiochromanenyl, 2,3-dihydro-1,2-benzisothiazolyl, 2,3 dihydro-1-benzothiophenyl, and 2,3-dihydro-1*H*-indenyl.

4. A compound of formula II or pharmaceutically acceptable salt, or stereoisomer thereof:



II

A is selected from aryl and heteroaryl;
n is 0 or 1;
m is 0, 1, 2, or 3;
p is 0, 1, 2, 3, or 4;
R^{1a} is selected from:
halogen,
Oxo (=O),
C_{1-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{0-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
(C_{1-10})heteroalkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10}alkyl,
C_{0-10} alkylamino(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
(C_{0-10} alkyl)$_{1-2}$ amino,
hydroxy,
-(C_{1-10} alkyl)OH,
-C_{0-10} alkylalkoxy, and
C_{1-6}haloalkyl;
R^{2a} is selected from:
halogen,
Oxo (=O),
C_{1-10} alkyl(oxy)$_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{0-10} alkylaminoC_{0-10} alkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkylaminoC_{0-10} alkyl,
(C_{0-10} alkyl)$_{1-2}$ amino,
-CO_2(C_{0-10} alkyl),
-(C_{0-10} alkyl)CO_2H,

hydroxy,
-(C_{1-10} alkyl)OH,
-C_{0-10} alkylalkoxy, and
C_{1-6}haloalkyl, wherein two R^{2a} may optionally join together with the ring atoms to which they are attached and form a 3 to 6 membered ring;

wherein R^{1a} and R^{2a} are independently optionally substituted with 1, 2, 3, or 4 R^{3a} substituents;

R^{3a} is independently selected from:

halogen,
C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, and
C_{1-10} heteroalkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
Oxo (=O),
hydroxy,
(C_{1-10} alkyl)OH,
C_{1-10} alkoxy, and
C_{1-6}haloalkyl;

R^{3a} is optionally substituted with 1, 2, or 3 R^{4a} substituents selected from hydrogen, hydroxy, (C_{1-6})alkyl, (C_{1-6})alkoxy, (C_{1-10} alkyl)OH, halogen, CO_2H, -(C_{0-6})alkylCN, -O(C=O)C_1-C_6 alkyl, NO_2, trifluoromethoxy, trifluoroethoxy, trifluoromethyl, trifluoroethyl, -N-C(O)O(C_{0-6})alkyl, C_{1-10} alkylsulfonyl, oxo (O=), aminosulfonyl, $-SO_2NH_2$, $-SO_2NH(C_{1-10}$ alkyl), $-SO_2N(C_{0-10}$ alkyl$)_2$, $-SO_2C_{1-6}$alkyl, $-SO_2CF_3$, $-SO_2CF_2H$, -C_{1-10} alkylsulfinyl, -$O_{(0-1)}(C_{1-10})$haloalkyl, amino(C_{1-6}alkyl)$_{0-2}$ and NH_2;

R^{1b} is selected from:

hydrogen,
halogen,
Oxo (=O),
C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{1-10} heteroalkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{2-10} alkenyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
aryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{3-8} cycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
heteroaryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

(C_{3-8})heterocycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
(C_{1-10})heteroalkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
C_{3-8} cycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
aryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
heteroaryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
(C_{3-8})heterocycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl,
C_{0-10} alkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
(C_{1-10})heteroalkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{3-8} cycloalkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
aryl C_{0-10} alkylaminoamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
heteroaryl C_{0-10} alkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
(C_{3-8})heterocycloalkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,
C_{0-10} alkylsulfonylC_{0-10} alkyl,
C_{1-10} heteroalkylsulfonylC_{0-10} alkyl,
(C_{3-8})cycloalkylC_{0-10}alkylsulfonylC_{0-10} alkyl,
(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfonylC_{0-10} alkyl,
heteroarylC_{0-10} alkylsulfonylC_{0-10} alkyl,
arylC_{0-10} alkylsulfonylC_{0-10} alkyl,
C_{1-10} alkylsulfamoylC_{0-10} alkyl,
C_{1-10} heteroalkylsulfamoylC_{0-10} alkyl,
(C_{3-8})cycloalkylC_{0-10} alkylsulfamoylC_{0-10} alkyl,
(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfamoylC_{0-10} alkyl,
heteroarylC_{0-10} alkylsulfamoylC_{0-10} alkyl,
arylC_{0-10} alkylsulfamoylC_{0-10} alkyl,
$(C_{0-10}$ alkyl$)_{1-2}$ amino,
$-CO_2(C_{0-10}$ alkyl),
$-(C_{0-10}$ alkyl$)CO_2H$,
$-SO_2NH_2$,
$-SO_2NH(C_{1-10}$ alkyl),
$-SO_2N(C_{0-10}$ alkyl$)_2$,

$-SO_2CF_3$,

$-SO_2CF_2H$,

C_{1-10} alkylsulfinylC_{0-10} alkyl,

C_{1-10} heteroalkylsulfinylC_{0-10}alkyl,

(C_{3-8})cycloalkylC_{0-10}alkylsulfinylC_{0-10}alkyl,

(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfinylC_{0-10}alkyl,

heteroarylC_{0-10} alkylsulfinylC_{0-10}alkyl,

arylC_{0-10}alkylsulfinylC_{0-10}alkyl,

C_{0-10} alkylsulfinylaminoC_{0-10} alkyl,

C_{1-4}acylamino C_{0-10} alkyl,

hydroxy,

$-(C_{1-10}$ alkyl)OH,

$-C_{0-10}$ alkylalkoxy,

cyano,

$(C_{1-6}$alkyl)cyano, and

C_{1-6}haloalkyl;

R^{2b} is selected from:

hydrogen,

halogen,

Oxo (=O),

C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{3-8} cycloalkyl,

(C_{3-8})heterocycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl,

C_{0-10} alkylaminoC_{0-10} alkyl,

(C_{1-10})heteroalkylaminoC_{0-10}alkyl,

C_{3-8} cycloalkyl C_{0-10} alkylaminoC_{0-10} alkyl,

aryl C_{0-10} alkylaminoC_{0-10} alkyl,

heteroaryl C_{0-10} alkylaminoC_{0-10} alkyl,

(C_{3-8})heterocycloalkyl C_{0-10} alkylaminoC_{0-10} alkyl,

C_{1-10} alkylsulfonyl,

(C_{3-8})cycloalkylC_{0-10}alkylsulfonyl,

(C_{3-8})cycloheteroalkylC_{0-10}alkylsulfonyl,

$(C_{0-10}$ alkyl$)_{1-2}$ amino,

$-CO_2(C_{0-10}$ alkyl),

$-(C_{0-10}$ alkyl$)CO_2H$,

$-SO_2CF_3$,

$-SO_2CF_2H$,

C_{1-10} alkylsulfinyl,

hydroxy,

$-(C_{1-10}$ alkyl$)OH$,

$-C_{0-10}$ alkylalkoxy,

cyano,

$(C_{1-6}$alkyl)cyano, and

C_{1-6}haloalkyl; wherein R^{1b} and R^{2b} are each optionally substituted with 1, 2, or 3 R^3 substituents;

R^3 is independently selected from: halogen, C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, Oxo (=O), amino, hydroxy, $(C_{1-10}$ alkyl$)OH$, C_{1-10}alkoxy, and C_{1-6}haloalkyl; wherein R^3 is optionally substituted with 1, 2, or 3 R^4 substituents; and

R^4 is independently selected from hydrogen, hydroxy, (C_{1-6})alkyl, (C_{1-6})alkoxy, $(C_{1-10}$ alkyl$)OH$, halogen, $-O(C=O)C_1$-C_6 alkyl, trifluoromethoxy, trifluoroethoxy, trifluoromethyl, trifluoroethyl, oxo (O=), $-O_{(0-1)}(C_{1-10})$haloalkyl, amino$(C_{1-6}$alkyl$)_{0-2}$ and NH_2.

5. A compound according to claim 4, wherein:

R^{1b} is selected from: hydrogen, halogen, Oxo (=O), C_{1-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{1-10} heteroalkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, aryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{3-8} cycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, heteroaryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, (C_{3-8})heterocycloalkyl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl, heteroaryl C_{0-10} alkyl$(oxy)_{0-1}$(carbonyl)$_{0-1}$aminoC_{0-10} alkyl, C_{0-10} alkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, heteroaryl C_{0-10} alkylamino$(oxy)_{0-1}$(carbonyl)$_{0-1}C_{0-10}$ alkyl, C_{0-10} alkylsulfonylC_{0-10} alkyl, (C_{3-8})cycloheteroalkylC_{0-10}alkylsulfonylC_{0-10} alkyl, C_{1-10} alkylsulfamoylC_{0-10} alkyl, (C_{3-8})cycloalkylC_{0-10} alkylsulfamoylC_{0-10} alkyl, $(C_{3-}$

8)cycloheteroalkylC0-10alkylsulfamoylC0-10alkyl, arylC0-10 alkylsulfamoylC0-10 alkyl, -(C0-10 alkyl)CO2H, -SO2NH2, -SO2NH(C1-10 alkyl), -SO2N(C0-10 alkyl)2, C0-10 alkylsulfinylaminoC0-10 alkyl, -(C1-10 alkyl)OH, -C0-10 alkylalkoxy, and C1-6haloalkyl;

R^{2b} selected from: hydrogen, halogen, C1-10 alkyl(oxy)0-1(carbonyl)0-1C0-10 alkyl, (C3-8)heterocycloalkyl C0-10 alkyl(oxy)0-1(carbonyl)0-1C0-10 alkyl, C3-8 cycloalkyl C0-10 alkylaminoC0-10 alkyl, and (C0-10 alkyl)1-2 amino;

and wherein R^{1b} and R^{2b} are optionally substituted with 1, 2, or 3 R^3 substituents.

6. A compound of claim 1 or a pharmaceutically acceptable salt, or a stereoisomer thereof selected from:

2-{3-[(4-fluorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{3-[(2-fluoropyridin-4-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}-5-{[1-cyclopropylethyl]amino}cyclohexanecarbonitrile;

5-hydroxy-2-(4-oxo-3-{[4-(trifluoromethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-azetidin-1-yl-2-(4-oxo-3-{[4-(trifluoromethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-{[1-cyclopropylethyl]amino}-2-(4-oxo-3-{[4-(trifluoromethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-{[1-cyclopropylethyl]amino}-2-(4-oxo-3-{[4-(trifluoromethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-azetidin-1-yl-2-{3-[(4-chloro-3-fluorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(4-chloro-3-fluorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}-5-(dimethylamino)cyclohexanecarbonitrile;

2-{3-[(4-chloro-3-fluorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}-5-{[1-cyclopropylethyl]amino}cyclohexanecarbonitrile;

5-azetidin-1-yl-2-{3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}-5-(dimethylamino)cyclohexanecarbonitrile;

5-azetidin-1-yl-2-(4-oxo-3-{[4-(trifluoromethoxy)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-{[1-cyclopropylethyl]amino}-2-(4-oxo-3-{[4-(trifluoromethoxy)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-(dimethylamino)-2-(4-oxo-3-{[4-(trifluoromethoxy)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{4-oxo-3-[(2,2,2-trifluoroethyl)amino]-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}-5-(3-hydroxy-3-methylazetidin-1-yl)cyclohexanecarbonitrile;

2-{3-[(4-chlorophenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}-5-(3-hydroxyazetidin-1-yl)cyclohexanecarbonitrile;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-*N*,*N*-dimethylbenzenesulfonamide;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzenesulfonamide;

(2-{3-[(2-fluoropyridin-4-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclopentanecarbonitrile;

(2-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile;

2-[4-oxo-3-({4-[2,2,2-trifluoro-1-hydroxyethyl]phenyl}amino)-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(4-oxo-3-{[1-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1*H*-isoindol-5-yl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

4-({1-[2-cyanocyclopentyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-*N,N*-dimethylbenzenesulfonamide;

2-(4-oxo-3-{[1-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1*H*-isoindol-5-yl]amino}-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile;

2-(4-oxo-3-{[4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile;

4-({1-[2-cyanocyclopentyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzenesulfonamide;

2-[3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-N-(1-methyl-1H-pyrazol-3-yl)acetamide;

N-[3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]-1,3-oxazole-5-carboxamide;

N-[3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]pyrimidine-2-carboxamide;

2-[3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-N-(1-methyl-1H-pyrazol-3-yl)acetamide;

tert-butyl [3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]carbamate;

2-(3-{[3-(aminomethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-N-(1-methylethyl)benzenesulfonamide;

N-benzyl-4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzenesulfonamide;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-N-(cyclopropylmethyl)benzenesulfonamide;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-N-(2-methoxyethyl)benzenesulfonamide;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-N-cyclohexylbenzenesulfonamide;

2-(3-{[4-(morpholin-4-ylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-[4-oxo-3-(phenylamino)-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[3-methyl-4-(pyrrolidin-1-ylcarbonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(4-oxo-3-{[3-(2H-1,2,3-triazol-2-ylmethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

N-[4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]-1,3-oxazole-5-carboxamide;

N-[4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]pyrimidine-2-carboxamide;

2-(3-{[3-(1-hydroxyethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

tert-butyl [4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)benzyl]carbamate;

2-(3-{[4-(aminomethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[3-(aminomethyl)-4-fluorophenyl]amino}-4-oxo-4,5-dihydro-*1H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[3-(morpholin-4-ylmethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

tert-butyl [5-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-2-fluorobenzyl]carbamate;

tert-butyl [3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-5-fluorobenzyl]carbamate;

2-{3-[(3-{[4-(1-hydroxy-1-methylethyl)-1*H*-1,2,3-triazol-1-yl]methyl}phenyl)amino]-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-(3-{[3-(1-hydroxy-2-methoxy-1-methylethyl)-4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[3-(1,3-dihydroxy-1-methylpropyl)-4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[3-(1,2-dihydroxy-1-methylethyl)-4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-[3-(2,3-dihydro-1*H*-isoindol-5-ylamino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-[3-({3-[(4-methyl-1*H*-1,2,3-triazol-1-yl)methyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-[3-({3-[1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

N-{1-[3-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-2,2,2-trifluoroethyl}-2-methylpropane-2-sulfinamide;

2-(4-oxo-3-{[3-(2,2,4-trimethyl-1,3-dioxolan-4-yl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{4-oxo-3-[(3-{[(2,2,2-trifluoroethyl)amino]methyl}phenyl)amino]-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-(3-{[3-(aminomethyl)-4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

6-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile;

N-[5-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-2-(dimethylsulfamoyl)benzyl]acetamide;

2-[3-({3-[(dimethylamino)methyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[3-(1,2-dihydroxy-1-methylethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

4-{[1-(5-cyanospiro[2.5]oct-6-yl)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl]amino}-*N*,*N*-dimethylbenzenesulfonamide;

2-(aminomethyl)-4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-*N*,*N*-dimethylbenzenesulfonamide;

2-(4-oxo-3-{[3-(1*H*-pyrazol-1-ylmethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(4-oxo-3-{[4-(pyrrolidin-1-ylcarbonyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(4-oxo-3-{[4-(1*H*-1,2,3-triazol-1-ylmethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[3-(1*H*-imidazol-1-ylmethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

6-(3-{[4-(methylsulfonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)spiro[2.5]octane-5-carbonitrile;

2-(3-{[4-hydroxy-4-(hydroxymethyl)-1,1-dioxido-3,4-dihydro-2*H*-thiochromen-6-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{3-[(2-methyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-(4-oxo-3-{[3-(1*H*-1,2,4-triazol-1-ylmethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(4-oxo-3-{[3-(1*H*-1,2,4-triazol-4-ylmethyl)phenyl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{3-[(4-{[4-(1-hydroxy-1-methylethyl)-1*H*-1,2,3-triazol-1-yl]methyl}phenyl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(2-tert-butyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1*H* -pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

N-{1-[4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)phenyl]-2,2,2-trifluoroethyl}-2-methylpropane-2-sulfinamide;

2-[3-({4-[1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-{4-oxo-3-[(4-{[(2,2,2-trifluoroethyl)amino]methyl}phenyl)amino]-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-[4-oxo-3-({4-[(pyrrolidin-1-ylsulfonyl)methyl]phenyl}amino)-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[1,1-dioxido-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{3-[(1,1-dioxido-2,3-dihydro-1-benzothiophen-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(2-ethyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-{3-[(2-tert-butyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclopentanecarbonitrile;

2-(3-{[1,1-dioxido-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclopentanecarbonitrile;

2-(4-oxo-3-{[2-(2,2,2-trifluoroethyl)-2,3-dihydro-1*H*-isoindol-5-yl]amino}-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

5-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-2,3-dihydro-1*H*-indene-2-carboxylic acid;

2-{3-[(2-methyl-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclopentanecarbonitrile;

2-(3-{[2-(cyclopropylmethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{3-[(2-methyl-2,3-dihydro-1*H*-isoindol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-[3-({4-[1-(dimethylamino)-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[2-(cyclopentylmethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{4-oxo-3-[(4-{1-[(2,2,2-trifluoroethyl)amino]ethyl}phenyl)amino]-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-*N*,*N*,2-trimethylbenzamide;

2-(3-{[3-methyl-4-(morpholin-4-ylcarbonyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

4-({1-[2-cyanocyclohexyl]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-3-yl}amino)-2-cyclopropyl-*N,N*-dimethylbenzamide;

2-[3-({4-[1-amino-2,2-difluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[4-(2,2-difluoro-1-hydroxyethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-[4-oxo-3-({4-[pyrrolidin-2-yl]phenyl}amino)-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-{4-oxo-3-[(4-{1-[(2,2,2-trifluoroethyl)amino]ethyl}phenyl)amino]-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-(3-{[2-(1-methylethyl)-2,3-dihydro-1*H*-isoindol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[2-(2-methylpropyl)-2,3-dihydro-1*H*-isoindol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-{3-[(2-ethyl-2,3-dihydro-1*H*-isoindol-5-yl)amino]-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl}cyclohexanecarbonitrile;

2-(3-{[2-(cyclopropylmethyl)-2,3-dihydro-1*H*-isoindol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-[3-({3-[(methylsulfanyl)methyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[2-(1-methylethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[2-(2-hydroxyethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-(3-{[2-(3-hydroxy-1,1-dimethylpropyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-[4-oxo-3-({4-[1-(1*H*-1,2,3-triazol-1-yl)ethyl]phenyl}amino)-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-[3-({4-[1-methyl-1-(1*H*-1,2,3-triazol-1-yl)ethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclohexanecarbonitrile;

2-(3-{[2-(3-hydroxy-2,2-dimethylpropyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile;

2-[3-({4-[1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclopentanecarbonitrile;

2-[3-({4-[1-amino-2,2,2-trifluoroethyl]phenyl}amino)-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl]cyclopentanecarbonitrile;

2-(3-{[2-(2-methoxyethyl)-1,1-dioxido-2,3-dihydro-1,2-benzisothiazol-5-yl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile; and

2-(3-{[3-(aminomethyl)phenyl]amino}-4-oxo-4,5-dihydro-1*H*-pyrazolo[4,3-c]pyridin-1-yl)cyclohexanecarbonitrile.

7. A pharmaceutical composition comprising a compound of Claim 1 or a pharamceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

8. A method for the treatment of a JAK-mediated disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable thereof.

9. A method of treating a condition in a mammal that can be ameliorated by the inhibition of Janus kinases JAK1 and JAK 2 which condition is selected from, arthritis, asthma and obstructive airways diseases, autoimmune diseases or disorders, and cancer comprising administering to the mammal in need of such treatment, a therapeutically effective amount of a compound according to Claim 1or a pharmaceutically acceptable salt or a stereoisomer thereof.

10. A method according to Claim 9, wherein said condition is arthritis.

11. A method according to Claim 10, wherein said condition is selected from rheumatoid arthritis, juvenile arthritis, and psoriatic arthritis.

12. A method according to Claim 9, wherein said condition is asthma or obstructive airways diseases.

13. A method according to Claim 9, wherein said condition is selected from: chronic asthma, late asthma, airway hyper-responsiveness, bronchitis, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, recurrent airway obstruction, and chronic obstruction pulmonary disease (COPD), and emphysema.

14. A method according to Claim 9, wherein said condition is autoimmune diseases or disorders.

15. A method of treating asthma in a mammal in need thereof, comprising administering a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

16. A method of treating arthritis in a mammal in need thereof, comprising administering a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

17. Use of a compound of Claim 1 or a pharmaceutically acceptable salt or a stereoisomer thereof in the manufacture of a medicament for the treatment of a disease or a disorder ameliorated by the inhibition of Janus kinases JAK1 and JAK 2.

18. Use of a compound of Claim 1 or a pharmaceutically acceptable salt or a stereoisomer thereof and a second active agent in the manufacture of a medicament for the treatment of a disease or a disorder ameliorated by the inhibition Janus kinases JAK1 and JAK 2.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CN2013/072867

A. CLASSIFICATION OF SUBJECT MATTER

See the extra sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: C07D 401/-; C07D 471/-; A61K 31/-; A61P 29/-

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC, CNPAT, CNKI, REGISTRY, CAPLUS: pyrazole, pyridine, JAK, inhibit+, carboxamide?, cycloalkyl, nitrile

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2011/112662A1(INCYTE CORPORATION et al.) 15 September 2011 (15.09.2011) the whole document	1-18
A	WO 2009/035575A1(MERCK & CO., INC. et al.) 19 March 2009 (19.03.2009) the whole document	1-18

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
15 July 2013 (15.07.2013)	**26 Dec. 2013 (26.12.2013)**
Name and mailing address of the ISA/CN The State Intellectual Property Office, the P.R.China 6 Xitucheng Rd., Jimen Bridge, Haidian District, Beijing, China 100088 Facsimile No. 86-10-62019451	Authorized officer SHI,Jie Telephone No. (86-10)82246672

Form PCT/ISA /210 (second sheet) (July 2009)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CN2013/072867

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8-16
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 8-16 are directed to the methods for the treatment of human or animal body by therapy. However, the search has been carried out and based on the following subject matter: the use of a compound according to any one of claims in the manufacture of medicaments for the treatment of diseases.

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CN2013/072867

Patent Documents referred in the Report	Publication Date	Patent Family	Publication Date
WO 2011/112662A1	15.09.2011	US 2011224190A1	15.09.2011
		CA 2792508A1	15.09.2011
		TW 201206923A	16.02.2012
		EP 2545045A1	16.01.2013
		MXPA 12010344A	30.11.2012
		KR 20130038834A	18.04.2013
WO 2009/035575A1	19.03.2009	AU 2008300026A1	19.03.2009
		CA 2698256A1	19.03.2009
		EP 2200612A1	30.06.2010
		US 2010197634A1	05.08.2010
		JP 2010539080A	16.12.2010
		EP 2200612B1	08.08.2012
		US 8349865B2	08.01.2013
		ES 2392600T3	12.12.2012

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CN2013/072867

Continuation of A: **CLASSIFICATION OF SUBJECT MATTER**

C07D 401/14 (2006.01) i

A61K 31/495 (2006.01) i

C07D 471/04 (2006.01) i

A61P 29/00 (2006.01) i